[{"symbol": "ABBV", "publishedDate": "2021-03-29 18:55:22", "title": "AbbVie (ABBV) Gains As Market Dips: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/c/n/drugs3-743970.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) closed the most recent trading day at $106.73, moving +0.71% from the previous trading session.", "url": "https://www.zacks.com/stock/news/1315125/abbvie-abbv-gains-as-market-dips-what-you-should-know"}, {"symbol": "ABBV", "publishedDate": "2021-03-29 07:12:00", "title": "This Stalwart's Growth Story Isn't Over Yet", "image": "https://cdn.snapi.dev/images/v1/1/a/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6186452flab-worker-woman-science-researchjpgw700opresize-742567.jpg", "site": "The Motley Fool", "text": "It's a big-name pharma with a storied history, but Eli Lilly still has plenty of room left to run.", "url": "https://www.fool.com/investing/2021/03/29/this-stalwarts-growth-story-isnt-over-yet/"}, {"symbol": "ABBV", "publishedDate": "2021-03-27 17:02:10", "title": "91 'Top Dividend Stocks On Earth': April's Kiplinger Update", "image": "https://cdn.snapi.dev/images/v1/d/x/drugs33-742088.jpg", "site": "Seeking Alpha", "text": "91 'Top Dividend Stocks On Earth': April's Kiplinger Update", "url": "https://seekingalpha.com/article/4416435-91-top-dividend-stocks-on-earth-aprils-kiplinger-update"}, {"symbol": "ABBV", "publishedDate": "2021-03-26 14:49:00", "title": "7 Big Pharmaceutical Stocks for Bigger Income", "image": "https://cdn.snapi.dev/images/v1/s/t/stocksnetapp1-741545.jpg", "site": "Kiplinger", "text": "Pharmaceutical stocks with stable, substantial dividends can hold their own in almost any environment, making them ideal for long-term income investors.", "url": "https://www.kiplinger.com/investing/stocks/dividend-stocks/602509/big-pharmaceutical-stocks-bigger-income"}, {"symbol": "ABBV", "publishedDate": "2021-03-26 12:53:17", "title": "This is Why AbbVie (ABBV) is a Great Dividend Stock", "image": "https://cdn.snapi.dev/images/v1/f/4/drugs22-741368.jpg", "site": "Zacks Investment Research", "text": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?", "url": "https://www.zacks.com/stock/news/1299453/this-is-why-abbvie-abbv-is-a-great-dividend-stock"}, {"symbol": "ABBV", "publishedDate": "2021-03-26 10:15:00", "title": "Top 10 Undervalued Income Stocks For 2021 - Value Beats Growth", "image": "https://cdn.snapi.dev/images/v1/0/b/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5805032fcoronavirus-stock-market-xaoojydjpgw700opresize-741049.jpg", "site": "Seeking Alpha", "text": "At the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far. In this report, we examine the reasons for that and will look at whether all 10 are still strong buys today.", "url": "https://seekingalpha.com/article/4416178-top-10-undervalued-income-stocks-for-2021-value-beats-growth"}, {"symbol": "ABBV", "publishedDate": "2021-03-26 07:46:42", "title": "5 High-Yielding Dividend Aristocrat Stocks Are Perfect Now for Worried Investors", "image": "https://cdn.snapi.dev/images/v1/m/n/drugs10-740704.jpg", "site": "24/7 Wall Street", "text": "With March almost over, many investors are looking to the second quarter and beyond.", "url": "https://247wallst.com/investing/2021/03/26/5-high-yielding-dividend-aristocrat-stocks-are-perfect-now-for-worried-investors/"}, {"symbol": "ABBV", "publishedDate": "2021-03-26 05:01:09", "title": "7 Value Stocks That Will Reward Investors Who Have Some Patience", "image": "https://cdn.snapi.dev/images/v1/q/a/computer-electronic33-740549.jpg", "site": "InvestorPlace", "text": "Value stocks aren't always a sure thing despite their reassuring metrics. These seven seem to be close to it though.", "url": "https://investorplace.com/2021/03/7-value-stocks-that-will-reward-investors-who-have-some-patience/"}, {"symbol": "ABBV", "publishedDate": "2021-03-23 18:56:18", "title": "AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/r/q/drugs31-736497.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) closed at $104.84 in the latest trading session, marking a -1% move from the prior day.", "url": "https://www.zacks.com/stock/news/1285083/abbvie-abbv-dips-more-than-broader-markets-what-you-should-know"}, {"symbol": "ABBV", "publishedDate": "2021-03-23 18:12:31", "title": "AbbVie Stock Shows Every Sign Of Being Fairly Valued", "image": "https://cdn.snapi.dev/images/v1/u/l/1579183057911-736448.jpg", "site": "GuruFocus", "text": "The stock of AbbVie (NYSE:ABBV, 30-year Financials) appears to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded.", "url": "https://www.gurufocus.com/news/1388062/abbvie-stock-shows-every-sign-of-being-fairly-valued"}, {"symbol": "ABBV", "publishedDate": "2021-03-22 14:33:48", "title": "Final Trades: Roku, Lam Research, AbbVie & more", "image": "https://cdn.snapi.dev/images/v1/s/g/final-trades-roku-lam-research-abbvie-more-734124.jpg", "site": "CNBC Television", "text": "The \"Halftime Report\" traders give their top picks to watch for the second half.", "url": "https://www.youtube.com/watch?v=jtAzqlrfkVA"}, {"symbol": "ABBV", "publishedDate": "2021-03-21 23:34:00", "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV", "image": "https://cdn.snapi.dev/images/v1/f/z/press15-732808.jpg", "site": "Newsfile Corp", "text": "New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc.(\"AbbVie\" or the \"Company\") (NYSE: ABBV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether AbbVie and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]...", "url": "https://www.newsfilecorp.com/release/78136/SHAREHOLDER-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-AbbVie-Inc.-ABBV"}, {"symbol": "ABBV", "publishedDate": "2021-03-21 13:08:49", "title": "Sell Alert: These 5 Dividend Blue Chips Are Way Too Expensive", "image": "https://cdn.snapi.dev/images/v1/i/s/top-moat-stocks-in-2020-veeva-servicenow-and-amazon-440x250-732636.jpg", "site": "Seeking Alpha", "text": "As markets make new highs, a lot of stocks are becoming overextended. Here are 5 which are now extremely overvalued.", "url": "https://seekingalpha.com/article/4415225-sell-alert-5-dividend-blue-chips-are-way-too-expensive"}, {"symbol": "ABBV", "publishedDate": "2021-03-19 16:42:44", "title": "5 High Dividend Yield Stocks Broadly Bought by Gurus", "image": "https://cdn.snapi.dev/images/v1/k/3/watch-what-the-market-is-telling-you-not-the-news-732108.jpg", "site": "GuruFocus", "text": "According to the High Dividend Yield Stocks page, a Premium feature of GuruFocus, five stocks with a dividend yield of at least 4% and double-digit guru buys over the past few months are AbbVie Inc. (NYSE:ABBV), Gilead Sciences Inc. (NASDAQ:GILD), Exxon Mobil Corp. (NYSE:XOM), Chevron Corp. (NYSE:CVX) and GlaxoSmithKline PLC (NYSE:GSK).", "url": "https://www.gurufocus.com/news/1387068/5-high-dividend-yield-stocks-broadly-bought-by-gurus"}, {"symbol": "ABBV", "publishedDate": "2021-03-18 19:26:00", "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV", "image": "https://cdn.snapi.dev/images/v1/j/l/press1-730769.jpg", "site": "PRNewsWire", "text": "NEW YORK, March 18, 2021 /PRNewswire/ --\u00a0Pomerantz LLP is investigating claims on behalf of investors of\u00a0AbbVie Inc.(\"AbbVie\" or the \"Company\")\u00a0(NYSE:\u00a0ABBV).\u00a0 Such investors are advised to contact Robert S.", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-abbvie-inc---abbv-301250679.html"}, {"symbol": "ABBV", "publishedDate": "2021-03-18 10:13:27", "title": "AbbVie (ABBV) Down as FDA Extends Review of Rinvoq sNDA", "image": "https://cdn.snapi.dev/images/v1/v/3/drugs23-729649.jpg", "site": "Zacks Investment Research", "text": "The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in active psoriatic arthritis by three months.", "url": "https://www.zacks.com/stock/news/1281961/abbvie-abbv-down-as-fda-extends-review-of-rinvoq-snda"}, {"symbol": "ABBV", "publishedDate": "2021-03-17 17:32:52", "title": "4 Top Stock Trades for Thursday: ABBV, TLT, PDD, FIVE", "image": "https://cdn.snapi.dev/images/v1/j/l/etf25-728634.jpg", "site": "InvestorPlace", "text": "AbbVie, the iShares 20+ Treasury Bond ETF, Pinduoduo and Five Below were our top stock trades for Thursday. Now, let's look at the charts.", "url": "https://investorplace.com/2021/03/4-top-stock-trades-for-thursday-abbv-tlt-pdd-five/"}, {"symbol": "ABBV", "publishedDate": "2021-03-17 15:40:10", "title": "AbbVie Shares Cross 5% Yield Mark", "image": "https://cdn.snapi.dev/images/v1/o/o/abbvie-shares-cross-5-yield-mark-728375.jpg", "site": "Forbes", "text": "In trading on Wednesday, shares of AbbVie were yielding above the 5% mark based on its quarterly dividend (annualized to $5.2), with the stock changing hands as low as $102.80 on the day.", "url": "https://www.forbes.com/sites/dividendchannel/2021/03/17/abbvie-shares-cross-5-yield-mark/"}, {"symbol": "ABBV", "publishedDate": "2021-03-17 15:36:23", "title": "Mr. Market Gives You A Discount On AbbVie", "image": "https://cdn.snapi.dev/images/v1/n/1/drugs11-728364.jpg", "site": "Seeking Alpha", "text": "AbbVie is down almost 6% after the FDA extends its review of one of its drugs.", "url": "https://seekingalpha.com/article/4414609-market-gives-you-discount-on-abbvie"}, {"symbol": "ABBV", "publishedDate": "2021-03-17 12:04:48", "title": "Did Pfizer Just Trip Up AbbVie's Chances For A New Arthritis Drug?", "image": "https://cdn.snapi.dev/images/v1/x/k/drugs7-727978.jpg", "site": "Investors Business Daily", "text": "AbbVie stock plunged Wednesday after the Food and Drug Administration requested additional information to assess the benefit of potential blockbuster drug Rinvoq in psoriatic arthritis. The post Did Pfizer Just Trip Up AbbVie's Chances For A New Arthritis Drug?", "url": "https://www.investors.com/news/technology/abbvie-stock-plunges-fda-delays-review-rinvoq-psoriatic-arthritis/"}, {"symbol": "ABBV", "publishedDate": "2021-03-17 11:39:57", "title": "ABBV Stock Price Fell Over 7% Intraday: Why It Happened", "image": "https://cdn.snapi.dev/images/v1/z/2/drugs6-727935.jpg", "site": "Pulse2", "text": "The stock price of AbbVie Inc (NYSE: ABBV) fell by over 7% intraday. This is why it happened.", "url": "https://pulse2.com/abbv-stock-price-nyse-abbvie-fell-over-7-intraday-why-it-happened/"}, {"symbol": "ABBV", "publishedDate": "2021-03-17 08:45:00", "title": "AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Adults with Active Psoriatic Arthritis", "image": "https://cdn.snapi.dev/images/v1/x/u/press8-727429.jpg", "site": "PRNewsWire", "text": "NORTH CHICAGO, Ill., March 17, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental\u00a0New Drug Application (sNDA) for upadacitinib in the treatment of adult patients with active psoriatic arthritis.", "url": "https://www.prnewswire.com/news-releases/abbvie-announces-extension-of-review-for-supplemental-new-drug-application-of-upadacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis-301248962.html"}, {"symbol": "ABBV", "publishedDate": "2021-03-17 07:32:24", "title": "3 Pharma Dividend Growth Stocks Yielding 4.5%", "image": "https://cdn.snapi.dev/images/v1/w/q/drugs7-727217.jpg", "site": "Seeking Alpha", "text": "I discuss 3 large cap pharma stocks that are yielding about 4.5% or more and are undervalued based on P/E ratio.", "url": "https://seekingalpha.com/article/4414476-3-pharma-dividend-growth-stocks-yielding-4_5-percent"}, {"symbol": "ABBV", "publishedDate": "2021-03-17 06:04:00", "title": "4 Pharma Stocks That Could Be Losers With the $1.9 Trillion Stimulus Package", "image": "https://cdn.snapi.dev/images/v1/p/o/podc5-727045.jpg", "site": "The Motley Fool", "text": "An easily overlooked provision in the legislation could be bad news for four drugmakers, in particular.", "url": "https://www.fool.com/investing/2021/03/17/4-pharma-stocks-that-could-be-losers-with-the-19-t/"}, {"symbol": "ABBV", "publishedDate": "2021-03-16 15:43:53", "title": "Connect Biopharma Pursues $150 Million U.S. IPO Plan", "image": "https://cdn.snapi.dev/images/v1/c/g/drugs1-726430.jpg", "site": "Seeking Alpha", "text": "Connect Biopharma Pursues $150 Million U.S. IPO Plan", "url": "https://seekingalpha.com/article/4414342-connect-biopharma-pursues-150-million-u-s-ipo-plan"}, {"symbol": "ABBV", "publishedDate": "2021-03-16 10:19:22", "title": "AbbVie Stock Inching Toward Highs Amid Drug Sale Talks", "image": "https://cdn.snapi.dev/images/v1/g/4/drugs6-725731.jpg", "site": "Schaeffers Research", "text": "AbbVie Inc (NYSE:ABBV) is in the spotlight this morning, after news that the pharmaceutical company is in talks to sell a $5 billion portfolio of women's drugs.", "url": "https://www.schaeffersresearch.com/content/news/2021/03/16/abbvie-stock-inching-toward-highs-amid-drug-sale-talks"}, {"symbol": "ABBV", "publishedDate": "2021-03-16 06:01:00", "title": "3 Stocks That'll Turn Your $1,400 Stimulus Check Into a Money Machine", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6180072fstimulus-check-with-100-billsjpgw700opresize-724992.jpg", "site": "The Motley Fool", "text": "Make money with your newfound cash with these three dividend stocks.", "url": "https://www.fool.com/investing/2021/03/16/3-stocks-thatll-turn-your-1400-stimulus-check-into/"}, {"symbol": "ABBV", "publishedDate": "2021-03-16 05:01:29", "title": "7 Blue-Chip Stocks With Strong Dividend Yields", "image": "https://cdn.snapi.dev/images/v1/9/x/top-stocks-to-buy-today-as-markets-respond-to-mixed-sentiment-724918.jpg", "site": "InvestorPlace", "text": "Blue-chip stocks appeal to investors with their stability, consistent returns and dividend yield. In this article, we look at seven blue-chip stocks with strong dividends that could offer big returns.", "url": "https://investorplace.com/2021/03/7-blue-chip-stocks-with-strong-dividend-yields/"}, {"symbol": "ABBV", "publishedDate": "2021-03-15 18:31:35", "title": "AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/y/k/drugs45-724712.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) closed at $110.26 in the latest trading session, marking a +1.89% move from the prior day.", "url": "https://www.zacks.com/stock/news/1279609/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know"}, {"symbol": "ABBV", "publishedDate": "2021-03-15 16:50:00", "title": "Exclusive: AbbVie in talks to sell $5 billion women's drugs portfolio - sources", "image": "https://cdn.snapi.dev/images/v1/d/t/m02d20210315t2i1554988653w940fhfwllplsqrlynxmpeh2e1m8-724562.jpg", "site": "Reuters", "text": "U.S. drugmaker AbbVie Inc is holding talks to sell a roughly $5 billion portfolio of women's drugs acquired last year through its $63 billion purchase of Botox maker Allergan Plc, sources familiar with the matter told Reuters.", "url": "https://www.reuters.com/article/us-abbvie-womenshealth-exclusive/exclusive-abbvie-in-talks-to-sell-5-billion-womens-drugs-portfolio-sources-idUSKBN2B72P2"}, {"symbol": "ABBV", "publishedDate": "2021-03-15 09:58:39", "title": "Sand In My Shoes - February Update", "image": "https://cdn.snapi.dev/images/v1/4/b/dwdf223-8-723636.jpg", "site": "Seeking Alpha", "text": "February was a fabulous month for equities as the S&P 500 rose 2.61% while small-cap and mid-cap names were up even more.", "url": "https://seekingalpha.com/article/4413947-sand-in-shoes-february-update"}, {"symbol": "ABBV", "publishedDate": "2021-03-15 07:07:00", "title": "3 Ways to Become a Millionaire Making Money in Your Sleep", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6171792fgetty-sleep-money-cash-nap-restjpgw700opresize-723053.jpg", "site": "The Motley Fool", "text": "Boost your future financial security -- almost effortlessly!", "url": "https://www.fool.com/investing/2021/03/15/3-ways-to-become-a-millionaire-making-money-in-you/"}, {"symbol": "ABBV", "publishedDate": "2021-03-14 06:01:00", "title": "3 High-Yield Dividend Stocks to Buy Now", "image": "https://cdn.snapi.dev/images/v1/w/h/what-will-the-stock-market-return-in-2020-722523.jpg", "site": "The Motley Fool", "text": "Great dividends. Great businesses.", "url": "https://www.fool.com/investing/2021/03/14/3-high-yield-dividend-stocks-to-buy-now/"}, {"symbol": "ABBV", "publishedDate": "2021-03-13 08:32:00", "title": "Why the Growth Isn't Over for This Best-in-Breed Biotech Stock", "image": "https://cdn.snapi.dev/images/v1/i/d/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6172152fgetty-lab-tech-vialsjpgw700opresize-722321.jpg", "site": "The Motley Fool", "text": "It's not getting much attention lately, but the future for Amgen looks strong.", "url": "https://www.fool.com/investing/2021/03/13/why-the-growth-isnt-over-for-this-best-in-breed-bi/"}, {"symbol": "ABBV", "publishedDate": "2021-03-13 07:38:28", "title": "The 'Boiler Room' Stock Pitch Recap: Nautilus, Uber, Lamar Advertising And More", "image": "https://cdn.snapi.dev/images/v1/t/w/reit5-722289.jpg", "site": "Benzinga", "text": "Every Friday, at 3 p.m. ET, Ritholtz Wealth Management CEO Josh Brown and Benzinga CEO Jason Raznick host \"The Boiler Room,\" a Clubhouse audio chat where listeners can pitch their favorite stock.", "url": "https://www.benzinga.com/trading-ideas/long-ideas/21/03/20152837/the-boiler-room-stock-pitch-recap-nautilus-uber-lamar-advertising-and-more"}, {"symbol": "ABBV", "publishedDate": "2021-03-11 10:28:18", "title": "Why AbbVie (ABBV) is a Great Dividend Stock Right Now", "image": "https://cdn.snapi.dev/images/v1/f/0/drugs1-719342.jpg", "site": "Zacks Investment Research", "text": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?", "url": "https://www.zacks.com/stock/news/1276903/why-abbvie-abbv-is-a-great-dividend-stock-right-now"}, {"symbol": "ABBV", "publishedDate": "2021-03-09 16:59:59", "title": "AbbVie and Roche Will be Hardest Hit by Patent Expirations", "image": "https://cdn.snapi.dev/images/v1/z/g/drugs26-715965.jpg", "site": "GuruFocus", "text": "Top-selling drugs from AbbVie Inc.(NYSE:ABBV) and Roche (RHHBY) head the list of medications that will lose patent protection this year. How the losses affect the companies' bottom lines\u2014and perhaps their share price\u2014will depend on how fast generic competitors encroach on their market share, how well other products fill any gaps and the success companies have in protecting their brand name drugs via creative methods.", "url": "https://www.gurufocus.com/news/1381772/abbvie-and-roche-will-be-hardest-hit-by-patent-expirations-"}, {"symbol": "ABBV", "publishedDate": "2021-03-09 06:50:05", "title": "5 Stocks to Watch Amid Continued Expansion in the Biotech Industry", "image": "https://cdn.snapi.dev/images/v1/z/y/drugs13-714244.jpg", "site": "Zacks Investment Research", "text": "The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)", "url": "https://www.zacks.com/stock/news/1275685/5-stocks-to-watch-amid-continued-expansion-in-the-biotech-industry"}, {"symbol": "ABBV", "publishedDate": "2021-03-09 06:09:00", "title": "Warren Buffett Just Bought These 3 High-Yield Dividend Stocks. Should You?", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6169432fsmiling-warren-buffett-tmfjpgw700opresize-714177.jpg", "site": "The Motley Fool", "text": "The Oracle of Omaha could be right about these recent picks -- at least for income-seeking investors.", "url": "https://www.fool.com/investing/2021/03/09/warren-buffett-just-bought-these-3-high-yield-divi/"}, {"symbol": "ABBV", "publishedDate": "2021-03-05 13:52:34", "title": "Big call buying in this biopharma stock", "image": "https://cdn.snapi.dev/images/v1/d/o/dodk222-711023.", "site": "CNBC Television", "text": "\"Halftime Report\" trader Pete Najarian spots unusual activity in the options market", "url": "https://www.youtube.com/watch?v=zQgxnTwQorY"}, {"symbol": "ABBV", "publishedDate": "2021-03-05 13:18:55", "title": "Top Stocks To Buy In March", "image": "https://cdn.snapi.dev/images/v1/t/o/top-stocks-to-buy-in-march-710944.jpg", "site": "Forbes", "text": "Tech investors have been running for the hills lately, with the Nasdaq giving up all of its 2021 gains. In the meantime, Q.ai's AI systems have found the top trending stocks this month to beat the market.", "url": "https://www.forbes.com/sites/qai/2021/03/05/top-stocks-to-buy-in-march/"}, {"symbol": "ABBV", "publishedDate": "2021-03-05 12:11:44", "title": "Why Is AbbVie (ABBV) Down 2.7% Since Last Earnings Report?", "image": "https://cdn.snapi.dev/images/v1/e/c/drugs36-710782.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?", "url": "https://www.zacks.com/stock/news/1274312/why-is-abbvie-abbv-down-27-since-last-earnings-report"}, {"symbol": "ABBV", "publishedDate": "2021-03-03 16:39:06", "title": "AbbVie Inc. (ABBV) Management Presents at Cowen 41st Annual Health Care Conference (Transcript)", "image": "https://cdn.snapi.dev/images/v1/z/e/transcript44-706904.jpg", "site": "Seeking Alpha", "text": "AbbVie Inc. (ABBV) Management Presents at Cowen 41st Annual Health Care Conference (Transcript)", "url": "https://seekingalpha.com/article/4411216-abbvie-inc-abbv-management-presents-cowen-41st-annual-health-care-conference-transcript"}, {"symbol": "ABBV", "publishedDate": "2021-03-03 15:59:48", "title": "The 91 Kiplinger 'Top Dividend Stocks On Earth' March Update", "image": "https://cdn.snapi.dev/images/v1/q/m/drugs8-706709.jpg", "site": "Seeking Alpha", "text": "The 91 Kiplinger 'Top Dividend Stocks On Earth' March Update", "url": "https://seekingalpha.com/article/4411171-91-kiplinger-top-dividend-stocks-on-earth-march-update"}, {"symbol": "ABBV", "publishedDate": "2021-03-03 05:31:49", "title": "7 Great Dividend Stocks Outside the Energy Sector", "image": "https://cdn.snapi.dev/images/v1/r/s/top-stocks-to-buy-today-as-rising-markets-kick-off-shortened-trading-week-705137.jpg", "site": "InvestorPlace", "text": "Dividend stocks come in many flavors although investors may associate them primarily with the energy sector. These seven stocks cross industries.", "url": "https://investorplace.com/2021/03/7-great-dividend-stocks-outside-the-energy-sector/"}, {"symbol": "ABBV", "publishedDate": "2021-03-02 11:18:32", "title": "AbbVie To Beef Up Neurology Pipeline With Option To Add Parkinson's Candidate", "image": "https://cdn.snapi.dev/images/v1/p/a/drugs41-703815.jpg", "site": "Benzinga", "text": "AbbVie Inc\u00a0(NYSE:\u00a0ABBV) has\u00a0landed an option to buy Mitokinin\u00a0upon completing IND-enabling studies on the latter's lead PINK1 compound for Parkinson's disease. Mitokinin's novel PINK1 compounds selectively increase the activity of PINK1, a master regulator of mitochondrial quality control that is genetically linked to Parkinson's disease.", "url": "https://www.benzinga.com/general/biotech/21/03/19939920/abbvie-to-beef-up-neurology-pipeline-with-option-to-add-parkinsons-candidate"}, {"symbol": "ABBV", "publishedDate": "2021-03-02 10:00:06", "title": "Berkshire: Warren Buffett Does Buybacks, Earnings Remain Strong", "image": "https://cdn.snapi.dev/images/v1/w/q/drugs36-703605.jpg", "site": "Seeking Alpha", "text": "Berkshire: Warren Buffett Does Buybacks, Earnings Remain Strong", "url": "https://seekingalpha.com/article/4410535-berkshire-buffett-buybacks-earnings-remain-strong"}, {"symbol": "ABBV", "publishedDate": "2021-03-02 06:01:00", "title": "Warren Buffett and Cathie Wood Just Bought This Juicy Dividend Stock. Should You?", "image": "https://cdn.snapi.dev/images/v1/1/u/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6158362f2-arrows-on-gold-target-with-dollar-signjpgw700opresize-702797.jpg", "site": "The Motley Fool", "text": "There's a pretty good chance the answer is \"yes.\"", "url": "https://www.fool.com/investing/2021/03/02/warren-buffett-and-cathie-wood-just-bought-this-ju/"}, {"symbol": "ABBV", "publishedDate": "2021-03-01 13:26:00", "title": "AbbVie Remains A Buy", "image": "https://cdn.snapi.dev/images/v1/d/d/drugs20-701568.jpg", "site": "Seeking Alpha", "text": "AbbVie's respective adjusted diluted EPS and FCF payout ratios of 44.7% and 46.0% strike a great balance between deleveraging and rewarding shareholders with generous dividend increases. Even with COVID headwinds, AbbVie generated 3.3% YoY operational revenue growth and 18.1% YoY adjusted diluted EPS growth in 2020.", "url": "https://seekingalpha.com/article/4410347-abbvie-remains-buy"}, {"symbol": "ABBV", "publishedDate": "2021-03-01 12:57:05", "title": "New Benjamin Graham List Names, 3 Ideal Dogs For March", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5805032fcoronavirus-stock-market-xaoojydjpgw700opresize-701537.jpg", "site": "Seeking Alpha", "text": "These 70 Graham Stocks were screened for revenue, assets, long-term-debt, and EPS growth as of Feb. 25, 2021, based on Graham's established criteria. Of the 70, representing all eleven Morningstar Sectors, 40 pay dividends. Broker targeted top 10 Graham dividend-paying net-gainers ranged 9.08%-26.73% topped by RGR and DHI as of 2/25/21.", "url": "https://seekingalpha.com/article/4410349-graham-dividend-value-stocks"}, {"symbol": "ABBV", "publishedDate": "2021-03-01 12:30:27", "title": "MORF Stock: Why Little-Known Morphic Holdings Is Up 100% Today", "image": "https://cdn.snapi.dev/images/v1/r/u/drugs18-701414.jpg", "site": "InvestorPlace", "text": "Little-known MORF stock is rocketing higher after Morphic Holdings shared positive interim data from a Phase 1 clinical trial. The post MORF Stock: Why Little-Known Morphic Holdings Is Up 100% Today appeared first on InvestorPlace.", "url": "https://investorplace.com/2021/03/morf-stock-why-little-known-morphic-holdings-is-up-100-today/"}, {"symbol": "ABBV", "publishedDate": "2021-03-01 11:52:26", "title": "7 Safe Stocks You Can Hold Onto Forever", "image": "https://cdn.snapi.dev/images/v1/y/k/computer-electronic36-701315.jpg", "site": "InvestorPlace", "text": "Euphoric markets are widening the gap between value and growth investments. Let's take a look at safe stocks to buy and hold forever.", "url": "https://investorplace.com/2021/03/safe-stocks-to-buy-7-safe-stocks-you-can-hold-onto-forever/"}, {"symbol": "ABBV", "publishedDate": "2021-02-27 09:45:00", "title": "5 Undervalued Income Stocks That Offer Safety", "image": "https://cdn.snapi.dev/images/v1/y/v/drugs48-699578.jpg", "site": "Seeking Alpha", "text": "5 Undervalued Income Stocks That Offer Safety", "url": "https://seekingalpha.com/article/4409609-rising-yields-threaten-market-darlings-are-5-undervalued-income-stocks-offer-safety"}, {"symbol": "ABBV", "publishedDate": "2021-02-26 13:42:55", "title": "3 Of The 5 Fastest-Growing Dividend Aristocrats May Offer Double Digit Returns", "image": "https://cdn.snapi.dev/images/v1/a/q/rallyrally-th5n29tpr7-698861.jpg", "site": "Seeking Alpha", "text": "The top 5 fastest-growing dividend aristocrats have grown their dividends at almost double the rate of NOBL. 3 of the top 5 fastest-growing dividend aristocrats may offer double-digit returns over the next 3 years.", "url": "https://seekingalpha.com/article/4409482-fastest-growing-dividend-aristocrats"}, {"symbol": "ABBV", "publishedDate": "2021-02-25 16:53:43", "title": "Prometheus Biosciences Starts $125 Million IPO Plan", "image": "https://cdn.snapi.dev/images/v1/0/c/drugs24-697042.jpg", "site": "Seeking Alpha", "text": "Prometheus Biosciences Starts $125 Million IPO Plan", "url": "https://seekingalpha.com/article/4409134-prometheus-biosciences-starts-125-million-ipo-plan"}, {"symbol": "ABBV", "publishedDate": "2021-02-25 13:43:26", "title": "AbbVie's Allergan Files US Application AGN-190584 For Presbyopia", "image": "https://cdn.snapi.dev/images/v1/y/a/drugs20.jpg", "site": "Benzinga", "text": "Allergan, an\u00a0AbbVie Inc\u00a0(NYSE:\u00a0ABBV), has\u00a0submitted a marketing application\u00a0to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the application by the end of 2021.", "url": "https://www.benzinga.com/general/biotech/21/02/19859576/abbvies-allergan-files-us-application-agn-190584-for-presbyopia"}, {"symbol": "ABBV", "publishedDate": "2021-02-25 07:12:38", "title": "AbbVie's Humira Gets FDA Approval For Pediatric Ulcerative Colitis", "image": "https://cdn.snapi.dev/images/v1/i/y/drugs5.jpg", "site": "Benzinga", "text": "The FDA has approved\u00a0AbbVie Inc's\u00a0(NYSE:\u00a0ABBV) Humira (adalimumab) to treat moderately to severely active ulcerative colitis in pediatric patients five years and older. Approved dosing for HUMIRA will be determined based on the child's weight.", "url": "https://www.benzinga.com/general/biotech/21/02/19847177/abbvies-humira-gets-fda-approval-for-pediatric-ulcerative-colitis"}, {"symbol": "ABBV", "publishedDate": "2021-02-24 19:14:00", "title": "HUMIRA\u00ae (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis", "image": "https://cdn.snapi.dev/images/v1/7/m/press15---u1rrhxu7be.jpg", "site": "PRNewsWire", "text": "NORTH CHICAGO, Ill., Feb. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA\u00ae (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. In...", "url": "https://www.prnewswire.com/news-releases/humira-adalimumab-receives-fda-approval-to-treat-pediatric-patients-living-with-moderately-to-severely-active-ulcerative-colitis-301235101.html"}, {"symbol": "ABBV", "publishedDate": "2021-02-23 17:25:05", "title": "2 Large Cap Stocks to Buy for Income and Growth Amid Tech Volatility", "image": "https://cdn.snapi.dev/images/v1/i/h/sosk111.jpg", "site": "Zacks Investment Research", "text": "Investors might want to add a few large cap names outside of the tech world that also provide income through solid dividend yields.", "url": "https://www.zacks.com/stock/news/1268343/2-large-cap-stocks-to-buy-for-income-and-growth-amid-tech-volatility"}, {"symbol": "ABBV", "publishedDate": "2021-02-22 16:59:29", "title": "GuruFocus Announces 3 Winners of 4th-Quarter Warren Buffett Contest", "image": "https://cdn.snapi.dev/images/v1/v/n/drugs24.jpg", "site": "GuruFocus", "text": "GuruFocus is proud to announce that there were three winners of the fourth-quarter Warren Buffett (Trades, Portfolio) contest: Richday101, Chihin and Nicola Guida. Richday101 and Chihin guessed correctly that Buffett (or Ted Weschler, or Todd Combs) purchased AbbVie Inc. (NYSE:ABBV), Merck & Co. Inc. (NYSE:MRK) and Bristol-Myers Squibb Co. (NYSE:BMY).", "url": "https://www.gurufocus.com/news/1366520/gurufocus-announces-3-winners-of-4thquarter-warren-buffett-contest"}, {"symbol": "ABBV", "publishedDate": "2021-02-22 14:16:15", "title": "3 Big Yield Opportunities", "image": "https://cdn.snapi.dev/images/v1/6/l/what-will-the-stock-market-return-in-2020.jpg", "site": "Seeking Alpha", "text": "Prudential Financial, AbbVie, and Franklin Resources currently have the highest dividend yields in the portfolio. Prudential, AbbVie, and Franklin post a 5.7%, 4.8%, and 4.3% dividend rate respectively.", "url": "https://seekingalpha.com/article/4407959-3-biggest-yields-in-dividends-500"}, {"symbol": "ABBV", "publishedDate": "2021-02-22 12:55:24", "title": "AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?", "image": "https://cdn.snapi.dev/images/v1/t/y/drugs13---rxk7x2q1kd.jpg", "site": "Zacks Investment Research", "text": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?", "url": "https://www.zacks.com/stock/news/1267427/abbvie-abbv-is-a-top-dividend-stock-right-now-should-you-buy"}, {"symbol": "ABBV", "publishedDate": "2021-02-22 12:29:42", "title": "AbbVie's Upadacitinib Shows Clinical Benefit In Second Late-Stage Ulcerative Colitis Study", "image": "https://cdn.snapi.dev/images/v1/e/q/drugs11---jtqueqbhoz.jpg", "site": "Benzinga", "text": "AbbVie Inc\u00a0(NYSE:\u00a0ABBV) announces data from the second Phase 3 study,\u00a0U-ACCOMPLISH, evaluating upadacitinib in patients with moderate to severe ulcerative colitis. The study met the primary and secondary endpoints.", "url": "https://www.benzinga.com/general/biotech/21/02/19775289/abbvies-upadacitinib-shows-clinical-benefit-in-second-late-stage-ulcerative-colitis-study"}, {"symbol": "ABBV", "publishedDate": "2021-02-22 08:45:00", "title": "Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ\u2122) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients", "image": "https://cdn.snapi.dev/images/v1/b/w/press14---t2bqlenkq4.jpg", "site": "PRNewsWire", "text": "NORTH CHICAGO, Ill., Feb. 22, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints in the Phase 3 induction study, U-ACCOMPLISH.1 In the...", "url": "https://www.prnewswire.com/news-releases/second-phase-3-induction-study-confirms-upadacitinib-rinvoq-improved-clinical-endoscopic-and-histologic-outcomes-in-ulcerative-colitis-patients-301231986.html"}, {"symbol": "ABBV", "publishedDate": "2021-02-21 06:33:00", "title": "Is It Too Late to Buy AbbVie Stock?", "image": "https://cdn.snapi.dev/images/v1/n/a/102244615-abbvie.jpg", "site": "The Motley Fool", "text": "In a market where many stocks look overvalued, this company has proven that there are still bargains to be found.", "url": "https://www.fool.com/investing/2021/02/21/is-it-too-late-to-buy-abbvie-stock/"}, {"symbol": "ABBV", "publishedDate": "2021-02-21 05:30:00", "title": "Ready to Supercharge Your Passive Income? 3 Dividend Stocks You Can't Go Wrong With", "image": "https://cdn.snapi.dev/images/v1/d/w/dwdf223-8---p4islbbzwh.jpg", "site": "The Motley Fool", "text": "Investing in these stocks could result in hundreds or thousands of dollars in passive income.", "url": "https://www.fool.com/investing/2021/02/21/ready-to-supercharge-your-passive-income-3-dividen/"}, {"symbol": "ABBV", "publishedDate": "2021-02-20 07:18:00", "title": "It's Already Doubled in 2021, and This Healthcare Juggernaut Is Just Getting Started", "image": "https://cdn.snapi.dev/images/v1/c/4/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6139452fgetty-female-dermatologistjpgw700opresize.jpg", "site": "The Motley Fool", "text": "Dermtech stock is up over 130% so far in 2021, and increased insurance acceptance is just one reason it could be a five-bagger in the next five years.", "url": "https://www.fool.com/investing/2021/02/20/its-already-doubled-in-2021-and-this-healthcare-ju/"}, {"symbol": "ABBV", "publishedDate": "2021-02-19 13:34:32", "title": "Final Trades: Abbvie, Waste Management, American Tower & more", "image": "https://cdn.snapi.dev/images/v1/d/d/ddo2g32.", "site": "CNBC Television", "text": "The \"Halftime Report\" traders give their top picks to watch for the second half.", "url": "https://www.youtube.com/watch?v=37Gz561S0iI"}, {"symbol": "ABBV", "publishedDate": "2021-02-19 10:42:50", "title": "Evolus Shares Surge After Settling Jeuveau Related Litigation With AbbVie, Medytox", "image": "https://cdn.snapi.dev/images/v1/q/i/drugs16.jpg", "site": "Benzinga", "text": "Evolus Inc\u00a0(NASDAQ:\u00a0EOLS),\u00a0AbbVie Inc\u00a0(NYSE:\u00a0ABBV), and\u00a0Medytox\u00a0announced settlement agreements to\u00a0fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau. It is a prescription medicine injected into muscles and used in adults temporarily to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).", "url": "https://www.benzinga.com/general/biotech/21/02/19750128/evolus-shares-surge-after-settling-jeuveau-related-litigation-with-abbvie-medytox"}, {"symbol": "ABBV", "publishedDate": "2021-02-19 05:19:00", "title": "Own Big Stock Winners? Handle Them the Warren Buffett Way", "image": "https://cdn.snapi.dev/images/v1/9/v/top-stocks-to-buy-today-as-rising-markets-kick-off-shortened-trading-week.jpg", "site": "The Motley Fool", "text": "If you own winning stocks, Berkshire Hathaway's legendary investor has a valuable lesson for you.", "url": "https://www.fool.com/investing/2021/02/19/own-big-stock-winners-handle-them-the-warren-buffe/"}, {"symbol": "ABBV", "publishedDate": "2021-02-19 02:41:08", "title": "Healthcare: A Wide Choice Of Large And Well-Established Companies", "image": "https://cdn.snapi.dev/images/v1/d/r/drugs49---wlnaj5cg4o.jpg", "site": "Seeking Alpha", "text": "The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets.", "url": "https://seekingalpha.com/article/4407320-healthcare-a-wide-choice-of-large-and-well-established-companies"}, {"symbol": "ABBV", "publishedDate": "2021-02-17 21:13:03", "title": "3 Great Blue Chip Dividend Stocks to Buy Now with Dow at Records", "image": "https://cdn.snapi.dev/images/v1/a/q/computer-electronic2---8epa9zzxr0.jpg", "site": "Zacks Investment Research", "text": "Investors should always be on the lookout for ways to diversify and bolster their portfolios. One great place to start is with large cap stocks that pay solid dividends.", "url": "https://www.zacks.com/stock/news/1265011/3-great-blue-chip-dividend-stocks-to-buy-now-with-dow-at-records"}, {"symbol": "ABBV", "publishedDate": "2021-02-17 11:11:17", "title": "Buffett's Berkshire Buys Oil, Heathcare and Telecoms in 4th Quarter", "image": "https://cdn.snapi.dev/images/v1/z/x/womanusingwhiteiphone-8ebc119ec83149b8bbf5b52787d25994.jpg", "site": "GuruFocus", "text": "Berkshire Hathaway's (NYSE:BRK.A) (NYSE:BRK.B) latest 13F report was filed last night. The report detailed the conglomerate's equity positions at the end of December 2020.", "url": "https://www.gurufocus.com/news/1361902/buffetts-berkshire-buys-oil-heathcare-and-telecoms-in-4th-quarter"}, {"symbol": "ABBV", "publishedDate": "2021-02-17 06:36:00", "title": "3 Top Healthcare Stocks That Can Make You Richer in 2021 (and Beyond)", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6132272fgettyimages-1136527903jpgw700opresize.jpg", "site": "The Motley Fool", "text": "What's better than rapid growth and a dividend payment?", "url": "https://www.fool.com/investing/2021/02/17/3-top-healthcare-stocks-that-can-make-you-richer-i/"}, {"symbol": "ABBV", "publishedDate": "2021-02-16 18:26:00", "title": "Warren Buffett's Berkshire Hathaway Traded Stock in Pharma, Banks", "image": "https://cdn.snapi.dev/images/v1/c/8/bp-aa853-buffet-b620-20170817102833.jpg", "site": "Barrons", "text": "Berkshire Hathaway disclosed fourth-quarter buys of Merck, Bristol-Myers, and AbbVie, while exiting Pfizer.", "url": "https://www.barrons.com/articles/warren-buffetts-berkshire-hathaway-sold-pfizer-gm-stock-51613517983"}, {"symbol": "ABBV", "publishedDate": "2021-02-16 16:44:00", "title": "Berkshire Hathaway ups drug-stock stakes while trimming Apple", "image": "https://cdn.snapi.dev/images/v1/l/w/stocksnetapp1.jpg", "site": "Market Watch", "text": "Warren Buffett's Berkshire Hathaway Inc. BRK.ABRK.B loaded up on drug, telecom and oil stocks while trimming its position in Apple Inc. AAPL over the past quarter, according to a Securities and Exchange Commission filing late Tuesday. Berkshire increased its stake in Abbvie Inc. ABBV by 20%, Bristol-Myers Squibb Co. BMY by 11%, and Merck & Co. MRK by 28%.", "url": "https://www.marketwatch.com/story/berkshire-hathaway-ups-drug-stock-stakes-while-trimming-apple-11613511846"}, {"symbol": "ABBV", "publishedDate": "2021-02-16 15:12:50", "title": "2 Of The 5 Highest Yielding Aristocrats Offer Potential Upside Right Now (Video)", "image": "https://cdn.snapi.dev/images/v1/v/a/best-stocks-to-buy-as-markets-rally-despite-elevated-volatility.jpg", "site": "Seeking Alpha", "text": "The top 5 highest yielding Dividend Aristocrats offer dividend yields double those of the member index. AT&T has a potential 20% upside to go along with their 7% dividend yield.", "url": "https://seekingalpha.com/article/4406400-2-of-5-highest-yielding-aristocrats-offer-potential-upside-right-now-video"}, {"symbol": "ABBV", "publishedDate": "2021-02-16 09:07:45", "title": "9 Safe Stocks for Your 401k", "image": "https://cdn.snapi.dev/images/v1/x/f/drugs20.jpg", "site": "InvestorPlace", "text": "While everybody is chasing the moon and the stars, it might be prudent for you to consider these safe stocks for your 401K. The post 9 Safe Stocks for Your 401k appeared first on InvestorPlace.", "url": "https://investorplace.com/2021/02/9-safe-stocks-for-your-401k/"}, {"symbol": "ABBV", "publishedDate": "2021-02-16 08:00:00", "title": "AbbVie: Inexpensive, High-Yield Dividend Aristocrat With Strong Execution", "image": "https://cdn.snapi.dev/images/v1/5/7/drugs18.jpg", "site": "Seeking Alpha", "text": "AbbVie: Inexpensive, High-Yield Dividend Aristocrat With Strong Execution", "url": "https://seekingalpha.com/article/4406206-abbvie-inexpensive-high-yield-dividend-aristocrat-with-strong-execution"}, {"symbol": "ABBV", "publishedDate": "2021-02-15 09:00:00", "title": "Why Growth Matters - In Plain English", "image": "https://cdn.snapi.dev/images/v1/o/d/drugs11.jpg", "site": "Seeking Alpha", "text": "We explain why growth is important, with visually appealing demonstrations.", "url": "https://seekingalpha.com/article/4406084-why-growth-matters-in-plain-english"}, {"symbol": "ABBV", "publishedDate": "2021-02-14 14:00:34", "title": "5 Closed-End Fund Buys To Get The Income Snowball Rolling For 2021", "image": "https://cdn.snapi.dev/images/v1/z/o/drugs8.jpg", "site": "Seeking Alpha", "text": "5 Closed-End Fund Buys To Get The Income Snowball Rolling For 2021", "url": "https://seekingalpha.com/article/4406053-5-closed-end-fund-buys-get-income-snowball-rolling-2021"}, {"symbol": "ABBV", "publishedDate": "2021-02-14 07:45:00", "title": "3 Embarrassingly Cheap Dividend Stocks", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6128312fgettyimages-1089395350jpgw700opresize.jpg", "site": "The Motley Fool", "text": "Cisco and two other companies pay high yields and trade at discount valuations.", "url": "https://www.fool.com/investing/2021/02/14/3-embarrassingly-cheap-dividend-stocks/"}, {"symbol": "ABBV", "publishedDate": "2021-02-13 17:23:14", "title": "AbbVie shares continue to trade in a bull market after better than expected Q4 results", "image": "https://cdn.snapi.dev/images/v1/m/x/1579183057911.jpg", "site": "Invezz", "text": "AbbVie (NYSE: ABBV) shares weakened last week by more than 3%, and the current price stands around $104. According to analysts, it's not hard to find reasons to invest in AbbVie, and as long the price is above $90, there is no risk of the trend reversal.", "url": "https://invezz.com/news/2021/02/13/abbvie-shares-continue-to-trade-in-a-bull-market-after-better-than-expected-q4-results/"}, {"symbol": "ABBV", "publishedDate": "2021-02-12 09:00:20", "title": "This Huge American Company Didn't Exist a Decade Ago", "image": "https://cdn.snapi.dev/images/v1/s/l/drugs37.jpg", "site": "24/7 Wall Street", "text": "Rome was not built in a day, and neither are multibillion-dollar corporations. The Fortune 500 list of the largest U.S.", "url": "https://247wallst.com/healthcare-business/2021/02/12/this-huge-american-company-didnt-exist-a-decade-ago/"}, {"symbol": "ABBV", "publishedDate": "2021-02-11 12:30:21", "title": "February 2021 Undervaluation - Financials, Real Estate, Industrials/IT And Pharma", "image": "https://cdn.snapi.dev/images/v1/s/e/drugs28.jpg", "site": "Seeking Alpha", "text": "February 2021 Undervaluation - Financials, Real Estate, Industrials/IT And Pharma", "url": "https://seekingalpha.com/article/4405272-february-2021-undervaluation-financials-real-estate-industrials-pharma"}, {"symbol": "ABBV", "publishedDate": "2021-02-11 12:06:18", "title": "AbbVie (ABBV) Inks CAR T Deal, Gets Botox Label Expansion Nod", "image": "https://cdn.snapi.dev/images/v1/h/g/drugs27.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) signs an agreement to research and develop two new CAR-T cell therapies. The FDA approves label expansion of Botox for pediatric patients.", "url": "https://www.zacks.com/stock/news/1261741/abbvie-abbv-inks-car-t-deal-gets-botox-label-expansion-nod"}, {"symbol": "ABBV", "publishedDate": "2021-02-10 17:54:20", "title": "Guess Which Stocks Warren Buffett Bought: 4th-Quarter Contest", "image": "https://cdn.snapi.dev/images/v1/t/q/drugs8---xtuzpuddff.jpg", "site": "GuruFocus", "text": "GuruFocus runs a contest every quarter in which people guess the stocks they think Warren Buffett (Trades, Portfolio) might have bought. The fourth-quarter contest begins today.", "url": "https://www.gurufocus.com/news/1356156/guess-which-stocks-warren-buffett-bought-4thquarter-contest"}, {"symbol": "ABBV", "publishedDate": "2021-02-10 08:15:00", "title": "AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products", "image": "https://cdn.snapi.dev/images/v1/q/q/press20---ia7svegrqi.jpg", "site": "PRNewsWire", "text": "NORTH CHICAGO, Ill. and BERKELEY, Calif., Feb. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the...", "url": "https://www.prnewswire.com/news-releases/abbvie-and-caribou-biosciences-announce-collaboration-and-license-agreement-for-car-t-cell-products-301225509.html"}, {"symbol": "ABBV", "publishedDate": "2021-02-09 18:47:05", "title": "3 Ways To Invest The $1,400 Stimulus Check", "image": "https://cdn.snapi.dev/images/v1/9/p/drugs24.jpg", "site": "Seeking Alpha", "text": "3 Ways To Invest The $1,400 Stimulus Check", "url": "https://seekingalpha.com/article/4404741-3-ways-to-invest-stimulus-check"}, {"symbol": "ABBV", "publishedDate": "2021-02-09 12:53:32", "title": "What Makes AbbVie (ABBV) a New Buy Stock", "image": "https://cdn.snapi.dev/images/v1/n/u/drugs14---r8p5pf26gl.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.", "url": "https://www.zacks.com/stock/news/1260055/what-makes-abbvie-abbv-a-new-buy-stock"}, {"symbol": "ABBV", "publishedDate": "2021-02-08 17:00:31", "title": "Coherus Deal Signals Pivot to New and Crowded Market", "image": "https://cdn.snapi.dev/images/v1/f/w/drugs46.jpg", "site": "GuruFocus", "text": "Shares of Redwood City, California-based Coherus BioSciences Inc. (NASDAQ:CHRS) are up about 13% just a week after announcing it has cut a $150 million deal with Chinese drugmaker Junshi Biosciences Co. Ltd. (HKSE:01877).", "url": "https://www.gurufocus.com/news/1352992/coherus-deal-signals-pivot-to-new-and-crowded-market"}, {"symbol": "ABBV", "publishedDate": "2021-02-07 06:01:00", "title": "3 Top Dividend Stocks to Buy Right Now", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6107232fdividends-on-sticky-notejpgw700opresize.jpg", "site": "The Motley Fool", "text": "These stocks offer great dividends and more.", "url": "https://www.fool.com/investing/2021/02/07/3-top-dividend-stocks-to-buy-right-now/"}, {"symbol": "ABBV", "publishedDate": "2021-02-04 18:08:27", "title": "My Best Advice to New Value Investors", "image": "https://cdn.snapi.dev/images/v1/m/2/drugs3.jpg", "site": "Zacks Investment Research", "text": "New to stocks? 7 tips to becoming a better value investor.", "url": "https://www.zacks.com/stock/news/1257817/my-best-advice-to-new-value-investors"}, {"symbol": "ABBV", "publishedDate": "2021-02-04 12:51:50", "title": "Why AbbVie (ABBV) is a Great Dividend Stock Right Now", "image": "https://cdn.snapi.dev/images/v1/n/8/drugs43.jpg", "site": "Zacks Investment Research", "text": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?", "url": "https://www.zacks.com/stock/news/1257661/why-abbvie-abbv-is-a-great-dividend-stock-right-now"}, {"symbol": "ABBV", "publishedDate": "2021-02-03 19:58:05", "title": "AbbVie Inc.'s (ABBV) CEO Richard Gonzalez on Q4 2020 Results - Earnings Call Transcript", "image": "https://cdn.snapi.dev/images/v1/e/4/transcript45.jpg", "site": "Seeking Alpha", "text": "AbbVie Inc.'s (ABBV) CEO Richard Gonzalez on Q4 2020 Results - Earnings Call Transcript", "url": "https://seekingalpha.com/article/4403215-abbvie-inc-s-abbv-ceo-richard-gonzalez-on-q4-2020-results-earnings-call-transcript"}, {"symbol": "ABBV", "publishedDate": "2021-02-03 17:18:54", "title": "4 Top Stock Trades for Thursday: AMZN, SPOT, BMY, ABBV", "image": "https://cdn.snapi.dev/images/v1/y/6/top-stocks-to-buy-today-as-markets-respond-to-mixed-sentiment.jpg", "site": "InvestorPlace", "text": "Amazon, Spotify, Bristol-Myers Squibb and AbbVie were our top stock trades for Thursday. Let's look at the charts of these earnings movers.", "url": "https://investorplace.com/2021/02/4-top-stock-trades-for-thursday-amzn-spot-bmy-abbv/"}, {"symbol": "ABBV", "publishedDate": "2021-02-03 11:22:04", "title": "AbbVie (ABBV) Q4 Earnings & Sales Top, 2021 Outlook Bright", "image": "https://cdn.snapi.dev/images/v1/u/e/drugs7.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) beats on fourth-quarter 2020 earnings and revenues. Shares up in pre-market trading.", "url": "https://www.zacks.com/stock/news/1256769/abbvie-abbv-q4-earnings-sales-top-2021-outlook-bright"}, {"symbol": "ABBV", "publishedDate": "2021-02-03 09:51:17", "title": "AbbVie (ABBV) Q4 Earnings and Revenues Surpass Estimates", "image": "https://cdn.snapi.dev/images/v1/l/j/drugs3.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) delivered earnings and revenue surprises of 2.46% and 0.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?", "url": "https://www.zacks.com/stock/news/1256648/abbvie-abbv-q4-earnings-and-revenues-surpass-estimates"}, {"symbol": "ABBV", "publishedDate": "2021-02-03 07:54:46", "title": "AbbVie: Q4 Earnings Insights", "image": "https://cdn.snapi.dev/images/v1/7/5/drugs48.jpg", "site": "Benzinga", "text": "Shares of AbbVie (NYSE:ABBV) rose 1.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 32.13% over the past year to $2.92, which beat the estimate of $2.85.", "url": "https://www.benzinga.com/news/earnings/21/02/19463017/abbvie-q4-earnings-insights"}, {"symbol": "ABBV", "publishedDate": "2021-02-03 07:50:51", "title": "AbbVie stock rallies after profit and revenue beats, upbeat outlook", "image": "https://cdn.snapi.dev/images/v1/y/0/drugs47.jpg", "site": "Market Watch", "text": "Shares of AbbVie Inc. rallied 1.7% in premarket trading Wednesday, after the biopharmaceutical company reported fourth-quarter profit and revenue that beat expectations, and provided an upbeat full-year outlook. Net income dropped to $36 million, or 1 cent a share, from $2.80 billion, or $1.88 a share, in the year-ago period.", "url": "https://www.marketwatch.com/story/abbvie-stock-rallies-after-profit-and-revenue-beats-upbeat-outlook-2021-02-03"}, {"symbol": "ABBV", "publishedDate": "2021-02-03 07:38:00", "title": "AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results", "image": "https://cdn.snapi.dev/images/v1/1/z/press17.jpg", "site": "PRNewsWire", "text": "NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. \"We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite...", "url": "https://www.prnewswire.com/news-releases/abbvie-reports-full-year-and-fourth-quarter-2020-financial-results-301221231.html"}, {"symbol": "ABBV", "publishedDate": "2021-02-02 13:53:38", "title": "Bolt Biotherapeutics Aims For $150 Million U.S. IPO", "image": "https://cdn.snapi.dev/images/v1/e/g/drugs40---cng5gy0w3e.jpg", "site": "Seeking Alpha", "text": "Bolt Biotherapeutics has filed proposed terms for a $150 million IPO. The firm is developing antibody conjugate treatments for various cancers.", "url": "https://seekingalpha.com/article/4402758-bolt-biotherapeutics-aims-for-150-million-u-s-ipo"}, {"symbol": "ABBV", "publishedDate": "2021-02-02 10:12:05", "title": "Earnings Outlook for AbbVie", "image": "https://cdn.snapi.dev/images/v1/e/s/drugs31.jpg", "site": "Benzinga", "text": "On Wednesday, February 03, AbbVie (NYSE:ABBV) will release its latest earnings report. Here is Benzinga's outlook for the company.", "url": "https://www.benzinga.com/news/earnings/21/02/19444022/earnings-outlook-for-abbvie"}, {"symbol": "ABBV", "publishedDate": "2021-02-02 05:01:15", "title": "7 Pharmaceutical Stocks\u00a0With\u00a0Compelling Pipelines", "image": "https://cdn.snapi.dev/images/v1/i/o/drugs16---a9qjqt4zsq.jpg", "site": "InvestorPlace", "text": "Covid-19 vaccines are getting all the glory after multi-bagger returns last year but these seven pharmaceutical stocks have a strong future ahead. The post 7 Pharmaceutical Stocks\u00a0With\u00a0Compelling Pipelines appeared first on InvestorPlace.", "url": "https://investorplace.com/2021/02/7-pharmaceutical-stocks-with-compelling-pipelines/"}, {"symbol": "ABBV", "publishedDate": "2021-02-01 10:37:11", "title": "Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q4 Earnings?", "image": "https://cdn.snapi.dev/images/v1/s/x/drugs4.jpg", "site": "Zacks Investment Research", "text": "AbbVie's (ABBV) Q4 top line is expected to have witnessed a recovery in demand amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.", "url": "https://www.zacks.com/stock/news/1255184/will-humira-cancer-drugs-drive-abbvie-abbv-q4-earnings"}, {"symbol": "ABBV", "publishedDate": "2021-01-31 21:29:13", "title": "5.1% Yielding AbbVie Is A Safe Anti-Bubble Blue-Chip In A Dangerous Bubble Filled Market", "image": "https://cdn.snapi.dev/images/v1/g/q/despite-a-65-rally-abbvie-stock-looks-like-it-can-gain-more.jpg", "site": "Seeking Alpha", "text": "Today we're seeing some of the most extreme speculation in history, including bankrupt companies soaring 700% in a single day. The difference between speculation and investment is the long-term risk profile. Sound investing over time = guaranteed success, while speculating for long enough = guaranteed losses.", "url": "https://seekingalpha.com/article/4402338-5_1-yielding-abbvie-is-safe-anti-bubble-blue-chip-in-dangerous-bubble-filled-market"}, {"symbol": "ABBV", "publishedDate": "2021-01-31 14:10:24", "title": "AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio", "image": "https://cdn.snapi.dev/images/v1/s/m/drugs49.jpg", "site": "Seeking Alpha", "text": "AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio", "url": "https://seekingalpha.com/article/4402305-azurrx-officially-covidminus-19-play-right-dose-for-your-portfolio"}, {"symbol": "ABBV", "publishedDate": "2021-01-31 08:00:00", "title": "AbbVie Is A Buy Even After The Recent Run Up", "image": "https://cdn.snapi.dev/images/v1/r/t/drugs47.jpg", "site": "Seeking Alpha", "text": "AbbVie is quickly diversifying its business. It has a strong track record and attractive growth prospects.", "url": "https://seekingalpha.com/article/4402154-abbvie-is-buy-even-after-recent-run-up"}, {"symbol": "ABBV", "publishedDate": "2021-01-31 06:04:00", "title": "These Dividend Stocks Are Practically Money Machines", "image": "https://cdn.snapi.dev/images/v1/x/z/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6095412f100-bills-sheetsjpgw700opresize.jpg", "site": "The Motley Fool", "text": "You can count on the dividends flowing and growing with these stocks.", "url": "https://www.fool.com/investing/2021/01/31/these-dividend-stocks-are-practically-money-machin/"}, {"symbol": "ABBV", "publishedDate": "2021-01-29 20:18:03", "title": "Buy Pharma Giant AbbVie Stock Before Q4 Earnings for Dividend and Value?", "image": "https://cdn.snapi.dev/images/v1/a/v/drugs46.jpg", "site": "Zacks Investment Research", "text": "Let's check out AbbVie to see if investors might want to buy the stock ahead of its fourth quarter fiscal 2020 financial release that's due out before the opening bell on Wednesday, Feb. 3.", "url": "https://www.zacks.com/stock/news/1254637/buy-pharma-giant-abbvie-stock-before-q4-earnings-for-dividend-and-value"}, {"symbol": "ABBV", "publishedDate": "2021-01-29 11:17:13", "title": "Will Recovery in AbbVie's (ABBV) Earnings Continue in Q4?", "image": "https://cdn.snapi.dev/images/v1/x/o/drugs38.jpg", "site": "Zacks Investment Research", "text": "Recovery in AbbVie's (ABBV) revenues is likely to have continued in the fourth quarter. Investors focus is likely to be on 2021 guidance when the company reports results in the wake of rising cases.", "url": "https://www.zacks.com/stock/news/1254276/will-recovery-in-abbvies-abbv-earnings-continue-in-q4"}, {"symbol": "ABBV", "publishedDate": "2021-01-26 14:32:21", "title": "Ironwood Drug Makes All-Flop List for 2020", "image": "https://cdn.snapi.dev/images/v1/j/j/drugs5---dbvwnct2mi.jpg", "site": "GuruFocus", "text": "Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) has the dubious distinction of owning one of the 10 biggest drug trial flops of 2020, according to FierceBiotech. The Boston-based company's once-promising treatment for gastroesophageal reflux disease was relegated to the trash bin in September when it failed a phase 3 study.", "url": "https://www.gurufocus.com/news/1340949/ironwood-drug-makes-allflop-list-for-2020"}, {"symbol": "ABBV", "publishedDate": "2021-01-26 08:00:00", "title": "Things Could Get Ugly Quickly - Bob Iaccino Joins Alpha Trader (Podcast)", "image": "https://cdn.snapi.dev/images/v1/8/d/podc3.jpg", "site": "Seeking Alpha", "text": "Things Could Get Ugly Quickly - Bob Iaccino Joins Alpha Trader (Podcast)", "url": "https://seekingalpha.com/article/4400957-things-get-ugly-quickly-bob-iaccino-joins-alpha-trader-podcast"}, {"symbol": "ABBV", "publishedDate": "2021-01-26 07:16:00", "title": "2 Stocks I'll Hold Forever", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5805032fcoronavirus-stock-market-xaoojydjpgw700opresize.jpg", "site": "The Motley Fool", "text": "You'll get richer if you hold them too.", "url": "https://www.fool.com/investing/2021/01/26/2-stocks-ill-hold-forever/"}, {"symbol": "ABBV", "publishedDate": "2021-01-26 05:46:00", "title": "Warren Buffett's 3 Biggest Stock Picks for 2021", "image": "https://cdn.snapi.dev/images/v1/u/9/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6096112fbuffett-image-biggerjpgw700opresize.jpg", "site": "The Motley Fool", "text": "Here's what the Oracle of Omaha is betting on for the coming year.", "url": "https://www.fool.com/investing/2021/01/26/warren-buffetts-3-biggest-stock-picks-for-2021/"}, {"symbol": "ABBV", "publishedDate": "2021-01-26 05:44:53", "title": "3 Amazing Dividend Aristocrats To Buy With The Market At All-Time Highs", "image": "https://cdn.snapi.dev/images/v1/m/y/dwdf223-8.jpg", "site": "Seeking Alpha", "text": "The stimulus euphoria rally continues, with the S&P just notching another record high and becoming 39% historically overvalued. But in every market there are blue-chip bargains available, even among the legendary dividend aristocrats.", "url": "https://seekingalpha.com/article/4400941-3-amazing-dividend-aristocrats-to-buy-market-all-time-highs"}, {"symbol": "ABBV", "publishedDate": "2021-01-25 11:30:00", "title": "European Commission Approves AbbVie's RINVOQ\u2122 (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis", "image": "https://cdn.snapi.dev/images/v1/i/s/press20---kby6kvwrjf.jpg", "site": "PRNewsWire", "text": "NORTH CHICAGO, Ill., Jan. 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV), today announced that the European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor for the treatment of active psoriatic arthritis (PsA) in adult...", "url": "https://www.prnewswire.com/news-releases/european-commission-approves-abbvies-rinvoq-upadacitinib-for-the-treatment-of-psoriatic-arthritis-and-ankylosing-spondylitis-301214178.html"}, {"symbol": "ABBV", "publishedDate": "2021-01-22 08:15:13", "title": "AbbVie Is Raising Several Green Flags", "image": "https://cdn.snapi.dev/images/v1/r/s/m02d20200731t2i1527855028w940fhfwllplsqrlynxnpeg6u139.jpg", "site": "Seeking Alpha", "text": "AbbVie presents a unique investment opportunity and is poised to deliver strong returns. Market leadership in key growth markets and a robust and innovative pipeline are key factors to offset any erosion of HUMIRA sales.", "url": "https://seekingalpha.com/article/4400348-abbvie-is-raising-several-green-flags"}, {"symbol": "ABBV", "publishedDate": "2021-01-21 18:08:15", "title": "AbbVie, Roche, Glaxo Are Experts at Product Launches", "image": "https://cdn.snapi.dev/images/v1/p/e/drugs47.jpg", "site": "GuruFocus", "text": "Investors considering pharmaceutical and biotechnology companies might want to factor in one important piece of data into their analysis: A high percentage of new products fail to reach sales forecasts made by industry analysts. This is according to a report from global management consulting firm L.E.K.", "url": "https://www.gurufocus.com/news/1337843/abbvie-roche-glaxo-are-experts-at-product-launches"}, {"symbol": "ABBV", "publishedDate": "2021-01-21 11:00:51", "title": "F-star Therapeutics: New Biologics Platform For Immunotherapy", "image": "https://cdn.snapi.dev/images/v1/n/w/drugs39.jpg", "site": "Seeking Alpha", "text": "F-star Therapeutics: New Biologics Platform For Immunotherapy", "url": "https://seekingalpha.com/article/4400164-f-star-therapeutics-new-biologics-platform-for-immunotherapy"}, {"symbol": "ABBV", "publishedDate": "2021-01-20 18:48:23", "title": "AbbVie (ABBV) Gains But Lags Market: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/q/r/drugs34.jpg", "site": "Zacks Investment Research", "text": "In the latest trading session, AbbVie (ABBV) closed at $112.62, marking a +0.39% move from the previous day.", "url": "https://www.zacks.com/stock/news/1249432/abbvie-abbv-gains-but-lags-market-what-you-should-know"}, {"symbol": "ABBV", "publishedDate": "2021-01-19 09:05:12", "title": "Invest Like A Billionaire With High Yield: THW", "image": "https://cdn.snapi.dev/images/v1/m/g/drugs10---qzacpqqvmc.jpg", "site": "Seeking Alpha", "text": "Invest Like A Billionaire With High Yield: THW", "url": "https://seekingalpha.com/article/4399114-invest-like-billionaire-high-yield-thw"}, {"symbol": "ABBV", "publishedDate": "2021-01-18 10:35:20", "title": "AbbVie: Undervalued Dividend Aristocrat Offering A 4.77% Yield", "image": "https://cdn.snapi.dev/images/v1/n/b/102244615-abbvie.jpg", "site": "Seeking Alpha", "text": "AbbVie Inc. has an established eight-year track record of producing outstanding returns and superior dividend growth. Created a solid growth platform consisting of industry-leading drugs, a robust pipeline that will mitigate the impact of biosimilar competition.", "url": "https://seekingalpha.com/article/4399500-abbvie-undervalued-dividend-aristocrat-offering-4_77-yield"}, {"symbol": "ABBV", "publishedDate": "2021-01-15 07:00:00", "title": "3 Green Flags for AbbVie in 2021 and 1 Red Flag", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6083452fgettyimages-1240944355jpgw700opresize.jpg", "site": "The Motley Fool", "text": "AbbVie's portfolio of immunology drugs is getting a shot in the arm.", "url": "https://www.fool.com/investing/2021/01/15/3-green-flags-for-abbvie-in-2021-and-1-red-flag/"}, {"symbol": "ABBV", "publishedDate": "2021-01-14 18:48:17", "title": "AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/a/z/drugs43.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) closed at $111.63 in the latest trading session, marking a -0.73% move from the prior day.", "url": "https://www.zacks.com/stock/news/1246975/abbvie-abbv-dips-more-than-broader-markets-what-you-should-know"}, {"symbol": "ABBV", "publishedDate": "2021-01-14 06:10:00", "title": "3 Great Dividend Stocks That Are Simply Too Cheap to Ignore", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6079072fdividends-on-sticky-notejpgw700opresize.jpg", "site": "The Motley Fool", "text": "High dividend yields plus low valuations could be just the ticket for income-seeking investors.", "url": "https://www.fool.com/investing/2021/01/14/3-great-dividend-stocks-that-are-simply-too-cheap/"}, {"symbol": "ABBV", "publishedDate": "2021-01-13 14:51:59", "title": "7 Pharmaceutical Stocks With Exciting Plans for 2021", "image": "https://cdn.snapi.dev/images/v1/o/f/drugs28.jpg", "site": "InvestorPlace", "text": "Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.", "url": "https://investorplace.com/2021/01/7-pharmaceutical-stocks-with-exciting-plans-for-2021/"}, {"symbol": "ABBV", "publishedDate": "2021-01-13 11:17:07", "title": "AbbVie (ABBV) Inks Deal to Acquire Medical Device Company", "image": "https://cdn.snapi.dev/images/v1/t/p/drugs24.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) signs an agreement to acquire privately held Cypris Medical, including the latter's Xact device which is used for performing face and neck lifts.", "url": "https://www.zacks.com/stock/news/1245936/abbvie-abbv-inks-deal-to-acquire-medical-device-company"}, {"symbol": "ABBV", "publishedDate": "2021-01-13 09:11:00", "title": "These 3 Value Stocks Are Absurdly Cheap Right Now", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6076312fsale-discount-tagsjpgw700opresize.jpg", "site": "The Motley Fool", "text": "Investors have collectively made some misguided assumptions about the condition these companies are actually in.", "url": "https://www.fool.com/investing/2021/01/13/these-3-value-stocks-are-absurdly-cheap-right-now/"}, {"symbol": "ABBV", "publishedDate": "2021-01-13 06:03:00", "title": "3 Dividend Aristocrats to Buy Right Now", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6079032f3-gold-eggs-in-money-basketjpgw700opresize.jpg", "site": "The Motley Fool", "text": "These stocks are as solid as they come.", "url": "https://www.fool.com/investing/2021/01/13/3-dividend-aristocrats-to-buy-right-now/"}, {"symbol": "ABBV", "publishedDate": "2021-01-12 19:02:05", "title": "AbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)", "image": "https://cdn.snapi.dev/images/v1/x/d/transcript1---qbiz1swtql.jpg", "site": "Seeking Alpha", "text": "AbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)", "url": "https://seekingalpha.com/article/4398646-abbvie-inc-abbv-ceo-rick-gonzalez-presents-39th-annual-jpmorgan-virtual-healthcare-conference"}, {"symbol": "ABBV", "publishedDate": "2021-01-12 18:48:20", "title": "AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/0/u/drugs21.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) closed at $109.78 in the latest trading session, marking a +0.7% move from the prior day.", "url": "https://www.zacks.com/stock/news/1245456/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know"}, {"symbol": "ABBV", "publishedDate": "2021-01-11 18:48:10", "title": "AbbVie (ABBV) Gains As Market Dips: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/4/x/drugs2.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) closed at $109.02 in the latest trading session, marking a +1.63% move from the prior day.", "url": "https://www.zacks.com/stock/news/1244751/abbvie-abbv-gains-as-market-dips-what-you-should-know"}, {"symbol": "ABBV", "publishedDate": "2021-01-11 12:20:41", "title": "7 Hot Stocks That Will Keep You Energized With 3%-Plus Yields", "image": "https://cdn.snapi.dev/images/v1/1/m/what-will-the-stock-market-return-in-2020.jpg", "site": "InvestorPlace", "text": "These hot stocks combine healthy dividends with lasting brand names, making them some of the smartest picks on the market. The post 7 Hot Stocks That Will Keep You Energized With 3%-Plus Yields appeared first on InvestorPlace.", "url": "https://investorplace.com/2021/01/7-hot-stocks-that-will-keep-you-energized-with-three-percent-plus-yields/"}, {"symbol": "ABBV", "publishedDate": "2021-01-10 22:11:33", "title": "Dividend Diligence On AbbVie With Seeking Alpha", "image": "https://cdn.snapi.dev/images/v1/9/i/despite-a-65-rally-abbvie-stock-looks-like-it-can-gain-more.jpg", "site": "Seeking Alpha", "text": "Dividend Diligence On AbbVie With Seeking Alpha", "url": "https://seekingalpha.com/article/4398152-dividend-diligence-on-abbvie-seeking-alpha"}, {"symbol": "ABBV", "publishedDate": "2021-01-09 06:10:00", "title": "How Safe Is AbbVie's Dividend?", "image": "https://cdn.snapi.dev/images/v1/n/g/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5997802fman-looking-at-drawings-of-money-bags-and-question-marksjpgw700opresize.jpg", "site": "The Motley Fool", "text": "Don't jump to a conclusion too quickly.", "url": "https://www.fool.com/investing/2021/01/09/how-safe-is-abbvies-dividend/"}, {"symbol": "ABBV", "publishedDate": "2021-01-09 06:07:00", "title": "3 Stocks That Are Absurdly Cheap Right Now", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6072022frising-stock-pricejpgw700opresize.jpg", "site": "The Motley Fool", "text": "They trade at low earnings multiples and could be excellent buys for 2021.", "url": "https://www.fool.com/investing/2021/01/09/3-stocks-that-are-absurdly-cheap-right-now/"}, {"symbol": "ABBV", "publishedDate": "2021-01-08 10:18:02", "title": "3 Low Forward Price-Earnings Ratio Stock Picks", "image": "https://cdn.snapi.dev/images/v1/s/t/stocks234---p4q5cmngui.jpg", "site": "GuruFocus", "text": "The three securities listed below could be of interest to investors, as their forward price-earnings ratios are lower than the S&P 500's historical average of 15. The projections of future earnings are based on data from Morningstar analysts.", "url": "https://www.gurufocus.com/news/1326833/3-low-forward-priceearnings-ratio-stock-picks"}, {"symbol": "ABBV", "publishedDate": "2021-01-08 09:47:21", "title": "AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies", "image": "https://cdn.snapi.dev/images/v1/q/i/drugs25.jpg", "site": "Zacks Investment Research", "text": "AbbVie's (ABBV) Skyrizi achieves improvements in clinical remission and endoscopic response in phase III studies in moderate to severe Crohn's disease patients.", "url": "https://www.zacks.com/stock/news/1243400/abbvies-abbv-skyrizi-succeeds-in-crohns-disease-studies"}, {"symbol": "ABBV", "publishedDate": "2021-01-07 15:58:34", "title": "7 Safe Stocks to Buy to Start Off the Year", "image": "https://cdn.snapi.dev/images/v1/l/5/sosk111.jpg", "site": "InvestorPlace", "text": "These safe stocks to buy have a low beta, attractive valuation and healthy dividends. Get in early this year to strengthen your portfolio.", "url": "https://investorplace.com/2021/01/7-safe-stocks-to-buy-to-start-off-the-year/"}, {"symbol": "ABBV", "publishedDate": "2021-01-07 13:38:11", "title": "8 Dividend Increases To Start 2021", "image": "https://cdn.snapi.dev/images/v1/o/i/asset-management27-v1uayxzxlp.jpg", "site": "Seeking Alpha", "text": "All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. An average increase of 8.4% and a median increase of 6.6%.", "url": "https://seekingalpha.com/article/4397775-8-dividend-increases-to-start-2021"}, {"symbol": "ABBV", "publishedDate": "2021-01-07 09:47:19", "title": "3 Biotech Technological Developments to Watch Out For in 2021", "image": "https://cdn.snapi.dev/images/v1/f/d/drugs11.jpg", "site": "Zacks Investment Research", "text": "Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021", "url": "https://www.zacks.com/stock/news/1242420/3-biotech-technological-developments-to-watch-out-for-in-2021"}, {"symbol": "ABBV", "publishedDate": "2021-01-07 08:45:00", "title": "Risankizumab (SKYRIZI\u00ae) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease", "image": "https://cdn.snapi.dev/images/v1/2/a/press17---yavul0fctw.jpg", "site": "PRNewsWire", "text": "NORTH CHICAGO, Ill., Jan. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive results from two Phase 3 induction studies, ADVANCE and MOTIVATE, showing both doses of risankizumab (600 mg and 1200 mg) met both primary endpoints of clinical remission and endoscopic response...", "url": "https://www.prnewswire.com/news-releases/risankizumab-skyrizi-demonstrates-significant-improvements-in-clinical-remission-and-endoscopic-response-in-two-phase-3-induction-studies-in-patients-with-crohns-disease-301202802.html"}, {"symbol": "ABBV", "publishedDate": "2021-01-06 11:17:17", "title": "4 High-Yield Stocks to Ring in the New Year", "image": "https://cdn.snapi.dev/images/v1/7/g/106419724-1583164885503rts34fgq-dahzkkx03s.jpg", "site": "GuruFocus", "text": "Due to gains made over the past few years and our focus on building up our lower-yielding positions, the yield on the portfolio my wife and I are building fell to just over 2% last year. One of the goals that I listed for our portfolio in 2021 was to increase the average yield of our holdings.", "url": "https://www.gurufocus.com/news/1324739/4-highyield-stocks-to-ring-in-the-new-year"}, {"symbol": "ABBV", "publishedDate": "2021-01-06 11:17:12", "title": "AbbVie's (ABBV) Skyrizi Succeeds in Psoriatic Arthritis Studies", "image": "https://cdn.snapi.dev/images/v1/7/s/drugs49.jpg", "site": "Zacks Investment Research", "text": "AbbVie's (ABBV) Skyrizi achieves improvements in disease activity across joint and skin symptoms in phase III studies in active psoriatic arthritis.", "url": "https://www.zacks.com/stock/news/1241891/abbvies-abbv-skyrizi-succeeds-in-psoriatic-arthritis-studies"}, {"symbol": "ABBV", "publishedDate": "2021-01-05 19:21:48", "title": "Jim Cramer: Dividend stock picks with potential market upside", "image": "https://cdn.snapi.dev/images/v1/n/i/jim-cramer-dividend-stock-picks-with-potential-market-upside.jpg", "site": "CNBC Television", "text": "Forget the bond market. If you want income, you need to find it in stocks, the \"Mad Money\" host said.", "url": "https://www.youtube.com/watch?v=nt4pXWBC_Zc"}, {"symbol": "ABBV", "publishedDate": "2021-01-05 18:48:14", "title": "AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/3/1/drugs39.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) closed at $106.50 in the latest trading session, marking a +1.03% move from the prior day.", "url": "https://www.zacks.com/stock/news/1241541/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know"}, {"symbol": "ABBV", "publishedDate": "2021-01-05 07:40:00", "title": "Got $1,000? These 2 Top Stocks Can Make You Rich", "image": "https://cdn.snapi.dev/images/v1/d/r/drugs38---ztocw5rpbs.jpg", "site": "The Motley Fool", "text": "These two pharmaceutical stocks can significantly boost your wealth in the long run.", "url": "https://www.fool.com/investing/2021/01/05/got-1000-these-2-top-stocks-can-make-you-rich/"}, {"symbol": "ABBV", "publishedDate": "2021-01-04 12:03:29", "title": "7 Cheap Stocks to Buy in January For a Quick Buck", "image": "https://cdn.snapi.dev/images/v1/s/0/s09222.", "site": "InvestorPlace", "text": "2020 has taken the market capitalizations of many strong companies to lows. That means there are some great options for cheap stocks to buy in January.", "url": "https://investorplace.com/2021/01/7-cheap-stocks-to-buy-in-january-for-a-quick-buck/"}, {"symbol": "ABBV", "publishedDate": "2021-01-04 08:05:48", "title": "AbbVie's Fair Value Is At Least $147 Per Share", "image": "https://cdn.snapi.dev/images/v1/e/d/drugs20.jpg", "site": "Seeking Alpha", "text": "ABBV's shares have rallied hard in recent weeks. But the market is still pricing in at least a partial failure of Humira replacements.", "url": "https://seekingalpha.com/article/4397165-abbvies-fair-value-is-least-147-per-share"}, {"symbol": "ABBV", "publishedDate": "2021-01-03 16:38:14", "title": "2020 Portfolio Review: What a Year", "image": "https://cdn.snapi.dev/images/v1/i/o/drugs16.jpg", "site": "GuruFocus", "text": "Without a doubt, 2020 will be a year few will ever forget. A global pandemic upended normal life for so many people.", "url": "https://www.gurufocus.com/news/1321708/2020-portfolio-review-what-a-year"}, {"symbol": "ABBV", "publishedDate": "2021-01-01 07:04:00", "title": "These 4 Micro-Cap Healthcare Stocks Gained the Most in 2020", "image": "https://cdn.snapi.dev/images/v1/3/z/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6064732fgettyimages-1189303727jpgw700opresize.jpg", "site": "The Motley Fool", "text": "Innovation paid off big for investors.", "url": "https://www.fool.com/investing/2021/01/01/these-4-micro-cap-healthcare-stocks-gained-the-mos/"}, {"symbol": "ABBV", "publishedDate": "2020-12-31 15:30:38", "title": "Warren Buffett's Top 5 Holdings Post Mixed Performances in 2020", "image": "https://cdn.snapi.dev/images/v1/o/1/computer-electronic12.jpg", "site": "GuruFocus", "text": "With the final day of an interesting and memorable year upon us, investors are looking at their portfolios to determine how they performed in 2020.", "url": "https://www.gurufocus.com/news/1321145/warren-buffetts-top-5-holdings-post-mixed-performances-in-2020"}, {"symbol": "ABBV", "publishedDate": "2020-12-31 13:40:47", "title": "Top 10 Undervalued High-Yield Income Stocks For 2021", "image": "https://cdn.snapi.dev/images/v1/w/y/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5805032fcoronavirus-stock-market-xaoojydjpgw700opresize.jpg", "site": "Seeking Alpha", "text": "2021 could be a year in which value stocks outperform. Income potential remains a key theme for 2021 and beyond, as interest rates remain at record lows.", "url": "https://seekingalpha.com/article/4396860-top-10-undervalued-high-yield-income-stocks-for-2021"}, {"symbol": "ABBV", "publishedDate": "2020-12-31 08:15:00", "title": "3 Stocks That Can Pay You More Than Social Security Benefits", "image": "https://cdn.snapi.dev/images/v1/e/t/etf48-3---khucwy3rym.jpg", "site": "The Motley Fool", "text": "Boost your retirement income with these stocks.", "url": "https://www.fool.com/investing/2020/12/31/3-stocks-that-can-pay-you-more-than-social-securit/"}, {"symbol": "ABBV", "publishedDate": "2020-12-31 07:22:00", "title": "3 Warren Buffett Stocks Worth Buying Now", "image": "https://cdn.snapi.dev/images/v1/h/x/warren-buffetts-berkshire-hathaway-plowed-more-than-5-billion-into-4-pharma-stocks-last-quarter-hes-been-teasing-a-bet-on-the-sector-for-more-than-20-years.jpg", "site": "The Motley Fool", "text": "Here are three great stocks to buy if you want to invest like the Oracle of Omaha.", "url": "https://www.fool.com/investing/2020/12/31/3-warren-buffett-stocks-worth-buying-now/"}, {"symbol": "ABBV", "publishedDate": "2020-12-31 06:33:00", "title": "How to Find the Best Dividend Stocks", "image": "https://cdn.snapi.dev/images/v1/5/i/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6064812fgetty-winners-losers-best-evaluate-findjpgw700opresize.jpg", "site": "The Motley Fool", "text": "It's hard to beat dividends -- they offer reliable (and growing) income, inflation protection, and support in retirement.", "url": "https://www.fool.com/investing/dividends-income/2020/12/31/how-to-find-the-best-dividend-stocks/"}, {"symbol": "ABBV", "publishedDate": "2020-12-30 06:12:43", "title": "2 Top Picks - Safe High Dividend Biotechs For 2021", "image": "https://cdn.snapi.dev/images/v1/i/d/drugs8.jpg", "site": "Seeking Alpha", "text": "The elusive conjunction of safety and growing yield is a holy grail for many investors. Seeking Alpha's quant system screens seven larger large cap biotech stocks with dividends ranging from 3.16% to 5.04%.", "url": "https://seekingalpha.com/article/4396693-2-top-picks-safe-high-dividend-biotechs-for-2021"}, {"symbol": "ABBV", "publishedDate": "2020-12-29 23:13:24", "title": "I Replaced A Jumbo CD With This Eclectic Portfolio Of Value-Conscious Dividend-Paying Stocks", "image": "https://cdn.snapi.dev/images/v1/9/b/writing-1149962-1920-1-7.jpg", "site": "Seeking Alpha", "text": "Like many conservative investors I prefer to put my fixed income into a 5 year CD ladder but this year's near 0% rates have changed my strategy. Since May I have built a portfolio of defensive dividend stocks intended to replace a 5 year CD I couldn't face rolling over at today's 1.30% rate.", "url": "https://seekingalpha.com/article/4396673-i-replaced-jumbo-cd-this-eclectic-portfolio-of-value-conscious-dividend-paying-stocks"}, {"symbol": "ABBV", "publishedDate": "2020-12-29 19:19:16", "title": "Undervalued Pharmaceutical Dividends For The New Year", "image": "https://cdn.snapi.dev/images/v1/w/1/euh22.jpg", "site": "Seeking Alpha", "text": "AbbVie and Bristol-Myers Squibb are major pharmaceuticals that have recently made large acquisitions that have significantly increased their total debt. However, both AbbVie and Bristol-Myers Squibb have robust drug pipelines and are actively expanding indications of key therapeutics to drive strong growth going forward.", "url": "https://seekingalpha.com/article/4396667-undervalued-pharmaceutical-dividends-for-new-year"}, {"symbol": "ABBV", "publishedDate": "2020-12-29 18:48:22", "title": "AbbVie (ABBV) Gains As Market Dips: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/u/o/drugs3.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) closed at $104.70 in the latest trading session, marking a +1.21% move from the prior day.", "url": "https://www.zacks.com/stock/news/1232099/abbvie-abbv-gains-as-market-dips-what-you-should-know"}, {"symbol": "ABBV", "publishedDate": "2020-12-29 09:00:00", "title": "2 Ideas For Yield Hunting In 2021, What I Added To The Watchlist", "image": "https://cdn.snapi.dev/images/v1/d/u/etf45-8.jpg", "site": "Seeking Alpha", "text": "AbbVie and VICI Properties have earned a spot on my 2021 dividend watchlist which consists of companies I am considering adding to my dividend income portfolio. AbbVie has a strong pipeline of medicines across Phase 1, 2, 3, and Submitted stages which should fuel future growth and generate additional income to its bottom line.", "url": "https://seekingalpha.com/article/4396488-2-ideas-for-yield-hunting-in-2021-what-i-added-to-watchlist"}, {"symbol": "ABBV", "publishedDate": "2020-12-29 07:51:00", "title": "Have $600 and 10 Years to Wait? Park It in These 3 Top Stocks", "image": "https://cdn.snapi.dev/images/v1/g/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6057882fyoung-investor-thinking-at-work-gettyjpgw700opresize.jpg", "site": "The Motley Fool", "text": "Here are three great stocks positioned to outperform for patient investors.", "url": "https://www.fool.com/investing/2020/12/29/have-600-and-10-years-to-wait-park-it-in-these-3-t/"}, {"symbol": "ABBV", "publishedDate": "2020-12-29 06:04:00", "title": "3 Stocks That'll Turn Your $600 Stimulus Check Into a Money Machine", "image": "https://cdn.snapi.dev/images/v1/h/a/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6063532fstimulus-check-with-100-billsjpgw700opresize.jpg", "site": "The Motley Fool", "text": "These stocks should provide solid dividends you can count on.", "url": "https://www.fool.com/investing/2020/12/29/3-stocks-thatll-turn-your-600-stimulus-check-into/"}, {"symbol": "ABBV", "publishedDate": "2020-12-28 16:41:29", "title": "3 A+ Stocks To Buy And Hold Forever", "image": "https://cdn.snapi.dev/images/v1/w/e/1blis-1.jpg", "site": "Seeking Alpha", "text": "Buying momentum in AT&T faded, as expected, as investors lost interest in its streaming subscription growth. Markets ignoring dividend-income stocks, as stock performance overshadows their strong margins.", "url": "https://seekingalpha.com/article/4396517-3-stocks-to-buy-and-hold-forever"}, {"symbol": "ABBV", "publishedDate": "2020-12-28 10:32:11", "title": "AbbVie (ABBV) Outperforms Industry Year to Date: Here's Why", "image": "https://cdn.snapi.dev/images/v1/d/7/drugs36.jpg", "site": "Zacks Investment Research", "text": "AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs, Skyrizi and Rinvoq are seeing strong sales uptake.", "url": "https://www.zacks.com/stock/news/1225143/abbvie-abbv-outperforms-industry-year-to-date-heres-why"}, {"symbol": "ABBV", "publishedDate": "2020-12-25 06:08:00", "title": "Got $5,000? These 3 Stocks Are Ridiculously Cheap Right Now", "image": "https://cdn.snapi.dev/images/v1/s/7/what-will-the-stock-market-return-in-2020.jpg", "site": "The Motley Fool", "text": "All three also offer attractive dividends.", "url": "https://www.fool.com/investing/2020/12/25/got-5000-these-3-stocks-are-ridiculously-cheap-rig/"}, {"symbol": "ABBV", "publishedDate": "2020-12-24 08:28:28", "title": "5 Highest-Yielding Dividend Aristocrat Stocks to Buy Now for 2021", "image": "https://cdn.snapi.dev/images/v1/2/k/the-best-4-dividend-aristocrats-for-2020.jpg", "site": "24/7 Wall Street", "text": "With 2020 thankfully almost over, many investors are looking to next year. While there is some hope that a return to normal could be achieved by the summer, one thing is for sure: the stock market is very overbought and some of the momentum stock trades are very crowded and could be poised to get hit hard.", "url": "https://247wallst.com/investing/2020/12/24/5-highest-yielding-dividend-aristocrat-stocks-to-buy-now-for-2021/"}, {"symbol": "ABBV", "publishedDate": "2020-12-23 07:25:00", "title": "3 Stocks to Buy With Dividends Yielding More Than 4%", "image": "https://cdn.snapi.dev/images/v1/f/b/gre45666-30.jpg", "site": "The Motley Fool", "text": "From a recession-proof stock to an out-of-favor oil play, these high dividend yielders could make you a lot of money.", "url": "https://www.fool.com/investing/2020/12/23/3-stocks-to-buy-with-dividends-yielding-more-than/"}, {"symbol": "ABBV", "publishedDate": "2020-12-23 06:50:00", "title": "Coronavirus Stimulus Checks: Top Stocks To Buy Now", "image": "https://cdn.snapi.dev/images/v1/j/m/asset-management40.jpg", "site": "The Motley Fool", "text": "$600 is enough to purchase a small stream of dividend income in a leading company.", "url": "https://www.fool.com/investing/2020/12/23/coronavirus-stimulus-checks-top-stocks-to-buy-now/"}, {"symbol": "ABBV", "publishedDate": "2020-12-22 18:48:09", "title": "AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/6/p/drugs6.jpg", "site": "Zacks Investment Research", "text": "AbbVie (ABBV) closed at $102.80 in the latest trading session, marking a -0.88% move from the prior day.", "url": "https://www.zacks.com/stock/news/1197532/abbvie-abbv-dips-more-than-broader-markets-what-you-should-know"}, {"symbol": "ABBV", "publishedDate": "2020-12-22 17:18:03", "title": "3 Stocks with Strong Dividends to Buy for Growth in 2021", "image": "https://cdn.snapi.dev/images/v1/n/8/98706-a534-11.jpg", "site": "Zacks Investment Research", "text": "Investors might want to consider adding stocks to their 2021 portfolios that pay a solid dividend and provide exposure to growth areas.", "url": "https://www.zacks.com/stock/news/1197206/3-stocks-with-strong-dividends-to-buy-for-growth-in-2021"}, {"symbol": "ABBV", "publishedDate": "2020-12-22 16:11:11", "title": "5 Health Care Stocks Outperforming the Benchmark", "image": "https://cdn.snapi.dev/images/v1/d/s/drugs3.jpg", "site": "GuruFocus", "text": "According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have outperformed the S&P 500 Index over the past 12 months through Dec. 22.", "url": "https://www.gurufocus.com/news/1317010/5-health-care-stocks-outperforming-the-benchmark"}, {"symbol": "ABBV", "publishedDate": "2020-12-22 09:47:27", "title": "Are Options Traders Betting on a Big Move in AbbVie (ABBV) Stock?", "image": "https://cdn.snapi.dev/images/v1/j/3/drugs46.jpg", "site": "Zacks Investment Research", "text": "Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.", "url": "https://www.zacks.com/stock/news/1195445/are-options-traders-betting-on-a-big-move-in-abbvie-abbv-stock"}, {"symbol": "ABBV", "publishedDate": "2020-12-22 08:30:00", "title": "New COVID Strain Leads To New Worries: 5 High-Yield Dividend Stocks That Are Still Safe", "image": "https://cdn.snapi.dev/images/v1/c/c/best-stocks-to-buy-as-markets-rally-despite-elevated-volatility.jpg", "site": "Seeking Alpha", "text": "A new COVID strain has been found in Great Britain, its transmission rate is up to 70% higher. This could lead to harsher lockdowns and more interruptions to businesses.", "url": "https://seekingalpha.com/article/4395763-new-covid-strain-leads-to-new-worries-5-high-yield-dividend-stocks-are-still-safe"}, {"symbol": "ABBV", "publishedDate": "2020-12-21 09:03:01", "title": "DGI For The DIY: Q3 2020 Dividend Portfolio Update", "image": "https://cdn.snapi.dev/images/v1/r/a/rallyrally---th5n29tpr7.jpg", "site": "Seeking Alpha", "text": "Dividend growth moderated in Q3, as portfolio income growth dropped to 4.5%. Two trades were made following dividend cuts from Dominion Energy and Wells Fargo.", "url": "https://seekingalpha.com/article/4395610-dgi-for-diy-q3-2020-dividend-portfolio-update"}, {"symbol": "ABBV", "publishedDate": "2020-12-21 00:28:21", "title": "These 2 Fast-Growing Buffett Blue-Chip Bargains Are 11% Of My Retirement Portfolio", "image": "https://cdn.snapi.dev/images/v1/d/7/drugs30.jpg", "site": "Seeking Alpha", "text": "These 2 Fast-Growing Buffett Blue-Chip Bargains Are 11% Of My Retirement Portfolio", "url": "https://seekingalpha.com/article/4395553-2-fast-growing-buffett-blue-chip-bargains-are-11-of-retirement-portfolio"}, {"symbol": "ABBV", "publishedDate": "2020-12-20 15:01:41", "title": "Week In Review: Week's China Life Science Investments Total $800 Million", "image": "https://cdn.snapi.dev/images/v1/i/x/service-please-how-best-buy-walmart-apple-and-amazon-plan-to-fortify-their-service-offerings.jpg", "site": "Seeking Alpha", "text": "Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing antibody, 47D11, to AbbVie.", "url": "https://seekingalpha.com/article/4395526-week-in-review-weeks-china-life-science-investments-total-800-million"}, {"symbol": "ABBV", "publishedDate": "2020-12-17 07:03:00", "title": "3 Dividend Stocks I'd Buy Right Now", "image": "https://cdn.snapi.dev/images/v1/1/0/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6045492fdividends-spelled-out-inwooden-blocks-2jpgw700opresize.jpg", "site": "The Motley Fool", "text": "These three stocks can provide dividend investors with a solid and safe yield and consistent growth. And all three are available at a bargain, for the time being.", "url": "https://www.fool.com/investing/2020/12/17/3-dividend-stocks-id-buy-right-now/"}, {"symbol": "ABBV", "publishedDate": "2020-12-16 18:48:18", "title": "AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/e/b/drugs2---cxaxw7hiyv.jpg", "site": "Zacks Investment Research", "text": "In the latest trading session, AbbVie (ABBV) closed at $104.64, marking a +1.77% move from the previous day.", "url": "https://www.zacks.com/stock/news/1173806/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know"}, {"symbol": "ABBV", "publishedDate": "2020-12-15 16:35:21", "title": "November Buys: 3 Monthly Paying CEFs, Plus Some Dividend Growth Opportunities", "image": "https://cdn.snapi.dev/images/v1/s/k/sk2ff2.", "site": "Seeking Alpha", "text": "November started out with a bang due to the election. Besides some early buying last month, it was another month of light buying throughout the remainder of November.", "url": "https://seekingalpha.com/article/4394921-november-buys-3-monthly-paying-cefs-plus-dividend-growth-opportunities"}, {"symbol": "ABBV", "publishedDate": "2020-12-15 14:55:24", "title": "Abbvie shares remain in focus for investors after the company increased the dividend by 10.2%", "image": "https://cdn.snapi.dev/images/v1/e/u/abbvie-1-740x416.jpg", "site": "Invezz", "text": "AbbVie (NYSE: ABBV) shares have advanced from $80 above $109 since the beginning of November, and the current price stands around $103. The company has reported better than expected results in Q3 and increased the quarterly dividend by 10.2%.", "url": "https://invezz.com/news/2020/12/15/abbvie-shares-remain-in-focus-for-investors-after-the-company-increased-the-dividend-by-10-2/"}, {"symbol": "ABBV", "publishedDate": "2020-12-15 13:31:51", "title": "Final Trades: AMD, AbbVie, Wingstop & more", "image": "https://cdn.snapi.dev/images/v1/f/u/final-trades-amd-abbvie-wingstop-more.jpg", "site": "CNBC Television", "text": "The \"Halftime Report\" traders give their top picks to watch for the second half.", "url": "https://www.youtube.com/watch?v=mbbw5fIE094"}, {"symbol": "ABBV", "publishedDate": "2020-12-14 20:33:51", "title": "Warren Buffett's Berkshire Hathaway has new stakes in AbbVie, Pfizer, Merck, Bristol-Myers Squibb", "image": "https://cdn.snapi.dev/images/v1/y/e/warren-buffetts-berkshire-hathaway-has-new-stakes-in-abbvie-pfizer-merck-bristol-myers-squibb.jpg", "site": "Yahoo Finance", "text": "Warren Buffett's Berkshire Hathaway released its newest holdings worth more than $1.8 billion with notable investments in some big pharma stocks like Merck and Pfizer. Yahoo Finance's Jared Blikre breaks it all down.", "url": "https://www.youtube.com/watch?v=2YDnF3BMX7w"}, {"symbol": "ABBV", "publishedDate": "2020-12-14 14:38:46", "title": "3 Health Care Companies That Recently Raised Dividends", "image": "https://cdn.snapi.dev/images/v1/h/k/drugs14.jpg", "site": "GuruFocus", "text": "Dividend increase announcements continue to pile up as 2020 draws to a close. The health care sector remains one of my favorite places to find stocks offering solid yields and lengthy track records of dividend growth.", "url": "https://www.gurufocus.com/news/1310730/3-health-care-companies-that-recently-raised-dividends"}, {"symbol": "ABBV", "publishedDate": "2020-12-13 15:29:26", "title": "Ride Through Another COVID Wave With These 5 Undervalued Dividend Growth Stocks", "image": "https://cdn.snapi.dev/images/v1/y/d/st23-1.jpg", "site": "Seeking Alpha", "text": "Another wave of COVID wave is upon us, with cases in various states rising to new record levels and shutdowns proliferating. Dividend Growth Stocks have historically offered reliable income that can see you through tough times. They have a history of outperforming during recessions and market troubles.", "url": "https://seekingalpha.com/article/4394475-ride-through-another-covid-wave-5-undervalued-dividend-growth-stocks"}, {"symbol": "ABBV", "publishedDate": "2020-12-12 08:10:00", "title": "2 High-Yielding Dividend Stocks to Buy if the Market Crashes Again", "image": "https://cdn.snapi.dev/images/v1/w/g/204.jpg", "site": "The Motley Fool", "text": "Things are looking up, but investors who prepare now for another nosedive may find great returns in these two companies.", "url": "https://www.fool.com/investing/2020/12/12/2-high-yielding-dividend-stocks-to-buy-if-the-mark/"}, {"symbol": "ABBV", "publishedDate": "2020-12-11 16:21:41", "title": "AbbVie: No Sense Of (Post) Humira Failure - My Price Target Is $120 - $150", "image": "https://cdn.snapi.dev/images/v1/r/c/drugs47.jpg", "site": "Seeking Alpha", "text": "AbbVie stock has surged since my last post, gaining 28% to trade at $107 at the time of writing. Q320 results returned the company to profitability - an impressive achievement given the integration of Allergan assets and pandemic pressures.", "url": "https://seekingalpha.com/article/4394350-abbvie-no-sense-of-post-humira-failure-price-target-is-120-150"}, {"symbol": "ABBV", "publishedDate": "2020-12-11 07:32:00", "title": "CHMP Recommends the Approvals of RINVOQ\u2122 (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis", "image": "https://cdn.snapi.dev/images/v1/9/p/press8---5jgesyjh3h.jpg", "site": "PRNewsWire", "text": "NORTH CHICAGO, Ill., Dec. 11, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ\u2122 (upadacitinib, 15 mg), an oral, once daily selective and reversible...", "url": "https://www.prnewswire.com/news-releases/chmp-recommends-the-approvals-of-rinvoq-upadacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis-and-ankylosing-spondylitis-301191192.html"}, {"symbol": "ABBV", "publishedDate": "2020-12-10 09:50:15", "title": "5 Dividend-Paying Pharmaceutical Stocks to Buy for Solid 2021 Total Return", "image": "https://cdn.snapi.dev/images/v1/7/y/drugs21.jpg", "site": "24/7 Wall Street", "text": "Many prognosticators across Wall Street feel that interest rates will start to rise in 2021 Deutsche Bank is negative on duration and sees the 10-year Treasury bond yield rising to 1.5% in the second quarter of 2021 from the current yield of 0.95%.", "url": "https://247wallst.com/healthcare-business/2020/12/10/5-dividend-paying-pharmaceutical-stocks-to-buy-for-solid-2021-total-return/"}, {"symbol": "ABBV", "publishedDate": "2020-12-10 00:17:00", "title": "The Only Warren Buffett Stock Worth Buying", "image": "https://cdn.snapi.dev/images/v1/d/i/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6041762fbuffett-image-biggerjpgw700opresize.jpg", "site": "The Motley Fool", "text": "Forget the rest. There's only one you need to focus on.", "url": "https://www.fool.com/investing/2020/12/10/the-only-warren-buffett-stock-worth-buying/"}, {"symbol": "ABBV", "publishedDate": "2020-12-08 04:38:01", "title": "Pfizer Vs. Merck Vs. AbbVie Vs.", "image": "https://cdn.snapi.dev/images/v1/z/l/drugs26.jpg", "site": "Seeking Alpha", "text": "Healthcare stocks are a staple of every portfolio. With an ageing population, healthcare stocks are here to stay.", "url": "https://seekingalpha.com/article/4393529-pfizer-vs-merck-vs-abbvie-vs-bristol-myers-vs-johnson-johnson-vs-amgen"}, {"symbol": "ABBV", "publishedDate": "2020-12-07 16:47:10", "title": "Alector: AL001's Phase 3 Initiation/Phase 2 Readout In 2021, $462M In Cash, And AbbVie's Promising Support, +38% Upside", "image": "https://cdn.snapi.dev/images/v1/s/y/drugs25.jpg", "site": "Seeking Alpha", "text": "Alector, Inc (Nasdaq:\u00a0ALEC) is a clinical-stage biopharmaceutical company focused on immuno-neurology, immune dysfunction studies related to degenerative brain disorders. Alector has 4-clinical phase therapeutics entirely targeting primarily neurological diseases including Alzheimer's and Frontotemporal Dementia. Alector also has 2-preclinical therapeutics, and 8 in the research phase.", "url": "https://seekingalpha.com/article/4393448-alector-al001s-phase-3-initiation-phase-2-readout-in-2021-462m-in-cash-and-abbvies-promising"}, {"symbol": "ABBV", "publishedDate": "2020-12-07 16:26:45", "title": "4 Buffett Fat Pitch High-Yield Blue-Chip Bargains Set To Soar", "image": "https://cdn.snapi.dev/images/v1/p/m/drugs24.jpg", "site": "Seeking Alpha", "text": "Just because the S&P 500 is 40% historically overvalued, doesn't mean you can't still find plenty of Buffett style \"fat pitch\" high-yield blue-chip bargains. 9/12 quality blue-chip BTI yields a safe 7.2%, is 51% undervalued, and analysts expect it could deliver 5-year total returns of 20.5% CAGR, 7.3X that of the S&P 500.", "url": "https://seekingalpha.com/article/4393451-4-buffett-fat-pitch-high-yield-blue-chip-bargains-set-to-soar"}, {"symbol": "ABBV", "publishedDate": "2020-12-07 13:46:51", "title": "7 Medical Marijuana Stocks for a Healthcare Revolution", "image": "https://cdn.snapi.dev/images/v1/h/d/ees23-7.jpg", "site": "InvestorPlace", "text": "Medicinal cannabis is no longer speculative. There are truly impactful treatments out there, as well as investment-worthy marijuana stocks.", "url": "https://investorplace.com/2020/12/seven-medical-marijuana-stocks-for-a-healthcare-revolution/"}, {"symbol": "ABBV", "publishedDate": "2020-12-07 05:01:05", "title": "7 Cheap Stocks to Buy Before the Market Realizes their Worth", "image": "https://cdn.snapi.dev/images/v1/y/q/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5893282fstack-of-100-dollar-billsjpgw700opresize.jpg", "site": "InvestorPlace", "text": "Almost everyone likes cheap stocks, because as investors, we don't like to overpay. Some are value traps, while others are treasure chests.", "url": "https://investorplace.com/2020/12/7-cheap-stocks-to-buy-before-the-market-realizes-their-worth-abbv-t-qcom-gs-nls-f/"}, {"symbol": "ABBV", "publishedDate": "2020-12-06 13:00:00", "title": "Combined Data from Multiple Phase 3 Studies of IMBRUVICA\u00ae (ibrutinib) Show Efficacy and Safety in High-Risk, Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Real-World Data Indicating Low Biomarker Testing Rates for These Patients", "image": "https://cdn.snapi.dev/images/v1/m/g/press18---zgz0cg4blu.jpg", "site": "PRNewsWire", "text": "NORTH CHICAGO, Ill., Dec. 6, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), today announced results from a long-term integrated analysis of two Phase 3 clinical studies and additional pooled analysis evaluating the effect of IMBRUVICA (ibrutinib) based therapies for the first-line treatment of...", "url": "https://www.prnewswire.com/news-releases/combined-data-from-multiple-phase-3-studies-of-imbruvica-ibrutinib-show-efficacy-and-safety-in-high-risk-previously-untreated-chronic-lymphocytic-leukemia-cll-and-real-world-data-indicating-low-biomarker-testing-rates-for-th-301186846.html"}, {"symbol": "ABBV", "publishedDate": "2020-12-06 06:12:00", "title": "3 Value Stocks Warren Buffett Owns That You Should Consider Buying Too", "image": "https://cdn.snapi.dev/images/v1/6/s/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6026562fwarren-buffett-tmfjpgw700opresize.jpg", "site": "The Motley Fool", "text": "The Oracle of Omaha knows a good bargain when he sees one.", "url": "https://www.fool.com/investing/2020/12/06/3-value-stocks-warren-buffett-owns-that-you-should/"}, {"symbol": "ABBV", "publishedDate": "2020-12-05 12:45:00", "title": "AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA\u00ae/VENCLYXTO\u00ae (venetoclax) in Chronic Lymphocytic Leukemia (CLL)", "image": "https://cdn.snapi.dev/images/v1/q/i/press6---m9xkmr48tg.jpg", "site": "PRNewsWire", "text": "NORTH CHICAGO, Ill., Dec. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new, updated results from the Phase 3 MURANO and CLL14 clinical trials evaluating VENCLEXTA\u00ae/VENCLYXTO\u00ae (venetoclax) fixed duration treatment combinations at the virtual 62nd American Society of...", "url": "https://www.prnewswire.com/news-releases/abbvie-presents-extended-follow-up-data-for-fixed-duration-treatment-venclextavenclyxto-venetoclax-in-chronic-lymphocytic-leukemia-cll-301186833.html"}, {"symbol": "ABBV", "publishedDate": "2020-12-05 12:30:00", "title": "IMBRUVICA\u00ae (ibrutinib) Plus VENCLEXTA\u00ae/VENCLYXTO\u00ae (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)", "image": "https://cdn.snapi.dev/images/v1/i/l/press3---rimybmsklw.jpg", "site": "PRNewsWire", "text": "NORTH CHICAGO, Ill., Dec. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial evaluating IMBRUVICA\u00ae (ibrutinib) in combination with VENCLEXTA\u00ae/VENCLYXTO\u00ae (venetoclax) in previously untreated patients with chronic...", "url": "https://www.prnewswire.com/news-releases/imbruvica-ibrutinib-plus-venclextavenclyxto-venetoclax-combination-shows-high-rates-of-disease-free-survival-one-year-post-treatment-in-previously-untreated-patients-with-chronic-lymphocytic-leukemia-cll-301186821.html"}, {"symbol": "ABBV", "publishedDate": "2020-12-03 13:53:40", "title": "3 Dividend Stocks for Big Total Returns in 2021", "image": "https://cdn.snapi.dev/images/v1/r/s/drugs10.jpg", "site": "InvestorPlace", "text": "These dividend stocks continue to outperform thier competition in yielding higher and consistent returns despite the impact of the pandemic The post 3 Dividend Stocks for Big Total Returns in 2021 appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets", "url": "https://investorplace.com/2020/12/3-dividend-stocks-for-big-total-returns-in-2021-abbv-jnj-mdt/"}, {"symbol": "ABBV", "publishedDate": "2020-12-03 13:17:05", "title": "AbbVie Inc. (ABBV) Presents at Piper Sandler 32nd Annual Healthcare Conference (Transcript)", "image": "https://cdn.snapi.dev/images/v1/y/b/transcript45.jpg", "site": "Seeking Alpha", "text": "AbbVie Inc. (ABBV) Presents at Piper Sandler 32nd Annual Healthcare Conference (Transcript)", "url": "https://seekingalpha.com/article/4392835-abbvie-inc-abbv-presents-piper-sandler-32nd-annual-healthcare-conference-transcript"}, {"symbol": "ABBV", "publishedDate": "2020-12-02 19:45:57", "title": "AbbVie (ABBV) Management on Evercore ISI 3rd Annual HealthCONx Conference", "image": "https://cdn.snapi.dev/images/v1/i/a/transcript15.jpg", "site": "Seeking Alpha", "text": "AbbVie (ABBV) Management on Evercore ISI 3rd Annual HealthCONx Conference", "url": "https://seekingalpha.com/article/4392665-abbvie-abbv-management-on-evercore-isi-3rd-annual-healthconx-conference"}, {"symbol": "ABBV", "publishedDate": "2020-12-01 13:01:43", "title": "4 Pharmaceutical Stocks That Aren't Worth Their Outsized 2020 Gains", "image": "https://cdn.snapi.dev/images/v1/w/s/drugs35.jpg", "site": "InvestorPlace", "text": "Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks investors should be weary of in the weeks ahead.", "url": "https://investorplace.com/2020/12/4-pharmaceutical-stocks-ino-regn-abbv-nvax-that-arent-worth-their-2020-gains/"}, {"symbol": "ABBV", "publishedDate": "2020-12-01 11:01:20", "title": "Buffett Buys Pharma: Two Out Of Four Seem Compelling", "image": "https://cdn.snapi.dev/images/v1/s/q/drugs32.jpg", "site": "Seeking Alpha", "text": "Berkshire's latest filing revealed the Oracle of Omaha and his team opening new positions in four pharma giants as of late. From a quality standpoint, all companies seem like a natural fit considering Buffett's reported preference for wide-moat businesses.", "url": "https://seekingalpha.com/article/4392293-buffett-buys-pharma-two-out-of-four-seem-compelling"}, {"symbol": "ABBV", "publishedDate": "2020-12-01 08:39:00", "title": "3 Pharma Stocks With Dividends Above 4% to Buy Now", "image": "https://cdn.snapi.dev/images/v1/a/m/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6022222fpharmaceutical-manufacturing-gettyjpgw700opresize.jpg", "site": "The Motley Fool", "text": "Should you buy these drugmaker stocks for their juicy dividend yields?", "url": "https://www.fool.com/investing/2020/12/01/3-pharma-stocks-with-dividends-above-4-to-buy-now/"}, {"symbol": "ABBV", "publishedDate": "2020-12-01 07:00:00", "title": "Despite A 65% Rally AbbVie Stock Looks Like It Can Gain More", "image": "https://cdn.snapi.dev/images/v1/u/z/despite-a-65-rally-abbvie-stock-looks-like-it-can-gain-more.jpg", "site": "Forbes", "text": "AbbVie stock is up 18% since the start of the year and it has gained around 62% from its March lows. Despite the recent rally, AbbVie could offer an upside in the near term, as the company's revenues in the last three quarters have grown by 30%, primarily aided by the Allergan acquisition.", "url": "https://www.forbes.com/sites/greatspeculations/2020/12/01/despite-a-65-rally-abbvie-stock-looks-like-it-can-gain-more/"}, {"symbol": "ABBV", "publishedDate": "2020-11-30 12:09:54", "title": "Eighth Review Of My Dividend Portfolio", "image": "https://cdn.snapi.dev/images/v1/f/z/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5686502fgettyimage-stockchartjpgw700opresize.jpg", "site": "Seeking Alpha", "text": "Top five holdings add up to 50% of my portfolio. Portfolio currently yields approximately 3.91%.", "url": "https://seekingalpha.com/article/4392066-eighth-review-of-dividend-portfolio"}, {"symbol": "ABBV", "publishedDate": "2020-11-29 08:25:10", "title": "Berkshire Hathaway Makes Big Bet on Pharma", "image": "https://cdn.snapi.dev/images/v1/b/g/asset-management33.jpg", "site": "GuruFocus", "text": "Despite solid gains in pharma sales and profits, Big Pharma's overall share value has pretty much stagnated over the past five years\u2014but better days appear to be ahead, in my opinion.", "url": "https://www.gurufocus.com/news/1298016/berkshire-hathaway-makes-big-bet-on-pharma"}, {"symbol": "ABBV", "publishedDate": "2020-11-28 06:24:00", "title": "Is AbbVie a Great Dividend Stock?", "image": "https://cdn.snapi.dev/images/v1/1/p/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5984922fpillsjpgw700opresize.jpg", "site": "The Motley Fool", "text": "The stock has a high yield -- and it also has something even more important.", "url": "https://www.fool.com/investing/2020/11/28/is-abbvie-a-great-dividend-stock/"}, {"symbol": "ABBV", "publishedDate": "2020-11-27 06:02:21", "title": "A Dividend Cornucopia Of 39 November Kiplinger/Analyst Favorites", "image": "https://cdn.snapi.dev/images/v1/r/y/etf36.jpg", "site": "Seeking Alpha", "text": "In October and July, Kiplinger Today listed Analyst and Kiplinger favorite dividend stocks. Analyst October favorites numbered 25, plus 15 from Kiplinger, with one repeated left 39 total. These 39 stocks ranged from 1.42% to 8.74% in annual yield and ranged from 0.13% to 33.33% in one-year price target upsides per brokers 11/25/20.", "url": "https://seekingalpha.com/article/4391757-dividend-cornucopia-of-39-november-kiplinger-analyst-favorites"}, {"symbol": "ABBV", "publishedDate": "2020-11-27 05:33:20", "title": "Top 10 Stocks Warren Buffett Just Bought", "image": "https://cdn.snapi.dev/images/v1/e/r/gettyimages-957725692-6dbce81323da4b118e7f88b79dfdf468.jpg", "site": "Insider Monkey", "text": "In this article we'll run through the Top 10 Stocks Warren Buffett Just Bought. If you're in a hurry to see the hedge fund legend's highest conviction new stock purchases, you can jump straight to the Top 5 Stocks Warren Buffett Just Bought .", "url": "https://www.insidermonkey.com/blog/top-10-stocks-warren-buffett-just-bought-892035/"}, {"symbol": "ABBV", "publishedDate": "2020-11-25 13:48:37", "title": "3 Dividend Aristocrats For Safe Dividends And High Total Returns", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5629462f100-bill-with-ben-franklin-wearing-a-maskjpgw700opresize.jpg", "site": "Benzinga", "text": "By Bob Ciura with Sure Dividend. The U.S. stock market has come roaring back from the lows seen in March and April, but the broader economy remains on unstable footing.", "url": "https://www.benzinga.com/trading-ideas/long-ideas/20/11/18536752/3-dividend-aristocrats-for-safe-dividends-and-high-total-returns"}, {"symbol": "ABBV", "publishedDate": "2020-11-25 07:22:00", "title": "Deep Dive: Only these five dividend stocks made the cut in a \u2018safer and better' screen", "image": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5400802frising-stock-chartjpgw700opresize---qstseo5zxm.jpg", "site": "Market Watch", "text": "The companies had to reach yield and sales hurdles.", "url": "https://www.marketwatch.com/story/only-these-five-dividend-stocks-made-the-cut-in-a-safer-and-better-screen-11606258156"}, {"symbol": "ABBV", "publishedDate": "2020-11-22 06:08:00", "title": "These 3 Dividend Stocks Are Practically Money Machines", "image": "https://cdn.snapi.dev/images/v1/a/t/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6009462f100-bills-in-a-counting-machinejpgw700opresize.jpg", "site": "The Motley Fool", "text": "You can likely count on these dividends flowing for a long time to come.", "url": "https://www.fool.com/investing/2020/11/22/these-3-dividend-stocks-are-practically-money-mach/"}, {"symbol": "ABBV", "publishedDate": "2020-11-21 08:30:00", "title": "Dividend Growth Up To 18%: These Aristocrats Deliver During The Pandemic", "image": "https://cdn.snapi.dev/images/v1/v/8/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5638282fmoney-seriesjpgw700opresize.jpg", "site": "Seeking Alpha", "text": "Dividend Aristocrats have proven to be reliable investments, no matter what the macro environment looks like. Some of them have continued to raise the dividend at an attractive pace during this pandemic.", "url": "https://seekingalpha.com/article/4390782-dividend-growth-up-to-18-aristocrats-deliver-during-pandemic"}, {"symbol": "ABBV", "publishedDate": "2020-11-21 07:30:00", "title": "Like Dividends? I Bet You'll Love These 3 Stocks", "image": "https://cdn.snapi.dev/images/v1/s/e/top23.jpg", "site": "The Motley Fool", "text": "These companies are not only well established, but they takes their payout's reliable growth seriously.", "url": "https://www.fool.com/investing/2020/11/21/like-dividends-i-bet-youll-love-these-3-stocks/"}, {"symbol": "ABBV", "publishedDate": "2020-11-21 06:12:00", "title": "3 High-Yield Dividend Stocks to Buy Now", "image": "https://cdn.snapi.dev/images/v1/j/f/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5979292fgettyimages-1209929125jpgw700opresize.jpg", "site": "The Motley Fool", "text": "These companies are increasing their dividends at a time when their yields are already very attractive.", "url": "https://www.fool.com/investing/2020/11/21/3-high-yield-dividend-stocks-to-buy-now/"}, {"symbol": "ABBV", "publishedDate": "2020-11-20 08:01:00", "title": "Warren Buffett Just Bought These Stocks", "image": "https://cdn.snapi.dev/images/v1/d/h/dhdy22.jpg", "site": "The Motley Fool", "text": "Berkshire Hathaway's 13-F filing shows the Oracle of Omaha's bullish on healthcare.", "url": "https://www.fool.com/investing/2020/11/20/warren-buffett-just-bought-these-stocks/"}, {"symbol": "ABBV", "publishedDate": "2020-11-19 14:36:04", "title": "AbbVie Inc. (ABBV) Presents at Wolfe Research Healthcare Conference (Transcript)", "image": "https://cdn.snapi.dev/images/v1/q/a/transcript24---8fr0lgloc2.jpg", "site": "Seeking Alpha", "text": "AbbVie Inc. (ABBV) Presents at Wolfe Research Healthcare Conference (Transcript)", "url": "https://seekingalpha.com/article/4390402-abbvie-inc-abbv-presents-wolfe-research-healthcare-conference-transcript"}, {"symbol": "ABBV", "publishedDate": "2020-11-19 08:30:08", "title": "5%-Yielding AbbVie: Double-Digit Dividend Raise And A Buffett Endorsement", "image": "https://cdn.snapi.dev/images/v1/v/x/drugs29.jpg", "site": "Seeking Alpha", "text": "AbbVie reported strong Q3 results, the pandemic is not a major headwind for the company. Following another double-digit dividend raise, AbbVie's dividend yield is 5.2%.", "url": "https://seekingalpha.com/article/4390204-5-yielding-abbvie-double-digit-dividend-raise-and-buffett-endorsement"}, {"symbol": "ABBV", "publishedDate": "2020-11-19 01:44:33", "title": "AbbVie Should Benefit From A Buffett Bounce", "image": "https://cdn.snapi.dev/images/v1/o/j/drugs28.jpg", "site": "Seeking Alpha", "text": "ABBV is a large biopharmaceutical corporation whose main drug is Humira. ABBV acquired Allergan last year, which provided it with diversification, as well as more substantial size and scale.", "url": "https://seekingalpha.com/article/4390203-abbvie-should-benefit-from-buffett-bounce"}, {"symbol": "ABBV", "publishedDate": "2020-11-18 17:00:00", "title": "AbbVie Announces Expiration and Final Results of Registered Exchange Offers", "image": "https://cdn.snapi.dev/images/v1/n/1/press20---7ehwrlkavm.jpg", "site": "PRNewsWire", "text": "NORTH CHICAGO, Ill., Nov. 18, 2020 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) (\"AbbVie\") announced today the expiration and final results of its offers to exchange (the \"Registered Exchange Offers\") any and all of its outstanding (i) $30,000,000,000 aggregate principal amount of senior...", "url": "https://www.prnewswire.com/news-releases/abbvie-announces-expiration-and-final-results-of-registered-exchange-offers-301176491.html"}, {"symbol": "ABBV", "publishedDate": "2020-11-18 08:28:57", "title": "Warren Buffett's Berkshire Hathaway plowed more than $5 billion into 4 pharma stocks last quarter. He's been teasing a bet on the sector for more than 20 years", "image": "https://cdn.snapi.dev/images/v1/w/a/warren-buffetts-berkshire-hathaway-plowed-more-than-5-billion-into-4-pharma-stocks-last-quarter-hes-been-teasing-a-bet-on-the-sector-for-more-than-20-years.jpg", "site": "Business Insider", "text": "Warren Buffett's Berkshire Hathaway plowed more than $5 billion in total into AbbVie, Bristol Myers Squibb, Merck, and Pfizer in the third quarter. Close followers of the company won't be surprised, as Buffett has been mulling a bet on the pharmaceutical sector for more than 20 years. \"You could've just bought the whole industry and done very well,\" the famed investor said at Berkshire's annual shareholder meeting in 1997. He was referring to the downturn in drug stocks in the early 1990s, sparked by President Bill Clinton's proposed healthcare reforms. \"We didn't do it. It was a mistake.\"", "url": "https://www.businessinsider.com/warren-buffett-berkshire-hathaway-buy-4-pharma-stocks-20-years-2020-11"}, {"symbol": "ABBV", "publishedDate": "2020-11-18 06:08:00", "title": "Here's Exactly Why Warren Buffett Loaded Up on Big Pharma Stocks", "image": "https://cdn.snapi.dev/images/v1/e/y/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6011112fwarren-buffett-tmfjpgw700opresize.jpg", "site": "The Motley Fool", "text": "The Oracle of Omaha and his investing lieutenants knew what they were doing in buying AbbVie, BMS, Merck, and Pfizer.", "url": "https://www.fool.com/investing/2020/11/18/heres-exactly-why-warren-buffett-loaded-up-on-big/"}, {"symbol": "ABBV", "publishedDate": "2020-11-17 12:28:00", "title": "Despite Buffett Bullishness, Stock Markets Are Falling", "image": "https://cdn.snapi.dev/images/v1/5/v/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6012052fbuffett-image-biggerjpgw700opresize.jpg", "site": "The Motley Fool", "text": "Find out what the Oracle of Omaha's company has been buying lately.", "url": "https://www.fool.com/investing/2020/11/17/despite-buffett-bullishness-stock-markets-are-fall/"}, {"symbol": "ABBV", "publishedDate": "2020-11-17 07:13:00", "title": "AbbVie, Merck, and Pfizer shares jump after Warren Buffett's Berkshire Hathaway reveals it bought them last quarter", "image": "https://cdn.snapi.dev/images/v1/a/b/abbvie-merck-and-pfizer-shares-jump-after-warren-buffetts-berkshire-hathaway-reveals-it-bought-them-last-quarter.jpg", "site": "Business Insider", "text": "AbbVie, Merck, Bristol Myers Squibb, and Pfizer are the latest beneficiaries of the \"Buffett Effect.\" The quartet of pharmaceutical stocks jumped in pre-market trading on Tuesday after Warren Buffett's Berkshire Hathaway revealed on Monday that it invested in them last quarter. AbbVie, Merck, and Pfizer gained as much as 2%, and BMS rose as much as 3%, whereas benchmark S&P futures slid around 0.5%.", "url": "https://www.businessinsider.com/abbvie-merck-pfizer-stock-price-warren-buffett-berkshire-hathaway-pharmaceuticals-2020-11"}, {"symbol": "ABBV", "publishedDate": "2020-11-16 18:54:44", "title": "Warren Buffett Bought 4 Pharma Giants in Q3", "image": "https://cdn.snapi.dev/images/v1/9/8/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6011182fwarren-buffett-4-tmf-may-2014jpgw700opresize.jpg", "site": "The Motley Fool", "text": "The Oracle of Omaha and his team opened new positions in the underperforming sector.", "url": "https://www.fool.com/investing/2020/11/16/warren-buffett-bought-4-pharma-giants-in-q3/"}, {"symbol": "ABBV", "publishedDate": "2020-11-16 17:28:14", "title": "Warren Buffett's Berkshire Hathaway makes big bets on drug stocks", "image": "https://cdn.snapi.dev/images/v1/j/w/200221091117-warren-buffett-1013-file-super-169.jpg", "site": "CNN Business", "text": "Warren Buffett's Berkshire Hathaway is making a big bet on the health care sector at a time when the Covid-19 pandemic continues to be a major crisis in the United States.", "url": "https://www.cnn.com/2020/11/16/investing/warren-buffett-berkshire-hathaway-drug-stocks/index.html"}, {"symbol": "ABBV", "publishedDate": "2020-11-16 10:28:45", "title": "3 Recession Proof Stocks to Buy Now", "image": "https://cdn.snapi.dev/images/v1/f/k/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6002432fgettyimages-1167797024jpgw700opresize.jpg", "site": "The Motley Fool", "text": "Investors worried about a recession should consider leading stocks in the utilities, basic consumer goods, and healthcare sectors.", "url": "https://www.fool.com/investing/2020/11/16/3-recession-proof-stocks-to-buy-now/"}, {"symbol": "ABBV", "publishedDate": "2020-11-16 08:55:28", "title": "Value Vs. Growth: Buy These 5 Top Dividend Stocks If You Want Both", "image": "https://cdn.snapi.dev/images/v1/8/8/service-please-how-best-buy-walmart-apple-and-amazon-plan-to-fortify-their-service-offerings.jpg", "site": "Seeking Alpha", "text": "Sometimes investors think they need to choose between value and growth, you can have both. However, in dividend investing, you often have to choose between value, yield and growth.", "url": "https://seekingalpha.com/article/4389264-value-vs-growth-buy-5-top-dividend-stocks-you-want"}, {"symbol": "ABBV", "publishedDate": "2020-11-13 09:33:21", "title": "Dividend Income Summary: Lanny's October 2020 Summary", "image": "https://cdn.snapi.dev/images/v1/y/1/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5650052fgettyimages-1210279643jpgw700opresize.jpg", "site": "Seeking Alpha", "text": "In October, we (my wife and I) received a total of $839.12 of dividend income. We had two massive dividend payments that came in from Philip Morris and Canadian Imperial.", "url": "https://seekingalpha.com/article/4388819-dividend-income-summary-lannys-october-2020-summary"}, {"symbol": "ABBV", "publishedDate": "2020-11-11 17:18:51", "title": "ABBV Stock Price: $120 Target By Bernstein", "image": "https://cdn.snapi.dev/images/v1/a/b/abbv1600-300x169.jpg", "site": "Pulse2", "text": "The stock price of biopharmaceutical company AbbVie Inc (NYSE: ABBV) has received a target price of $120. These are the details.", "url": "https://pulse2.com/abbv-stock-nyse-abbvie-price-120-target-by-bernstein/"}, {"symbol": "ABBV", "publishedDate": "2020-11-10 19:30:58", "title": "Why these biotech, pharma stocks have more upside: Analyst", "image": "https://cdn.snapi.dev/images/v1/m/q/why-these-biotech-pharma-stocks-have-more-upside-analyst.jpg", "site": "CNBC Television", "text": "CNBC's Kelly Evans talks with Ronny Gal of Bernstein to discuss how to invest in health care and pharma stocks right now. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi \u00bb Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision \u00bb Subscribe to CNBC: https://cnb.cx/SubscribeCNBC \u00bb Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis.", "url": "https://www.youtube.com/watch?v=9t19zL3tjCU"}, {"symbol": "ABBV", "publishedDate": "2020-11-10 12:35:45", "title": "5 Leading Healthcare Stocks Surging On Pent-Up Demand", "image": "https://cdn.snapi.dev/images/v1/h/t/biotech38---hxdmyuzpuc.jpg", "site": "Insider Monkey", "text": "As Mr. Valuation, I find myself constantly reminding investors that value investing requires patience. However, value investing also requires the willingness to get your money in front of attractive valuation when it is discovered. Trying to time your purchases perfectly can just as easily cause you to miss out on significant gains as it is to participate in them. More directly stated, significant undervaluation can stimulate strong pent-up demand causing stock prices to rise rapidly. Therefore, if you are not already in front of those advances, you can miss out on a lot of profit and opportunity.", "url": "https://www.insidermonkey.com/blog/5-leading-healthcare-stocks-surging-on-pent-up-demand-889339/"}, {"symbol": "ABBV", "publishedDate": "2020-11-10 06:29:16", "title": "GlaxoSmithKline Or AbbVie: Choices In High-Yield Pharma", "image": "https://cdn.snapi.dev/images/v1/k/o/drugs1.jpg", "site": "Seeking Alpha", "text": "GSK and ABBV are both attractively valued and high-yield picks available in the pharma space, discounted for their respective generics-eroded segments. We think that neither is a bad option in the long term, but would opt for GSK due to its lesser focus on oncology, a market that is becoming more and more crowded.", "url": "https://seekingalpha.com/article/4387478-glaxosmithkline-abbvie-choices-in-high-yield-pharma"}, {"symbol": "ABBV", "publishedDate": "2020-11-09 17:36:24", "title": "AbbVie: Delivering Yet Another Double-Digit Dividend Increase", "image": "https://cdn.snapi.dev/images/v1/o/o/drugs42.jpg", "site": "Seeking Alpha", "text": "AbbVie delivered yet another robust dividend increase, building on its dividend increase streak since it was spun off from Abbott Laboratories in 2013. AbbVie's operating fundamentals have remained strong despite COVID-19, with the company posting 13.2% YTD YoY adjusted diluted EPS growth.", "url": "https://seekingalpha.com/article/4387271-abbvie-delivering-yet-another-double-digit-dividend-increase"}, {"symbol": "ABBV", "publishedDate": "2020-11-09 12:27:53", "title": "7 Stable Blue-Chip Stocks for Today's Volatile Economy", "image": "https://cdn.snapi.dev/images/v1/o/k/okd22---tvoxqtj9ws.jpg", "site": "InvestorPlace", "text": "Blue-chip stocks can generate large returns over time, making for great investments in a turbulent economy. Here are my top 7 picks.", "url": "https://investorplace.com/2020/11/blue-chip-stocks-you-can-count-on-in-todays-volatile-economy/"}, {"symbol": "ABBV", "publishedDate": "2020-11-08 07:06:16", "title": "The 92 Stock Rose Portfolio October Update And Quality Evaluation Buy List", "image": "https://cdn.snapi.dev/images/v1/u/o/drugs19.jpg", "site": "Seeking Alpha", "text": "28 dividend payments brought income up delightfully by 10.2% from 2019 and up 11.7% from July 2020. Scary is the total portfolio value is down year to date by 10.2% including dividends and option cash with 2.4% of it just from October.", "url": "https://seekingalpha.com/article/4386627-92-stock-rose-portfolio-october-update-and-quality-evaluation-buy-list"}, {"symbol": "ABBV", "publishedDate": "2020-11-06 07:00:15", "title": "AbbVie Joins The Coronavirus Drug Hunt \u2014 Is AbbVie Stock A Buy?", "image": "https://cdn.snapi.dev/images/v1/x/c/drug1.jpg", "site": "Investors Business Daily", "text": "AbbVie stock slipped when a House committee looking at drug prices said it would issue a subpoena, but the Allergan owner is working on coronavirus treatments. Is AbbVie stock a buy now?", "url": "https://www.investors.com/news/technology/abbvie-stock-buy-now/"}, {"symbol": "ABBV", "publishedDate": "2020-11-05 23:09:58", "title": "5 Leading Healthcare Stocks Surging On Pent-Up Demand", "image": "https://cdn.snapi.dev/images/v1/9/v/drugs50---7chu6g7nxb.jpg", "site": "Seeking Alpha", "text": "The primary message behind this article is that value is worth waiting for, especially when a dividend is associated. Several high-quality companies in these subsectors posted strong price advances.", "url": "https://seekingalpha.com/article/4385631-5-leading-healthcare-stocks-surging-on-pent-up-demand"}, {"symbol": "ABBV", "publishedDate": "2020-11-05 04:46:03", "title": "65 November Dividend Aristocrats", "image": "https://cdn.snapi.dev/images/v1/6/5/drugs12.jpg", "site": "Seeking Alpha", "text": "\"S&P 500\u00ae Dividend Aristocrats measure performance of S&P 500 companies that have increased dividends every year for 25 consecutive years.\"---us.spindices.com. The 65 Aristocrats of November 2020 represent ten of eleven Morningstar Sectors (no Technology). Broker targeted-top-ten net-gainers ranged 19.36%-45.91% topped by XOM & CVX 11/3/20.", "url": "https://seekingalpha.com/article/4385154-65-november-dividend-aristocrats"}, {"symbol": "ABBV", "publishedDate": "2020-11-04 12:46:29", "title": "6 Health Care Stocks That Won Massively From the 2020 Election", "image": "https://cdn.snapi.dev/images/v1/d/f/drugs6.jpg", "site": "24/7 Wall Street", "text": "Making predictions about the winners and losers of an election is a hard job. After all, the pollsters cannot ever seem to get their polling correct.", "url": "https://247wallst.com/healthcare-business/2020/11/04/6-health-care-stocks-that-won-massively-from-the-2020-election/"}, {"symbol": "ABBV", "publishedDate": "2020-11-04 08:53:53", "title": "Republican Hold On Senate Seen As Plus For Drug Companies", "image": "https://cdn.snapi.dev/images/v1/d/r/drugs30---bbzw9njnud.jpg", "site": "Investors Business Daily", "text": "While the presidential race is undecided awaiting final results from key states, it appears Republicans could retain control of the Senate, and AbbVie stock and other biotech stocks rose. The post Republican Hold On Senate Seen As Plus For Drug Companies appeared first on Investor's Business Daily.", "url": "https://www.investors.com/news/technology/abbvie-stock-leasd-pack-biotech-stock-gains-republicans-could-retain-senate-majority/"}, {"symbol": "ABBV", "publishedDate": "2020-11-02 07:00:00", "title": "3 Top Stocks With High Dividend Yields", "image": "https://cdn.snapi.dev/images/v1/q/r/3okjn333-4.jpg", "site": "The Motley Fool", "text": "These three investments provide dividends of at least 4%, along with growth potential and a safe payout ratio.", "url": "https://www.fool.com/investing/2020/11/02/3-top-stocks-with-high-dividend-yields/"}, {"symbol": "ABBV", "publishedDate": "2020-11-01 14:30:23", "title": "Pounding the Table for AbbVie", "image": "https://cdn.snapi.dev/images/v1/u/2/drugs45.jpg", "site": "GuruFocus", "text": "AbbVie Inc. (NYSE:ABBV), a name I have felt is undervalued for some time, reported third-quarter earnings results Friday morning that easily topped Wall Street's estimates. The company also gave yet another double-digit dividend increase.", "url": "https://www.gurufocus.com/news/1272638/pounding-the-table-for-abbvie"}, {"symbol": "ABBV", "publishedDate": "2020-10-30 16:17:13", "title": "AbbVie Inc.'s (ABBV) CEO Rick Gonzalez on Q3 2020 Results - Earnings Call Transcript", "image": "https://cdn.snapi.dev/images/v1/s/r/transcript7.jpg", "site": "Seeking Alpha", "text": "AbbVie Inc.'s (ABBV) CEO Rick Gonzalez on Q3 2020 Results - Earnings Call Transcript", "url": "https://seekingalpha.com/article/4383381-abbvie-inc-s-abbv-ceo-rick-gonzalez-on-q3-2020-results-earnings-call-transcript"}, {"symbol": "ABBV", "publishedDate": "2020-10-30 14:18:00", "title": "How AbbVie Beat Expectations in Q3", "image": "https://cdn.snapi.dev/images/v1/g/f/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5977222flab-worker-holding-up-capsulejpgw700opresize.jpg", "site": "The Motley Fool", "text": "A strong performance from Humira was a big factor in the pharmaceutical company's success.", "url": "https://www.fool.com/investing/2020/10/30/how-abbvie-beat-expectations-in-q3/"}, {"symbol": "ABBV", "publishedDate": "2020-10-30 12:10:17", "title": "AbbVie News: 5 Things for ABBV Investors to Know About Q3", "image": "https://cdn.snapi.dev/images/v1/d/j/drugs36.jpg", "site": "InvestorPlace", "text": "AbbVie (ABBV) news for Friday includes results from the biopharmaceutical company's earnings report for the third quarter of 2020. The post AbbVie News: 5 Things for ABBV Investors to Know About Q3 appeared first on InvestorPlace.", "url": "https://investorplace.com/2020/10/abbvie-earnings-news-q3-highlights/"}, {"symbol": "ABBV", "publishedDate": "2020-10-30 08:05:32", "title": "AbbVie beats earnings expectations, raises its outlook and boosts dividend", "image": "https://cdn.snapi.dev/images/v1/r/k/abbvie-allerganjpgquality90stripall.jpg", "site": "Market Watch", "text": "Shares of AbbVie Inc. gained 0.2% in premarket trading Friday, after the biopharmaceutical and health care company reported third-quarter earnings that beat expectations, raised its full-year outlook and boosted its dividend by 10%. Net income rose to $2.31 billion, or $1.29 a share, from $1.88 billion, or $1.26 a share, in the year-ago period.", "url": "https://www.marketwatch.com/story/abbvie-beats-earnings-expectations-raises-its-outlook-and-boosts-dividend-2020-10-30"}, {"symbol": "ABBV", "publishedDate": "2020-10-30 08:03:33", "title": "AbbVie Earnings Top Views On Rising Humira Sales", "image": "https://cdn.snapi.dev/images/v1/g/i/drugs31---5mduyuappc.jpg", "site": "Investors Business Daily", "text": "AbbVie earnings topped third-quarter views, helped by rising Humira sales. ABBV stock rose modestly before Friday's market open.", "url": "https://www.investors.com/news/technology/abbvie-earnings-humira-sales-abbv-stock/"}, {"symbol": "ABBV", "publishedDate": "2020-10-30 07:53:00", "title": "AbbVie raises 2020 profit forecast as COVID-19 hit eases", "image": "https://cdn.snapi.dev/images/v1/h/l/m02d20201030t2i1539413193w940fhfwllplsqrlynxmpeg9t121.jpg", "site": "Reuters", "text": "Drugmaker AbbVie Inc posted better-than-expected quarterly sales and raised its full-year adjusted profit forecast on Friday, as demand for its Botox and other treatments showed signs of recovery from the COVID-19 pandemic hit.", "url": "https://www.reuters.com/article/us-abbvie-results/abbvie-raises-2020-profit-forecast-as-covid-19-hit-eases-idUSKBN27F1P1"}, {"symbol": "ABBV", "publishedDate": "2020-10-30 07:00:00", "title": "2 No-Brainer Dividend Stocks Yielding More Than 4%", "image": "https://cdn.snapi.dev/images/v1/c/9/gre45666-30.jpg", "site": "The Motley Fool", "text": "These two drugmakers are unlikely to slash or suspend their dividend payments -- even in the midst of a recession.", "url": "https://www.fool.com/investing/2020/10/30/2-no-brainer-dividend-stocks-yielding-more-than-4/"}, {"symbol": "ABBV", "publishedDate": "2020-10-29 02:05:00", "title": "AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ\u2122 (upadacitinib) in Atopic Dermatitis", "image": "https://cdn.snapi.dev/images/v1/r/r/conf5.jpg", "site": "PRNewsWire", "text": "NORTH CHICAGO, Ill., Oct. 29, 2020 /PRNewswire/ -- Late-breaking data analyses to be presented by AbbVie (NYSE: ABBV) at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress show that significantly more atopic dermatitis patients treated with upadacitinib (15...", "url": "https://www.prnewswire.com/news-releases/abbvie-to-present-new-analyses-from-pivotal-phase-3-studies-for-rinvoq-upadacitinib-in-atopic-dermatitis-301162496.html"}, {"symbol": "ABBV", "publishedDate": "2020-10-28 15:45:44", "title": "Top 5 Trades of the Eaton Vance Worldwide Health Sciences Fund", "image": "https://cdn.snapi.dev/images/v1/z/a/asset-management29.jpg", "site": "GuruFocus", "text": "The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the third quarter of the year earlier this week.", "url": "https://www.gurufocus.com/news/1269573/top-5-trades-of-the-eaton-vance-worldwide-health-sciences-fund"}, {"symbol": "ABBV", "publishedDate": "2020-10-28 08:59:39", "title": "7 Cutting-Edge Biotech Stocks for Tomorrow\u00a0", "image": "https://cdn.snapi.dev/images/v1/e/4/drugs41.jpg", "site": "InvestorPlace", "text": "Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.", "url": "https://investorplace.com/2020/10/7-cutting-edge-biotech-stocks-for-tomorrow/"}, {"symbol": "ABBV", "publishedDate": "2020-10-27 12:32:43", "title": "7 High-Yield And High-Growth Undervalued Dividend Stocks To Buy Now", "image": "https://cdn.snapi.dev/images/v1/d/e/dew2wed22---rmzccjtylc.jpg", "site": "Seeking Alpha", "text": "It is the combination of dividend yield and dividend growth which creates the magic of dividend investing. Combining high yield and high growth can have dramatic impacts on your income.", "url": "https://seekingalpha.com/article/4381680-7-high-yield-and-high-growth-undervalued-dividend-stocks-to-buy-now"}, {"symbol": "ABBV", "publishedDate": "2020-10-27 06:12:00", "title": "3 Stocks You Can Still Buy on Sale in a Ridiculously Expensive Market", "image": "https://cdn.snapi.dev/images/v1/t/a/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5965122fthree-arrows-hitting-dollar-sign-on-targetjpgw700opresize.jpg", "site": "The Motley Fool", "text": "And they all offer attractive dividends, too.", "url": "https://www.fool.com/investing/2020/10/27/3-stocks-you-can-still-buy-on-sale-in-a-ridiculous/"}, {"symbol": "ABBV", "publishedDate": "2020-10-26 09:30:25", "title": "Inexpensive AbbVie's High Dividend Yield Makes It A Buy", "image": "https://cdn.snapi.dev/images/v1/4/n/drugs44.jpg", "site": "Seeking Alpha", "text": "AbbVie is seeing success with new drugs. The company offers an attractive dividend yield and trades at a low valuation.", "url": "https://seekingalpha.com/article/4381268-inexpensive-abbvies-high-dividend-yield-makes-buy"}, {"symbol": "ABBV", "publishedDate": "2020-10-25 06:52:37", "title": "15 Of 39 Kiplinger/Analyst Favorite October Dividend Treats", "image": "https://cdn.snapi.dev/images/v1/q/l/dwdf223-8.jpg", "site": "Seeking Alpha", "text": "In October and July Kiplinger Today listed Analyst and Kiplinger favorite dividend stocks. Analyst October favorites numbered 25, plus 15 from Kiplinger, with one repeated left 39 total. These 39 stocks ranged 1.50% to 10.11% in annual-yield and ranged 2.49% to 87.04% in one-year price-target-upsides per brokers 10/22/20.", "url": "https://seekingalpha.com/article/4381191-15-of-39-kiplinger-analyst-favorite-october-dividend-treats"}, {"symbol": "ABBV", "publishedDate": "2020-10-22 20:18:43", "title": "13 Of 56 Outstanding Dividend Stocks Stand Tall For November", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "From May to July, Kiplinger Today listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays.", "url": "https://seekingalpha.com/article/4380720-13-of-56-outstanding-dividend-stocks-stand-tall-for-november"}, {"symbol": "ABBV", "publishedDate": "2020-10-20 23:41:35", "title": "AbbVie: Stock Will Break $100 Once Management And Market Are On Same Page (NYSE:ABBV)", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "AbbVie stock looked to have strong momentum in July, but Q2 results triggered a slide from $100, to $84 at the the time of writing.", "url": "https://seekingalpha.com/article/4380120-abbvie-stock-will-break-100-management-and-market-are-on-page"}, {"symbol": "ABBV", "publishedDate": "2020-10-19 00:00:00", "title": "Antiviral Drugs Market will Exhibit Neutral Impact during 2020-2024 | Growing Cases of Viral Infections to Improve the Market Growth | Technavio", "image": "https://mms.businesswire.com/media/20201019005416/en/831290/23/IRTNTR43207.jpg", "site": "businesswire", "text": "The Global Antiviral Drugs Market will grow by USD 43.37 bn during 2020-2024", "url": "https://www.businesswire.com/news/home/20201019005416/en/Antiviral-Drugs-Market-will-Exhibit-Neutral-Impact-during-2020-2024-Growing-Cases-of-Viral-Infections-to-Improve-the-Market-Growth-Technavio"}, {"symbol": "ABBV", "publishedDate": "2020-10-16 09:16:53", "title": "5 High-Yield Stocks for 5%-Plus Dividend Payouts", "image": "https://investorplace.com/wp-content/uploads/2019/07/dividends-tickers.jpg", "site": "https://investorplace.com", "text": "Times have been tough lately for income investors, but these high-yield stocks whose dividends are safe remain worth a second look.", "url": "https://investorplace.com/2020/10/5-high-yield-stocks-abbv-enb-pm-unm-ibm-for-5-plus-dividend-payouts/"}, {"symbol": "ABBV", "publishedDate": "2020-10-15 08:16:20", "title": "Buy AbbVie Before It Raises Dividends Again (NYSE:ABBV)", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "AbbVie has multiple product launches in 2021 that will bring billions more in revenue. Strong free cash flow available for a dividend hike.", "url": "https://seekingalpha.com/article/4379160-buy-abbvie-raises-dividends-again"}, {"symbol": "ABBV", "publishedDate": "2020-10-14 00:00:00", "title": "UCL tests prove Airlite paint kills coronaviruses", "image": "http://www.businesswire.com/images/bwlogo_square.png", "site": "businesswire", "text": "UCL has tested a paint from Airlite to prove is can kill strains of coronavirus. \nGrosvenor Britain & Ireland have made Airlite its paint of choice", "url": "https://www.businesswire.com/news/home/20201014005074/en/UCL-tests-prove-Airlite-paint-kills-coronaviruses"}, {"symbol": "ABBV", "publishedDate": "2020-10-13 21:47:17", "title": "50 October Dividend Stocks Billionaires Love", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "Kiplinger Investing publishes opportune stock and fund lists for investors online. This Billionaire List by Dan Burrows, first published on 9/4/20, was updated on 10/9/20.", "url": "https://seekingalpha.com/article/4378938-50-october-dividend-stocks-billionaires-love"}, {"symbol": "ABBV", "publishedDate": "2020-10-10 17:43:38", "title": "65 Dividend Aristocrats Optimal October Outcomes", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "S&P 500 Dividend Aristocrats measure performance of S&P 500 companies that have increased dividends every year for 25 consecutive years. - us.spindices.com.", "url": "https://seekingalpha.com/article/4378467-65-dividend-aristocrats-optimal-october-outcomes"}, {"symbol": "ABBV", "publishedDate": "2020-10-09 07:40:57", "title": "Trust Co. of Oklahoma Takes $487,000 Position in AbbVie Inc. (NYSE:ABBV)", "image": "https://www.marketbeat.com/logos/abbvie-inc-logo.jpg", "site": "https://www.thelincolnianonline.com", "text": "Trust Co. of Oklahoma bought a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 5,555 shares of the company\u2019s stock, valued at approximately $487,000. Several other large investors have also bought and sold shares of [\u2026]", "url": "https://www.thelincolnianonline.com/2020/10/09/trust-co-of-oklahoma-takes-487000-position-in-abbvie-inc-nyseabbv.html"}, {"symbol": "ABBV", "publishedDate": "2020-10-09 00:00:00", "title": "Ophthalmology Therapeutics Market | Increasing Prevalence of Eye Diseases to Boost the Market Growth | Technavio", "image": "https://mms.businesswire.com/media/20201009005248/en/829041/23/IRTNTR40882.jpg", "site": "businesswire", "text": "The Global Ophthalmology Therapeutics Market will grow by USD 10.42 bn during 2020-2024", "url": "https://www.businesswire.com/news/home/20201009005248/en/Ophthalmology-Therapeutics-Market-Increasing-Prevalence-of-Eye-Diseases-to-Boost-the-Market-Growth-Technavio"}, {"symbol": "ABBV", "publishedDate": "2020-10-08 09:34:46", "title": "The global active pharmaceutical ingredients market is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8%", "image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "site": "marketwatch", "text": "New York, Oct 08, 2020 (GLOBE NEWSWIRE via COMTEX) --\nNew York, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report...", "url": "https://www.marketwatch.com/press-release/the-global-active-pharmaceutical-ingredients-market-is-projected-to-reach-usd-2483-billion-by-2025-from-usd-1873-billion-in-2020-at-a-cagr-of-58-2020-10-08"}, {"symbol": "ABBV", "publishedDate": "2020-10-08 08:24:51", "title": "The 33 Dividend Stocks Fit For Our Times October Update", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "Kiplinger listed five sets of dividend stocks qualified to survive the COVID-19 pandemic. Barron's weekly added one more.", "url": "https://seekingalpha.com/article/4378099-33-dividend-stocks-fit-for-times-october-update"}, {"symbol": "ABBV", "publishedDate": "2020-10-07 19:36:59", "title": "My Dividend Growth Portfolio Q3 Update: 28 Holdings, 16 Sells, 12 Buys, 3.89% Yield", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "I received $67.56 in dividends for the quarter compared to $23.17 for Q3 of 2019. Hitting new highs in dividend income.", "url": "https://seekingalpha.com/article/4378045-dividend-growth-portfolio-q3-update-28-holdings-16-sells-12-buys-3_89-yield"}, {"symbol": "ABBV", "publishedDate": "2020-10-07 06:29:12", "title": "Immunotherapy drugs market Report Analysis, Share, Revenue, Growth Rate With Forecast Overview", "image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "site": "marketwatch", "text": "Oct 07, 2020 (AmericaNewsHour) --\nThis market research report includes a detailed segmentation of the global immunotherapy drugs market by drug type...", "url": "https://www.marketwatch.com/press-release/immunotherapy-drugs-market-report-analysis-share-revenue-growth-rate-with-forecast-overview-2020-10-07"}, {"symbol": "ABBV", "publishedDate": "2020-10-07 06:01:34", "title": "Hepatocellular Carcinoma Drugs Market Size, Share 2020 Global Business Growth, Trend, Segmentation, Top Key Players Analysis Industry, Opportunities and Forecast to 2024", "image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "site": "marketwatch", "text": "Oct 07, 2020 (The Expresswire) --\nGlobal \"Hepatocellular Carcinoma Drugs Market\" 2020 provides strong industry focus with top Countries by key...", "url": "https://www.marketwatch.com/press-release/hepatocellular-carcinoma-drugs-market-size-share-2020-global-business-growth-trend-segmentation-top-key-players-analysis-industry-opportunities-and-forecast-to-2024-2020-10-07"}, {"symbol": "ABBV", "publishedDate": "2020-10-05 10:48:31", "title": "Transplantation Market Growth, Competitive Landscape, Segment Forecasts and Regional Outlook 2020 - 2027", "image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "site": "marketwatch", "text": "Oct 05, 2020 (Profound via COMTEX) --\nThe study offers valuable information about the global Transplantation market to illustrate how the market would grow...", "url": "https://www.marketwatch.com/press-release/transplantation-market-growth-competitive-landscape-segment-forecasts-and-regional-outlook-2020---2027-2020-10-05"}, {"symbol": "ABBV", "publishedDate": "2020-10-05 10:09:38", "title": "Drugs for HIV Market 2020 : Comprehensive Analysis, Top Countries Data, Market Size, Future Estimations, Growth Drivers and Forecast to 2026", "image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "site": "marketwatch", "text": "Oct 05, 2020 (The Expresswire) --\nThe Global \"Drugs for HIV Market\" is anticipated to rise at a considerable rate during the forecast period, between 2020...", "url": "https://www.marketwatch.com/press-release/drugs-for-hiv-market-2020-comprehensive-analysis-top-countries-data-market-size-future-estimations-growth-drivers-and-forecast-to-2026-2020-10-05"}, {"symbol": "ABBV", "publishedDate": "2020-10-05 07:30:19", "title": "Microbiome Therapeutics Market 2020 Industry Size, Share, Regional Growth Analysis, Share, Trends and Forecast 2026", "image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "site": "marketwatch", "text": "Oct 05, 2020 (The Expresswire) --\nMicrobiome is one of the fastest growing fields in biology. Fortune Business Insights, in a report titled \u201cMicrobiome...", "url": "https://www.marketwatch.com/press-release/microbiome-therapeutics-market-2020-industry-size-share-regional-growth-analysis-share-trends-and-forecast-2026-2020-10-05"}, {"symbol": "ABBV", "publishedDate": "2020-10-05 06:37:30", "title": "Drugs for HIV Market 2020 - Global Industry Research Update, Future Scope, Size Estimation, Revenue, Pricing Trends, Regional Outlook and Forecast to 2026", "image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "site": "marketwatch", "text": "Oct 05, 2020 (The Expresswire) --\nThe latest report published with an innovative statistics of the market titled as Drugs for HIV Marketacknowledges Size...", "url": "https://www.marketwatch.com/press-release/drugs-for-hiv-market-2020---global-industry-research-update-future-scope-size-estimation-revenue-pricing-trends-regional-outlook-and-forecast-to-2026-2020-10-05"}, {"symbol": "ABBV", "publishedDate": "2020-10-05 06:37:27", "title": "Bi-Specific Antibodies Therapy Market: 2020 Global Industry Trends, Growth, Share, Size And 2026 Forecast Research Report", "image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "site": "marketwatch", "text": "Oct 05, 2020 (The Expresswire) --\nThe latest report published with an innovative statistics of the market titled as Bi-Specific Antibodies Therapy...", "url": "https://www.marketwatch.com/press-release/bi-specific-antibodies-therapy-market-2020-global-industry-trends-growth-share-size-and-2026-forecast-research-report-2020-10-05"}, {"symbol": "ABBV", "publishedDate": "2020-10-05 00:00:00", "title": "HIV treatment has no benefit for hospitalised COVID-19 patients: study", "image": "https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEG94237_M.jpg", "site": "investing", "text": "HIV treatment has no benefit for hospitalised COVID-19 patients: study", "url": "https://www.investing.com/news/coronavirus/hiv-treatment-has-no-benefit-for-hospitalised-covid19-patients-study-2316322"}, {"symbol": "ABBV", "publishedDate": "2020-10-03 14:55:07", "title": "Regenxbio Advances Clinical Program, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:RGNX)", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "Regenxbio announces expansion of RGX-121 clinical program. AbbVie announces pulling Fibristal from the Canadian market.", "url": "https://seekingalpha.com/article/4377462-regenxbio-advances-clinical-program-and-news-good-bad-and-ugly-of-biopharma"}, {"symbol": "ABBV", "publishedDate": "2020-10-01 12:34:30", "title": "Global Fabry Disease Therapeutic Market Size, Top Countries Statistics, Scope, Sales, Growth Drivers, Opportunities, Industry Trends and Forecasts to 2026", "image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "site": "marketwatch", "text": "Oct 01, 2020 (The Expresswire) --\n\u201cFabry Disease Therapeutic Market\" report provides a detailed evaluation of the market by highlighting information on...", "url": "https://www.marketwatch.com/press-release/global-fabry-disease-therapeutic-market-size-top-countries-statistics-scope-sales-growth-drivers-opportunities-industry-trends-and-forecasts-to-2026-2020-10-01"}, {"symbol": "ABBV", "publishedDate": "2020-10-01 11:44:36", "title": "Seasonal Affective Disorder Therapeutics Market 2020 Disclosing Latest Trends and Advancement Outlook 2025", "image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "site": "marketwatch", "text": "Oct 01, 2020 (Market Insight Reports) --\nThe Seasonal Affective Disorder Therapeutics Market as of late Published Global Market look into study with in...", "url": "https://www.marketwatch.com/press-release/seasonal-affective-disorder-therapeutics-market-2020-disclosing-latest-trends-and-advancement-outlook-2025-2020-10-01"}, {"symbol": "ABBV", "publishedDate": "2020-09-30 12:30:15", "title": "Solving One of the Largest Drivers of Disease: Inflammation", "image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "site": "marketwatch", "text": "NEW YORK, Sept. 30, 2020 /PRNewswire via COMTEX/ --\nNEW YORK, Sept. 30, 2020 /PRNewswire/ --\u00a0Inflammation typically occurs in the body as a natural response...", "url": "https://www.marketwatch.com/press-release/solving-one-of-the-largest-drivers-of-disease-inflammation-2020-09-30"}, {"symbol": "ABBV", "publishedDate": "2020-09-28 00:00:00", "title": "Global Anti-Viral Therapies Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com", "image": "https://mms.businesswire.com/media/20200928005613/en/371054/23/ResearchAndMarkets_800px.jpg", "site": "businesswire", "text": "The", "url": "https://www.businesswire.com/news/home/20200928005613/en/Global-Anti-Viral-Therapies-Market-Forecast-to-2027---COVID-19-Impact-and-Analysis---ResearchAndMarkets.com"}, {"symbol": "ABBV", "publishedDate": "2020-09-26 00:00:00", "title": "Eczema Therapeutics Market- Roadmap for Recovery from COVID-19 | Geopolitical Uncertainties to Boost the Market Growth | Technavio", "image": "https://mms.businesswire.com/media/20200925005337/en/824716/23/IRTNTR40707.jpg", "site": "businesswire", "text": "The Global Eczema Therapeutics Market will grow by USD 3.60 bn during 2020-2024", "url": "https://www.businesswire.com/news/home/20200925005337/en/Eczema-Therapeutics-Market--Roadmap-for-Recovery-from-COVID-19-Geopolitical-Uncertainties-to-Boost-the-Market-Growth-Technavio"}, {"symbol": "ABBV", "publishedDate": "2020-09-25 03:41:05", "title": "56 Outstanding Dividend Stocks For October From Kiplinger", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "From May to July Kiplinger Today listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays.", "url": "https://seekingalpha.com/article/4376242-56-outstanding-dividend-stocks-for-october-from-kiplinger"}, {"symbol": "ABBV", "publishedDate": "2020-09-23 00:00:00", "title": "Anti-inflammatory Therapeutics Market- Roadmap for Recovery from COVID-19|Increase In Prevalence Of IMID to boost the Market Growth | Technavio", "image": "https://mms.businesswire.com/media/20200922005958/en/823668/23/IRTNTR41324.jpg", "site": "businesswire", "text": "The Global Anti-inflammatory Therapeutics Market will grow by USD 30.62 bn during 2020-2024", "url": "https://www.businesswire.com/news/home/20200922005958/en/Anti-inflammatory-Therapeutics-Market--Roadmap-for-Recovery-from-COVID-19Increase-In-Prevalence-Of-IMID-to-boost-the-Market-Growth-Technavio"}, {"symbol": "ABBV", "publishedDate": "2020-09-22 12:30:10", "title": "AbbVie: I Don't Wanna Miss This Thing (NYSE:ABBV)", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "2020 is shaping up to be another record year for AbbVie. Six months into the pandemic, AbbVie has mastered the crisis better than expected and once again demonstrated the power of its strong and resilient portfolio.", "url": "https://seekingalpha.com/article/4375609-abbvie-i-dont-wanna-miss-this-thing"}, {"symbol": "ABBV", "publishedDate": "2020-09-19 00:00:00", "title": "COVID-19 Recovery Analysis: Monoclonal Antibodies Market | Advent of Low-priced Biosimilar Monoclonal Antibodies to Boost the Market Growth | Technavio", "image": "https://mms.businesswire.com/media/20200918005327/en/822750/23/IRTNTR44342.jpg", "site": "businesswire", "text": "The Global Monoclonal Antibodies Market will grow by $ 54.55 bn during 2020-2024", "url": "https://www.businesswire.com/news/home/20200918005327/en/COVID-19-Recovery-Analysis-Monoclonal-Antibodies-Market-Advent-of-Low-priced-Biosimilar-Monoclonal-Antibodies-to-Boost-the-Market-Growth-Technavio"}, {"symbol": "ABBV", "publishedDate": "2020-09-18 17:54:57", "title": "50 Billionaire Holdings, 27 Pay Dividends, 2 To Buy In September", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "Kiplinger Investing publishes opportune stock and fund lists for investors online. This Billionaire List by Dan Burrows, first published 9/4/20, was updated 9/16/20.", "url": "https://seekingalpha.com/article/4375196-50-billionaire-holdings-27-pay-dividends-2-to-buy-in-september"}, {"symbol": "ABBV", "publishedDate": "2020-09-18 09:35:28", "title": "AbbVie - Still A 20% Undervalued, High-Yielding Buy (NYSE:ABBV)", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "I wrote about AbbVie about a year ago, and have mentioned the company in many of my monthly and undervaluation-focused articles.", "url": "https://seekingalpha.com/article/4375084-abbvie-still-20-undervalued-high-yielding-buy"}, {"symbol": "ABBV", "publishedDate": "2020-09-17 21:55:02", "title": "Interest Rates And Their Impact On Stock Values", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "When it comes to long-term returns and risk, valuation matters, and it matters a lot. People believe that lower interest rates justify higher valuations because equities become the only game in town when interest rates are as low as they are today.", "url": "https://seekingalpha.com/article/4375017-interest-rates-and-impact-on-stock-values"}, {"symbol": "ABBV", "publishedDate": "2020-09-17 00:00:00", "title": "Intrauterine Contraceptive Devices (IUD) Market: COVID-19 Business Continuity Plan | Evolving Opportunities with AbbVie Inc. and Bayer AG | Technavio", "image": "https://mms.businesswire.com/media/20200917005067/en/822002/23/IRTNTR44874.jpg", "site": "businesswire", "text": "The Global Intrauterine Contraceptive Devices (IUD) Market will grow by $ 597.40 mn during 2020-2024", "url": "https://www.businesswire.com/news/home/20200917005067/en/Intrauterine-Contraceptive-Devices-IUD-Market-COVID-19-Business-Continuity-Plan-Evolving-Opportunities-with-AbbVie-Inc.-and-Bayer-AG-Technavio"}, {"symbol": "ABBV", "publishedDate": "2020-09-16 03:26:35", "title": "Is The Stock Worthy? CHF Solutions, Inc. (NASDAQ:CHFS), AbbVie Inc. (NYSE:ABBV) - Stocks Equity", "image": "http://www.stocksequity.com/wp-content/uploads/2019/04/1-55.jpg", "site": "http://www.stocksequity.com", "text": "CHF Solutions, Inc. (NASDAQ:CHFS) with the stream of 8.97% also noticed, India AbbVie Inc. (NYSE:ABBV) encountered a rapid change of 0.46% in the last hour of Tuesday\u2019s trading session. CHF \u2026", "url": "http://www.stocksequity.com/active-stocks/is-the-stock-worthy-chf-solutions-inc-nasdaqchfs-abbvie-inc-nyseabbv/"}, {"symbol": "ABBV", "publishedDate": "2020-09-15 07:34:24", "title": "AbbVie: The Time Is Now", "image": "https://static.seekingalpha.com/uploads/2020/9/15/5847171-16001656385103571_origin.png", "site": "seekingalpha.com", "text": "ABBV has sold off in recent weeks. Biotechs are starting to outperform.", "url": "https://seekingalpha.com/article/4374345-abbvie-time-is-now"}, {"symbol": "ABBV", "publishedDate": "2020-09-15 01:00:49", "title": "Dividend Aristocrats See 6 Star September Selections", "image": "https://static.seekingalpha.com/uploads/2020/9/15/748328-16001430878354704_origin.png", "site": "seekingalpha.com", "text": "S&P 500\u00ae Dividend Aristocrats measure performance of S&P 500 companies that have increased dividends every year for 25 consecutive years.---us.spindices.com.", "url": "https://seekingalpha.com/article/4374305-dividend-aristocrats-see-6-star-september-selections"}, {"symbol": "ABBV", "publishedDate": "2020-09-13 10:32:46", "title": "Dividend Income Update: August 2020", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha.com", "text": "August was a little underwhelming for me as my income dropped a bit, but this was due to sales made last year.", "url": "https://seekingalpha.com/article/4373934-dividend-income-update-august-2020"}, {"symbol": "ABBV", "publishedDate": "2020-09-11 12:00:02", "title": "Drugmaker AbbVie pressures reluctant employees to return to work, raising safety questions", "image": "https://image.cnbcfm.com/api/v1/image/104321344-RTR4S7O9.jpg?v=1580163570", "site": "cnbc", "text": "Even if employees have demonstrated an ability to do their jobs from home, the company expects them to report to the office to foster creativity and innovation under its phased-in return-to-work plan.", "url": "https://www.cnbc.com/2020/09/11/pharmacabbvie-employees-raise-safety-concerns-with-return-to-work-plans.html"}, {"symbol": "ABBV", "publishedDate": "2020-09-10 11:30:00", "title": "When Tech Stocks Fail You, Choose These 5 Undervalued, Low-Risk Dividend Aristocrats", "image": "https://static3.seekingalpha.com/uploads/2020/9/9/28873105-15996501463641293.jpg", "site": "seekingalpha.com", "text": "Tech clearly has been the winner so far in 2020, thanks to positive sentiment. Much of these gains were driven by multiple expansion, not by underlying earnings growth.", "url": "https://seekingalpha.com/article/4373445-when-tech-stocks-fail-you-choose-5-undervalued-low-risk-dividend-aristocrats"}, {"symbol": "ABBV", "publishedDate": "2020-09-10 07:43:33", "title": "20 More Stocks I Hope To Buy During The Next Market Sell-Off (High Yield Edition)", "image": "https://ci3.googleusercontent.com/proxy/k2_VNRd9s0yNursHE9Wccu2ZYxtRv92CJhLGKaAL5ukDvxuWTFKNxMesLyYBrxxmdq1ywL-ptJMM7dLV8ShetazOKzv5lQKA1Fry4KmYlFka71L97G86CW0rENH1NAaOwUg_=s0-d-e1-ft#https://static.seekingalpha.com/cdn/s3/marketing/157082881372847572571/image.png", "site": "seekingalpha.com", "text": "In this article, I use yield thresholds, instead of valuation multiples, to arrive at recession wish list buy targets.", "url": "https://seekingalpha.com/article/4373482-20-stocks-i-hope-to-buy-during-next-market-sell-off-high-yield-edition"}, {"symbol": "ABBV", "publishedDate": "2020-09-09 05:52:27", "title": "September 2020 Stocks - Financials, Real Estate, Industrials, IT And Pharma", "image": "https://static2.seekingalpha.com/uploads/2020/5/29/saupload_1200px-Reinsurance_Group_of_America_logo.svg_thumb1.png", "site": "seekingalpha.com", "text": "The time has come once again to look at what sort of companies you'll want to be buying, this time as we move into September of 2020.", "url": "https://seekingalpha.com/article/4373196-september-2020-stocks-financials-real-estate-industrials-and-pharma"}, {"symbol": "ABBV", "publishedDate": "2020-09-09 03:52:05", "title": "A 91 Kiplinger 'Most Reliable Dividend Stocks On Earth' September Update", "image": "https://static2.seekingalpha.com/uploads/2020/9/8/748328-15995887217257388.png", "site": "seekingalpha.com", "text": "Kiplinger insights for investors online, offered this list of 91 Top Dividend Stocks From Around The World July 13.", "url": "https://seekingalpha.com/article/4373184-91-kiplinger-most-reliable-dividend-stocks-on-earth-september-update"}, {"symbol": "ABBV", "publishedDate": "2020-09-08 04:46:29", "title": "AbbVie I-Mab Cancer Deal, And Other News: The Good, Bad And Ugly Of Biopharma", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha.com", "text": "AbbVie inks multi-billion cancer deal with I-Mab. Chi-Med begins global phase III trial of cancer treatment.", "url": "https://seekingalpha.com/article/4372972-abbvie-i-mab-cancer-deal-and-news-good-bad-and-ugly-of-biopharma"}, {"symbol": "ABBV", "publishedDate": "2020-09-07 06:59:02", "title": "Nicholas Ward's Dividend Growth Portfolio: August 2020 Review", "image": "https://static2.seekingalpha.com/uploads/2020/9/2/5939041-15991034977826867.png", "site": "seekingalpha.com", "text": "My passive income increased 15.9% year over year. My portfolio posted gains of 8.6% during August.", "url": "https://seekingalpha.com/article/4372875-nicholas-wards-dividend-growth-portfolio-august-2020-review"}, {"symbol": "ABBV", "publishedDate": "2020-09-07 01:15:15", "title": "33 Dividend Stocks Fit For COVID-19 Times: A September Update", "image": "https://static2.seekingalpha.com/uploads/2020/9/4/748328-15992766847620354.png", "site": "seekingalpha.com", "text": "Kiplinger listed five sets of dividend stocks qualified to survive the Covid-19 pandemic. Barron's weekly added one more.", "url": "https://seekingalpha.com/article/4372848-33-dividend-stocks-fit-for-covidminus-19-times-september-update"}, {"symbol": "ABBV", "publishedDate": "2020-09-06 22:50:57", "title": "Calm Down: This Time Won't Be Different", "image": "https://static.seekingalpha.com/uploads/2020/9/5/29440305-1599295271741029.jpg", "site": "seekingalpha.com", "text": "The market closed down last week. Investors are getting jittery.", "url": "https://seekingalpha.com/article/4372844-calm-down-this-time-wont-be-different"}, {"symbol": "ABBV", "publishedDate": "2020-09-06 12:21:27", "title": "Week In Review: I-Mab Partners CD47 With AbbVie In $2 Billion Deal", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha.com", "text": "Shanghai's I-Mab out-licensed ex-China rights for lemzoparlimab, its anti-CD47 mAb, to AbbVie in a blockbuster $2 billion agreement.", "url": "https://seekingalpha.com/article/4372814-week-in-review-i-mab-partners-cd47-abbvie-in-2-billion-deal"}, {"symbol": "ABBV", "publishedDate": "2020-09-05 09:37:14", "title": "August 2020 Dividend Portfolio Update", "image": "https://static.seekingalpha.com/uploads/2020/9/3/38506186-15991728111584718.png", "site": "seekingalpha.com", "text": "Markets were racing to all-time highs in August fueled by technology stocks and the mega caps. I am continuing my monthly investment plans and suspiciously follow the massive rally in technology stocks.", "url": "https://seekingalpha.com/article/4372749-august-2020-dividend-portfolio-update"}, {"symbol": "ABBV", "publishedDate": "2020-09-04 02:45:56", "title": "My Dividend Growth Portfolio August Review: 38 Holdings, No Trades", "image": "https://static3.seekingalpha.com/images/marketing_images/stock_market/portfolio2_cc0.jpeg", "site": "seekingalpha.com", "text": "I received $768 in August, which was down from May and down from August 2019. I made no trades over the month as stocks continue their meteoric rise.", "url": "https://seekingalpha.com/article/4372553-dividend-growth-portfolio-august-review-38-holdings-no-trades"}, {"symbol": "ABBV", "publishedDate": "2020-09-04 00:54:37", "title": "Humira Battles: AbbVie's Upa Versus Gilead's Filgo-Redux", "image": "https://static3.seekingalpha.com/uploads/2020/8/31/3024641-1598889435671154.png", "site": "seekingalpha.com", "text": "AbbVie's upa (now RINVOQ) has lived up to my expectations. Filgo, which many had pegged as the superior of the two, has faltered on the way to the bout.", "url": "https://seekingalpha.com/article/4372548-humira-battles-abbvies-upa-versus-gileads-filgo-redux"}, {"symbol": "ABBV", "publishedDate": "2020-09-03 18:47:12", "title": "The Sell-Off Accelerates, What To Do Now", "image": "https://static.seekingalpha.com/uploads/2020/9/3/486106-15991532517022426.png", "site": "seekingalpha.com", "text": "The S&P 500's sell-off accelerates. The best sectors and stocks to consider when it bottoms.", "url": "https://seekingalpha.com/article/4372506-sell-off-accelerates-what-to-now"}, {"symbol": "ABBV", "publishedDate": "2020-09-03 18:36:56", "title": "The Rose 89 Stock Portfolio August 2020 Update", "image": "https://static2.seekingalpha.com/uploads/2020/9/2/1400641-15990789131174338.png", "site": "seekingalpha.com", "text": "20 company dividend payments were received, increasing income by 32%, reversing the low income of July, making Q3 up 2.5% from April and May of Q2.", "url": "https://seekingalpha.com/article/4372503-rose-89-stock-portfolio-august-2020-update"}, {"symbol": "ABBV", "publishedDate": "2020-09-03 13:06:26", "title": "August 2020 Portfolio Update - More Cash, More Investments", "image": "https://static1.seekingalpha.com/uploads/2020/8/23/49836612-15981728874440708.png", "site": "seekingalpha.com", "text": "The time has come to look over August's investments and dividends. Markets continue to recover, though some sectors remain in turmoil.", "url": "https://seekingalpha.com/article/4372393-august-2020-portfolio-update-cash-investments"}, {"symbol": "ABBV", "publishedDate": "2020-09-03 07:50:44", "title": "Blue Chip DRiP Portfolio: August Dividends + Covered Call Income", "image": "https://static3.seekingalpha.com/images/marketing_images/numbers_words_signs/words_phrases/dividends_red_marker.jpeg", "site": "seekingalpha.com", "text": "August dividend income was stronger than anticipated, considering the widespread cuts and our recent stock liquidation to buy a home.", "url": "https://seekingalpha.com/article/4372303-blue-chip-drip-portfolio-august-dividends-covered-call-income"}, {"symbol": "ABBV", "publishedDate": "2020-08-31 10:00:00", "title": "AbbVie: Dividend Growth Stock Trading At A BIG Discount", "image": "https://static.seekingalpha.com/uploads/2020/8/29/5764111-15986748751392562_origin.png", "site": "seekingalpha.com", "text": "ABBV shares are trading at a forward earnings multiple of 7.7x. The company has a loaded pipeline and a slew of new drugs with HUGE potential.", "url": "https://seekingalpha.com/article/4371659-abbvie-dividend-growth-stock-trading-big-discount"}, {"symbol": "ABBV", "publishedDate": "2020-08-30 05:38:52", "title": "56 Kiplinger Outstanding Dividend Stocks For September", "image": "https://static.seekingalpha.com/uploads/2020/8/29/748328-1598749381603249_origin.png", "site": "seekingalpha.com", "text": "Kiplinger Today in July listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays.", "url": "https://seekingalpha.com/article/4371532-56-kiplinger-outstanding-dividend-stocks-for-september"}, {"symbol": "ABBV", "publishedDate": "2020-08-30 04:22:25", "title": "BeiGene COVID-19 Deal And Other News: The Good, Bad And Ugly Of Biopharma", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha.com", "text": "BeiGene signs deal with Singlomics for neutralizing COVID-19 antibodies. UroGen flunks Phase 2 RTGel combo study.", "url": "https://seekingalpha.com/article/4371529-beigene-covidminus-19-deal-and-news-good-bad-and-ugly-of-biopharma"}, {"symbol": "ABBV", "publishedDate": "2020-08-29 07:58:36", "title": "Why I Bought AbbVie Despite 43% Appreciation This Year", "image": "https://static.seekingalpha.com/images/marketing_images/fair_use_logos_products/sacl_abbv_abbvie_logo_bluejpeg", "site": "seekingalpha.com", "text": "AbbVie faces some looming questions about the loss of mega-blockbuster Humira in 2023, and a highly leveraged balance sheet.", "url": "https://seekingalpha.com/article/4371505-why-i-bought-abbvie-despite-43-appreciation-this-year"}, {"symbol": "ABBV", "publishedDate": "2020-08-28 15:10:10", "title": "You Can Still Buy Industrial And Technology Stocks, But Risk Controls Are Key", "image": "", "site": "seekingalpha.com", "text": "", "url": "https://seekingalpha.com/article/4371440-you-can-still-buy-industrial-and-technology-stocks-risk-controls-are-key"}, {"symbol": "ABBV", "publishedDate": "2020-08-28 09:36:21", "title": "Tracking Dan Loeb's Third Point Portfolio - Q2 2020 Update", "image": "https://static1.seekingalpha.com/uploads/2020/8/28/106657-1598610973143449.jpg", "site": "seekingalpha.com", "text": "Dan Loeb's 13F portfolio value increased from $6.27B to $7.30B this quarter. The number of positions increased from 30 to 36.", "url": "https://seekingalpha.com/article/4371338-tracking-dan-loebs-third-point-portfolio-q2-2020-update"}, {"symbol": "ABBV", "publishedDate": "2020-08-27 11:05:00", "title": "Don\u2019t settle for skimpy bond yields and make dividend stocks your best income play, fixed-income veteran says", "image": "https://s.marketwatch.com/public/resources/images/MW-IN254_ABBV_2_ZG_20200826122412.jpg", "site": "marketwatch", "text": "The fixed-income market \u2018is as much of a challenge as I have seen in 41 years,\u2019 says Dan Genter, CEO of RNC Genter Capital Management.", "url": "https://www.marketwatch.com/story/dont-settle-for-skimpy-bond-yields-and-make-dividend-stocks-your-best-income-play-fixed-income-veteran-says-2020-08-27"}, {"symbol": "ABBV", "publishedDate": "2020-08-27 00:00:00", "title": "Global Immunosuppressant Drugs Market 2020-2025 with COVID-19 Impact Analysis and Profilings of 16 Major Players - ResearchAndMarkets.com", "image": "https://mms.businesswire.com/media/20200827005606/en/371054/23/ResearchAndMarkets_800px.jpg", "site": "businesswire", "text": "The", "url": "https://www.businesswire.com/news/home/20200827005606/en/Global-Immunosuppressant-Drugs-Market-2020-2025-COVID-19-Impact"}, {"symbol": "ABBV", "publishedDate": "2020-08-25 16:31:14", "title": "XLV: The Healthcare Sector Is Underestimated", "image": "https://static2.seekingalpha.com/uploads/2020/8/24/saupload_e365826a993cd034699f8a7dd8754427.png", "site": "seekingalpha.com", "text": "XLV is a diversified healthcare ETF including some of the larger caps in the S&P 500. Despite knowing some upside, it has been underperforming when comparing with peers.", "url": "https://seekingalpha.com/article/4370720-xlv-healthcare-sector-is-underestimated"}, {"symbol": "ABBV", "publishedDate": "2020-08-25 11:17:00", "title": "These \u2018Dividend Aristocrat\u2019 stocks have been raising their dividends for decades, and there have been no dividend cuts during the pandemic", "image": "https://s.marketwatch.com/public/resources/images/MW-IN103_Raythe_ZH_20200824151502.jpg", "site": "marketwatch", "text": "Dozens of other S&P 500 companies, in contrast, have reduced their payouts.", "url": "https://www.marketwatch.com/story/these-dividend-aristocrat-stocks-have-been-raising-their-dividends-for-decades-and-there-have-been-no-dividend-cuts-during-the-pandemic-2020-08-25"}, {"symbol": "ABBV", "publishedDate": "2020-08-25 00:00:00", "title": "Insights on the Multiple Sclerosis Therapies Global Market to 2027 - Opportunity Analysis and Industry Forecast - ResearchAndMarkets.com", "image": "https://mms.businesswire.com/media/20200825005524/en/371054/23/ResearchAndMarkets_800px.jpg", "site": "businesswire", "text": "The", "url": "https://www.businesswire.com/news/home/20200825005524/en/Insights-Multiple-Sclerosis-Therapies-Global-Market-2027"}, {"symbol": "ABBV", "publishedDate": "2020-08-22 07:24:19", "title": "Market Neutral Strategy: Long AbbVie, Short Gilead", "image": "https://static3.seekingalpha.com/images/marketing_images/numbers_words_signs/numbers/percentage.jpeg", "site": "seekingalpha.com", "text": "With an overvalued stock market reaching for record high ratios vs. underlying business profits and sales, hedged long/short portfolio designs are worth consideration.", "url": "https://seekingalpha.com/article/4370247-market-neutral-strategy-long-abbvie-short-gilead"}, {"symbol": "ABBV", "publishedDate": "2020-08-20 12:32:19", "title": "Tracking David Tepper's Appaloosa Management Portfolio - Q2 2020 Update", "image": "https://static3.seekingalpha.com/uploads/2020/8/20/106657-1597936441822164.jpg", "site": "seekingalpha.com", "text": "David Tepper\u2019s 13F portfolio value increased from $3.27B to $5.76B this quarter. Appaloosa added AT&T while increasing Alibaba Group Holdings during the quarter.", "url": "https://seekingalpha.com/article/4369949-tracking-david-teppers-appaloosa-management-portfolio-q2-2020-update"}, {"symbol": "ABBV", "publishedDate": "2020-08-20 07:44:16", "title": "15 Wonderful Blue-Chip Buys I Just Made For My Retirement Portfolio", "image": "https://static1.seekingalpha.com/uploads/2020/8/19/47572571-15978522017034597.jpg", "site": "seekingalpha.com", "text": "The S&P 500 has ended its bear market, after seeing the greatest 100-day rally in history, and recovering new record highs just 104 trading days after March 23rd lows.", "url": "https://seekingalpha.com/article/4369875-15-wonderful-blue-chip-buys-i-just-made-for-retirement-portfolio"}, {"symbol": "ABBV", "publishedDate": "2020-08-19 23:02:11", "title": "3 Strong, Diverse Dividend Stocks to Buy with Market at New Highs", "image": "", "site": "Yahoo", "text": "It might be best to find stable stocks that offer solid dividend yields. So let's examine three highly-ranked stocks from three different industries that fit the bill...", "url": "https://finance.yahoo.com/news/3-strong-diverse-dividend-stocks-230211395.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-19 15:04:00", "title": "FDA Denies Approval for Gilead Sciences&#39; Potential Blockbuster Arthritis Drug", "image": "", "site": "Yahoo", "text": "Onlookers had been expecting a thumbs up for filgotinib. Now, that won't happen for at least another year.", "url": "https://finance.yahoo.com/m/d0f22b8d-f4dc-31a3-88f4-3dc45e3834b0/fda-denies-approval-for.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-19 14:42:00", "title": "Potential Gilead Blockbusters Were Rejected By the FDA. Why That\u2019s the \u2018Near-Worst-Case Scenario\u2019 for the Stock.", "image": "", "site": "Yahoo", "text": "The Food and Drug Administration rejected Gilead Sciences\u2019 application for a would-be blockbuster arthritis drug Tuesday night, blindsiding investors.", "url": "https://finance.yahoo.com/m/1b3bd588-4a6e-368c-9cf9-17abfd08e20d/potential-gilead-blockbusters.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-19 13:59:19", "title": "Dow Jones Today, Stocks Mixed; Target Heads Retail Rally; Biotechs Momenta, Gilead, Biomarin Swing Wild On Merger, FDA News", "image": "", "site": "Yahoo", "text": "Target and United Airlines staked early leads as financials led the Dow Jones today, but stocks struggled in mixed trade.", "url": "https://finance.yahoo.com/m/de82d955-19b6-3ecf-8ee4-e9cd0b8dab59/dow-jones-today%2C-stocks.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-19 12:15:19", "title": "Dow Jones Today, Futures Fight To Hold Gains; Target Heads Retail Rally; Gilead Swoons As FDA Balks", "image": "", "site": "Yahoo", "text": "Target and Southwest Airlines staked early leads, Intel led the Dow, but stock futures struggled to hold Wednesday's narrow early gains.", "url": "https://finance.yahoo.com/m/de82d955-19b6-3ecf-8ee4-e9cd0b8dab59/dow-jones-today%2C-futures.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-19 10:54:16", "title": "The Retiree's Dividend Portfolio - Jane's July Update: Resilient Dividends", "image": "https://static2.seekingalpha.com/images/marketing_images/electricity/energy_up_money_grow_idea.jpeg", "site": "seekingalpha.com", "text": "Jane's retirement accounts generated a total of $2,028.65 of dividend income for July 2020 vs. $1,988.24 of dividend income for July of 2019.", "url": "https://seekingalpha.com/article/4369700-retirees-dividend-portfolio-janes-july-update-resilient-dividends"}, {"symbol": "ABBV", "publishedDate": "2020-08-19 09:49:18", "title": "Tracking John Paulson's Paulson & Company Portfolio - Q2 2020 Update", "image": "https://static.seekingalpha.com/uploads/2020/8/19/106657-15978355694264793.jpg", "site": "seekingalpha.com", "text": "John Paulson\u2019s 13F portfolio value increased from $2.62B to $3.13B this quarter. Paulson & Company's largest three positions are Bausch Health, Horizon Therapeutics, and SPDR Gold ETF.", "url": "https://seekingalpha.com/article/4369686-tracking-john-paulsons-paulson-company-portfolio-q2-2020-update"}, {"symbol": "ABBV", "publishedDate": "2020-08-19 06:30:00", "title": "If You Like Attractively Valued Blue-Chips, You'll Love These 7 Dividend Growth Stocks", "image": "https://static1.seekingalpha.com/uploads/2020/8/15/47572571-1597477641004706.jpg", "site": "seekingalpha.com", "text": "Top-quality blue-chip dividend growth stocks are one of the most effective ways of compounding both income and wealth over time.", "url": "https://seekingalpha.com/article/4369588-you-like-attractively-valued-blue-chips-love-7-dividend-growth-stocks"}, {"symbol": "ABBV", "publishedDate": "2020-08-19 00:00:00", "title": "Gilead Analysts Trim Expectations After 'Very Unexpected' Adverse FDA Ruling", "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/syringe-1884784_1920_52.jpg", "site": "benzinga", "text": "Gilead Sciences, Inc. (NASDAQ: GILD) faces\u00a0a  regulatory setback  as filgotinib,\u00a0\u00a0an investigational drug it is co-developing with GALAPAGOS NV/S ADR (NASDAQ: GLPG...", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/20/08/17156935/gilead-analysts-trim-expectations-after-very-unexpected-adverse-fda-ruling"}, {"symbol": "ABBV", "publishedDate": "2020-08-18 15:35:04", "title": "Dividend Aristocrats Show Six Best Mid-August Selections", "image": "https://static3.seekingalpha.com/uploads/2020/8/18/748328-159776110576333.png", "site": "seekingalpha.com", "text": "S&P 500\u00ae Dividend Aristocrats measure performance of S&P 500 companies that have increased dividends every year for 25 consecutive years.-- us.spindices.com.", "url": "https://seekingalpha.com/article/4369557-dividend-aristocrats-show-six-best-mid-august-selections"}, {"symbol": "ABBV", "publishedDate": "2020-08-18 11:41:35", "title": "U.S. activists complain that virtual shareholder meetings let companies silence them", "image": "", "site": "Yahoo", "text": "Justin Danhof has used annual shareholder meetings to question companies on social issues for the last nine years.  This year, Danhof often found himself ignored, as companies held their shareholder meetings remotely during the COVID-19 pandemic, and asked investors to submit their questions online.  Danhof said his questions on topics such as companies' dealings with China or restrictions on financing gun makers were answered in only 13 of the 27 virtual shareholder meetings he and his representatives attended.", "url": "https://finance.yahoo.com/news/u-activists-complain-virtual-shareholder-114135191.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-18 09:37:12", "title": "AbbVie: A Solid 5% Yield With The Potential For Growth", "image": "https://static3.seekingalpha.com/uploads/2020/8/17/51530267-1597640394014597.png", "site": "seekingalpha.com", "text": "AbbVie is a major pharmaceutical that recently acquired Allergan to reduce their dependence on sales from their blockbuster therapeutic Humira due to expire in 2023.", "url": "https://seekingalpha.com/article/4369444-abbvie-solid-5-yield-potential-for-growth"}, {"symbol": "ABBV", "publishedDate": "2020-08-17 21:02:12", "title": "AbbVie: A Trifecta Of Yield, Growth, And Total Return Potential", "image": "https://static2.seekingalpha.com/uploads/2020/8/16/16583532-15976262164230165.png", "site": "seekingalpha.com", "text": "Since its spin-off from Abbott Laboratories in 2013, AbbVie has delivered strong dividend growth. AbbVie delivered 0.8% YoY revenue growth through H1 2020 and 8.2% YoY adjusted diluted EPS growth.", "url": "https://seekingalpha.com/article/4369357-abbvie-trifecta-of-yield-growth-and-total-return-potential"}, {"symbol": "ABBV", "publishedDate": "2020-08-17 11:34:12", "title": "3 Reasons AbbVie Is Ready To Bounce", "image": "https://static2.seekingalpha.com/uploads/2020/8/16/saupload_06c62846b0db8518a752bee781f19137.png", "site": "seekingalpha.com", "text": "Rinvoq a compelling blockbuster. Allergan tailwinds explained.", "url": "https://seekingalpha.com/article/4369185-3-reasons-abbvie-is-ready-to-bounce"}, {"symbol": "ABBV", "publishedDate": "2020-08-16 10:42:00", "title": "3 Dividend Stocks Yielding More Than 4% That Are Safe Buys Right Now", "image": "", "site": "Yahoo", "text": "Here are three dividend stocks yielding more than 4% that are safe buys right now.  Brookfield Infrastructure Partners' (NYSE: BIP) dividend currently yields 4.4%.  Brookfield Infrastructure, as its name indicates, owns and manages infrastructure assets.", "url": "https://finance.yahoo.com/m/ec7492e8-bfd6-30b3-9c89-fe9ea7e6e560/3-dividend-stocks-yielding.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-14 15:45:03", "title": "AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?", "image": "", "site": "Yahoo", "text": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.", "url": "https://finance.yahoo.com/news/abbvie-abbv-top-dividend-stock-154503552.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-14 15:29:03", "title": "The Zacks Analyst Blog Highlights: Home Depot, AbbVie, Broadcom, 3M and Morgan Stanley", "image": "", "site": "Yahoo", "text": "The Zacks Analyst Blog Highlights: Home Depot, AbbVie, Broadcom, 3M and Morgan Stanley", "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-home-152903382.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-14 10:00:00", "title": "Motorhome Retirement: July Update - Yellowstone!", "image": "https://static.seekingalpha.com/uploads/2020/8/12/36303236-15972471956775231.jpg", "site": "seekingalpha.com", "text": "We continued our summer adventure with a trip to Yellowstone National Park. Income exceeded expenses for the month.", "url": "https://seekingalpha.com/article/4368089-motorhome-retirement-july-update-yellowstone"}, {"symbol": "ABBV", "publishedDate": "2020-08-14 08:56:05", "title": "Tracking David Abrams' Abrams Capital Management Portfolio - Q2 2020 Update", "image": "https://static1.seekingalpha.com/uploads/2020/8/14/106657-15974038991275961.jpg", "site": "seekingalpha.com", "text": "David Abrams' 13F portfolio value increased this quarter from $2.54B to $3.09B. The number of positions decreased from 22 to 20.", "url": "https://seekingalpha.com/article/4368707-tracking-david-abrams-abrams-capital-management-portfolio-q2-2020-update"}, {"symbol": "ABBV", "publishedDate": "2020-08-14 06:30:00", "title": "Investing For The Long Run: Navigating A Bifurcated Market", "image": "https://static3.seekingalpha.com/uploads/2020/8/13/55431-15972970642858818.jpg", "site": "seekingalpha.com", "text": "Current market moves may trap the long-term investor. The Great Reset Matrix is a helpful tool for keeping eyes on the future.", "url": "https://seekingalpha.com/article/4368593-investing-for-long-run-navigating-bifurcated-market"}, {"symbol": "ABBV", "publishedDate": "2020-08-14 01:03:20", "title": "Reader Favorites And Rogues July 8 To August 7 Peg 30 Ripe Dividends For Picking", "image": "https://static3.seekingalpha.com/uploads/2020/8/13/748328-15973500410387187.png", "site": "seekingalpha.com", "text": "July 6-August 7: Readers of Fredrik Arnold articles mentioned 50 equities in their comments. Some lamented bad news, so bad news investments (rogues) mixed with (mostly) favorites.", "url": "https://seekingalpha.com/article/4368652-reader-favorites-and-rogues-july-8-to-august-7-peg-30-ripe-dividends-for-picking"}, {"symbol": "ABBV", "publishedDate": "2020-08-13 23:17:13", "title": "David Abrams Sells 2 Holdings, Drills Into Kinder Morgan in 2nd Quarter", "image": "", "site": "Yahoo", "text": "Klarman student releases portfolio Continue reading...", "url": "https://finance.yahoo.com/news/david-abrams-sells-2-holdings-231713639.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-13 17:17:05", "title": "Top Analyst Reports for Home Depot, AbbVie & Broadcom", "image": "", "site": "Yahoo", "text": "Top Analyst Reports for Home Depot, AbbVie & Broadcom", "url": "https://finance.yahoo.com/news/top-analyst-reports-home-depot-171705237.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-13 13:14:01", "title": "AbbVie Outperforms Large-Cap Pharma Industry Year to Date", "image": "", "site": "Yahoo", "text": "AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are seeing strong sales uptake.", "url": "https://finance.yahoo.com/news/abbvie-outperforms-large-cap-pharma-131401459.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-13 09:36:41", "title": "Genomic Medicine: Summer 2020 Update", "image": "https://static.seekingalpha.com/uploads/2020/8/12/400846-15972498827889986.png", "site": "seekingalpha.com", "text": "FDA approvals, new guidance statements, and RMAT requests all show the pace of genomics is accelerating.", "url": "https://seekingalpha.com/article/4368306-genomic-medicine-summer-2020-update"}, {"symbol": "ABBV", "publishedDate": "2020-08-12 23:03:08", "title": "Tracking Tweedy Browne Portfolio - Q2 2020 Update", "image": "https://static3.seekingalpha.com/uploads/2020/8/12/106657-15972805629816418.jpg", "site": "seekingalpha.com", "text": "Tweedy Browne\u2019s 13F portfolio value increased from $2.15B to $2.51B this quarter. The largest five individual stock positions are Alphabet, Berkshire Hathaway, Johnson & Johnson, Cisco Systems, and Baidu, and they account for ~55% of the portfolio.", "url": "https://seekingalpha.com/article/4368201-tracking-tweedy-browne-portfolio-q2-2020-update"}, {"symbol": "ABBV", "publishedDate": "2020-08-12 21:45:00", "title": "New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients", "image": "", "site": "Yahoo", "text": "AbbVie (NYSE: ABBV) today announced the publication of results from the Phase 3 VIALE-A clinical study in patients with AML in the New England Journal of Medicine (NEJM). The study, which evaluated newly-diagnosed AML patients who had not yet been treated and were unable to tolerate traditional intensive chemotherapy, found that venetoclax in combination with azacitidine extended overall survival (OS) compared to azacitidine plus placebo. The manuscript titled, \"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia,\" was published in the August 13, 2020 issue of NEJM.3", "url": "https://finance.yahoo.com/news/england-journal-medicine-publishes-positive-214500683.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-12 19:44:14", "title": "Tweedy Browne Adds Morgan Stanley, AbbVie to Portfolio", "image": "", "site": "Yahoo", "text": "Firm reveals top trades of the 2nd quarter Continue reading...", "url": "https://finance.yahoo.com/news/tweedy-browne-adds-morgan-stanley-194414545.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-11 17:36:42", "title": "AbbVie: Another Opportunity (NYSE:ABBV)", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "AbbVie has dipped back to $92 following the COVID-19 hits to revenues. The company has already seen sales rebound close to normalized levels setting record pro-forma revenues in 2H.", "url": "https://seekingalpha.com/article/4367582-abbvie-another-opportunity"}, {"symbol": "ABBV", "publishedDate": "2020-08-11 16:10:44", "title": "33 Fit Dividend Stocks For Our Times: The August Assortment", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "Kiplinger listed five sets of dividend stocks qualified to survive the COVID-19 pandemic. Barron's weekly added one more.", "url": "https://seekingalpha.com/article/4367541-33-fit-dividend-stocks-for-times-august-assortment"}, {"symbol": "ABBV", "publishedDate": "2020-08-10 14:21:18", "title": "Nicholas Ward's Dividend Growth Portfolio: July 2020 Update", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "Disney's dividend suspension came back to bite me this month. However, year-to-date, my passive income is still up 10.5% compared to the first 7 months of 2019.", "url": "https://seekingalpha.com/article/4367042-nicholas-wards-dividend-growth-portfolio-july-2020-update"}, {"symbol": "ABBV", "publishedDate": "2020-08-10 00:00:00", "title": "Analysis on Impact of COVID-19- Global Hepatocellular Carcinoma Drugs Market 2020-2024 | Evolving Opportunities with AbbVie Inc. and Amgen Inc. | Technavio", "image": "https://mms.businesswire.com/media/20200810005402/en/811625/23/IRTNTR44339.jpg", "site": "businesswire", "text": "The Global Hepatocellular Carcinoma Drugs Market will grow by $ 85.10 mn during 2020-2024", "url": "https://www.businesswire.com/news/home/20200810005402/en/Analysis-Impact-COVID-19--Global-Hepatocellular-Carcinoma-Drugs"}, {"symbol": "ABBV", "publishedDate": "2020-08-08 19:56:15", "title": "Dividend Challenger Highlights: Week Of August 9", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "A weekly summary of dividend activity for Dividend Challengers. Companies which changed their dividends.", "url": "https://seekingalpha.com/article/4366443-dividend-challenger-highlights-week-of-august-9"}, {"symbol": "ABBV", "publishedDate": "2020-08-07 16:24:20", "title": "5 Health Care Companies Outperforming the Market", "image": "", "site": "Yahoo", "text": "UnitedHealth on the list Continue reading...", "url": "https://finance.yahoo.com/news/5-health-care-companies-outperforming-162420296.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-07 15:58:46", "title": "3 High Yield Stock Picks for the Dividend Investor", "image": "", "site": "Yahoo", "text": "Their dividend yields beat that of the S&P 500 Continue reading...", "url": "https://finance.yahoo.com/news/3-high-yield-stock-picks-155846422.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-07 15:30:03", "title": "Pharma Stock Roundup: ABBV, MRK Q2 Earnings &amp; Coronavirus Updates in Focus", "image": "", "site": "Yahoo", "text": "Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.", "url": "https://finance.yahoo.com/news/pharma-stock-roundup-abbv-mrk-153003990.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-07 01:56:22", "title": "Humira maker to settle California lawsuit for $24 million", "image": "null", "site": "abcnews", "text": "The maker of the drug Humira will pay $24 million to settle a California lawsuit that alleged it violated the state;s insurance fraud law", "url": "https://abcnews.go.com/Business/wireStory/humira-maker-settle-california-lawsuit-24-million-72226569"}, {"symbol": "ABBV", "publishedDate": "2020-08-07 01:56:17", "title": "Humira maker to settle California lawsuit for $24 million", "image": "null", "site": "abcnews", "text": "The maker of the drug Humira will pay $24 million to settle a California lawsuit that alleged it violated the state;s insurance fraud law", "url": "https://abcnews.go.com/Health/wireStory/humira-maker-settle-california-lawsuit-24-million-72226568"}, {"symbol": "ABBV", "publishedDate": "2020-08-06 17:42:51", "title": "Early Sales of Eli Lilly&#39;s Migraine Drug Disappoint", "image": "", "site": "Yahoo", "text": "The company is confident Reyvow will reach $13 billion by 2027 Continue reading...", "url": "https://finance.yahoo.com/news/early-sales-eli-lillys-migraine-174251095.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-06 00:00:00", "title": "PARP (Poly ADP-Ribose Polymerase) Inhibitors Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Expanded Application of PARP Inhibitors to Boost the Market Growth | Technavio", "image": "https://mms.businesswire.com/media/20200806005444/en/810910/23/IRTNTR43323.jpg", "site": "businesswire", "text": "The Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market will grow by USD 810.23 mn during 2020-2024", "url": "https://www.businesswire.com/news/home/20200806005444/en/PARP-Poly-ADP-Ribose-Polymerase-Inhibitors-Market-Analysis"}, {"symbol": "ABBV", "publishedDate": "2020-08-04 23:44:11", "title": "3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio", "image": "", "site": "Yahoo", "text": "Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries...", "url": "https://finance.yahoo.com/news/3-diverse-large-cap-stocks-234411816.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-04 14:03:05", "title": "ABBVIE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) | MarketScreener", "image": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png", "site": "https://www.marketscreener.com", "text": "", "url": "https://www.marketscreener.com/ABBVIE-INC-12136589/news/ABBVIE-MANAGEMENT-S-DISCUSSION-AND-ANALYSIS-OF-FINANCIAL-CONDITION-AND-RESULTS-OF-OPERATIONS-form-31054010/"}, {"symbol": "ABBV", "publishedDate": "2020-08-04 10:34:00", "title": "How Neurocrine Biosciences Crushed It in Q2", "image": "", "site": "Yahoo", "text": "Neurocrine Biosciences' (NASDAQ: NBIX) 30% plunge earlier this year during the coronavirus-fueled market meltdown is practically all but forgotten now.  Here's what you need to know about Neurocrine's impressive Q2 update.  Neurocrine reported revenue of $302.4 million in the second quarter, a 65% increase from the $183.5 million reported in the prior-year period.", "url": "https://finance.yahoo.com/m/ae2662f3-d78a-3839-9033-e769981c6a0e/how-neurocrine-biosciences.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-04 00:00:00", "title": "COVID-19 Impacts: Antiviral Drugs Market Will Accelerate at a CAGR of Over 9% Through 2020-2024 | Growing Cases of Viral Infections to Boost Growth | Technavio", "image": "https://mms.businesswire.com/media/20200804005069/en/809927/23/IRTNTR43207.jpg", "site": "businesswire", "text": "The Global Antiviral Drugs Market will grow by USD 43.37 bn during 2020-2024", "url": "https://www.businesswire.com/news/home/20200804005069/en/COVID-19-Impacts-Antiviral-Drugs-Market-Accelerate-CAGR"}, {"symbol": "ABBV", "publishedDate": "2020-08-03 20:13:12", "title": "VOYAGER THERAPEUTICS, INC. : Termination of a Material Definitive Agreement (form 8-K) | MarketScreener", "image": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png", "site": "https://www.marketscreener.com", "text": "", "url": "https://www.marketscreener.com/VOYAGER-THERAPEUTICS-INC-24872703/news/VOYAGER-THERAPEUTICS-INC-Termination-of-a-Material-Definitive-Agreement-form-8-K-31047760/"}, {"symbol": "ABBV", "publishedDate": "2020-08-03 19:31:00", "title": "Coronavirus update: U.S. death toll climbs to 155,000, as COVID-19 enters \u2018dangerous new phase\u2019", "image": "https://s.marketwatch.com/public/resources/images/MW-IL675_Birx_0_ZG_20200803121745.jpg", "site": "marketwatch", "text": "The U.S. tally for new confirmed cases of the coronavirus that causes COVID-19 continued its march toward 5 million, with the death toll closing in on...", "url": "https://www.marketwatch.com/story/coronavirus-update-us-death-toll-climbs-toward-150000-as-covid-19-enters-dangerous-new-phase-2020-08-03"}, {"symbol": "ABBV", "publishedDate": "2020-08-03 11:56:29", "title": "AbbVie, Amgen and Takeda start testing drugs as COVID-19 treatments", "image": "https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg", "site": "marketwatch", "text": "AbbVie Inc. undefined, Amgen Inc. undefined, and Takeda Pharmaceutical Co. Ltd. undefined announced they started enrolling patients in a clinical trial...", "url": "https://www.marketwatch.com/story/abbvie-amgen-and-takeda-start-testing-drugs-as-covid-19-treatments-2020-08-03"}, {"symbol": "ABBV", "publishedDate": "2020-08-03 11:56:00", "title": "AbbVie, Amgen and Takeda start testing drugs as COVID-19 treatments", "image": "", "site": "Yahoo", "text": "AbbVie Inc. , Amgen Inc. , and Takeda Pharmaceutical Co. Ltd.  announced they started enrolling patients in a clinical trial testing three of their drugs as treatments for severely ill and hospitalized COVID-19 patients. This includes the still investigational HIV therapy cenicriviroc, psoriasis medication Otezla, and the anti-inflammatory drug Firazyr. The companies are using a platform aimed at minimizing the number of clinical-trial participants and the time it takes to test those drugs under an umbrella group called the COVID R&D Alliance. Since the start of the year, AbbVie's stock is up 7.2%, shares of Amgen have gained 1.5%, and Takeda's stock is down 7.4%. The S&P 500  is up 1.2%.", "url": "https://finance.yahoo.com/m/ec9fa9e4-b773-3a77-b1bb-13492a9ab276/abbvie%2C-amgen-and-takeda.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-03 11:30:00", "title": "Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial", "image": "", "site": "Yahoo", "text": "Today, members of the COVID R&D Alliance AbbVie, Inc. (NYSE: ABBV), Amgen Inc. (NASDAQ: AMGN), and Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) announced the first patients enrolled in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The I-SPY COVID Trial will evaluate the efficacy of cenicriviroc, a chemokine (CCR2 and CCR5) dual-receptor antagonist, Otezla\u00ae (apremilast), a PDE4 inhibitor, and Firazyr\u00ae (icatibant injection), a bradykinin B2 receptor antagonist in severely ill, hospitalized COVID-19 patients who require high-flow oxygen.", "url": "https://finance.yahoo.com/news/members-covid-r-d-alliance-113000960.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-03 11:29:34", "title": "AbbVie Inc.&#39;s (NYSE:ABBV) P/E Is On The Mark", "image": "", "site": "Yahoo", "text": "When close to half the companies in the United States have price-to-earnings ratios (or \"P/E's\") below 17x, you may...", "url": "https://finance.yahoo.com/news/abbvie-inc-nyse-abbv-p-112934976.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-03 11:00:00", "title": "A Giant Pension Sold Apple and Intel Stock. Here Are Two Stocks It Bought.", "image": "", "site": "Yahoo", "text": "The New York State Teachers\u2019 Retirement System trimmed investments in Apple and Intel stock in the second quarter. The pension also bought more Nvidia and AbbVie stock.", "url": "https://finance.yahoo.com/m/dc874884-8fce-333e-b237-be3fd759760e/a-giant-pension-sold-apple.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-03 09:30:00", "title": "Nasdaq Indexes Lead Way on Both Sides of Atlantic", "image": "https://images.wsj.net/im-216077/social", "site": "wsj", "text": "In the U.S., the stock-exchange operator\u2019s indexes are the country\u2019s best-performing major stock benchmarks this year. In Europe, the Nasdaq-owned Copenhagen exchange\u2019s index is leading the charge.", "url": "https://www.wsj.com/articles/nasdaq-indexes-lead-way-on-both-sides-of-atlantic-11596447000"}, {"symbol": "ABBV", "publishedDate": "2020-08-03 00:00:00", "title": "Rival drugmakers launch joint trial of medicines for COVID-19", "image": "https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEG720MW_M.jpg", "site": "investing", "text": "Rival drugmakers launch joint trial of medicines for COVID-19", "url": "https://www.investing.com/news/coronavirus/rival-drugmakers-launch-joint-trial-of-medicines-for-covid19-2250705"}, {"symbol": "ABBV", "publishedDate": "2020-08-02 20:31:18", "title": "The Market Continues to Undervalue AbbVie", "image": "", "site": "Yahoo", "text": "The stock trades with a single-digit multiple despite strong growth rates from products outside of Humira Continue reading...", "url": "https://finance.yahoo.com/news/market-continues-undervalue-abbvie-203118595.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-02 13:07:00", "title": "2 Stocks to Supplement Your Social Security Income", "image": "", "site": "Yahoo", "text": "According to data published by the U.S. Social Security Administration (SSA) in December 2019, the median monthly benefit paid out to retired individuals is just $1,503.  The SSA estimates that approximately nine out of 10 persons aged 65 and up collect Social Security and anticipates paying more than $1 trillion to roughly 65 million people this year.  The good news is, by investing in tried-and-true large-cap stocks, you can supplement your Social Security income and strengthen your financial position during an economic downturn.", "url": "https://finance.yahoo.com/m/5ba3790c-dcca-33f4-8c68-79d1230bcbb4/2-stocks-to-supplement-your.html"}, {"symbol": "ABBV", "publishedDate": "2020-08-02 11:20:57", "title": "Gilead: Perhaps A Value Trap No Longer", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha.com", "text": "GILD sank back into its familiar pattern of disappointing the Street, selling off below $70 again after reporting Q2 results.", "url": "https://seekingalpha.com/article/4363620-gilead-perhaps-value-trap-no-longer"}, {"symbol": "ABBV", "publishedDate": "2020-08-01 00:32:53", "title": "AbbVie (ABBV) Q2 2020 Earnings Call Transcript", "image": "", "site": "Yahoo", "text": "ABBV earnings call for the period ending June 30, 2020.", "url": "https://finance.yahoo.com/m/72e19094-2a74-319d-aa5f-082cb3eec319/abbvie-%28abbv%29-q2-2020.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-31 20:33:13", "title": "AbbVie Earnings Top, Drug Giant Rebounds Bullishly, Flashes Buy Signal", "image": "", "site": "Yahoo", "text": "AbbVie earnings and sales topped views. The drug giant raised full-year EPS targets including newly acquired Allergan. AbbVie stock rose into a buy area.", "url": "https://finance.yahoo.com/m/12c63847-eccb-34af-b14e-d1ff2a06eaf2/abbvie-earnings-top%2C-drug.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-31 17:09:05", "title": "AbbVie&#39;s (ABBV) Q2 Earnings and Revenues Beat Estimates", "image": "", "site": "Yahoo", "text": "AbbVie (ABBV) beats on second-quarter 2020 earnings and revenues. Shares up in pre-market trading.", "url": "https://finance.yahoo.com/news/abbvies-abbv-q2-earnings-revenues-170905443.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-31 16:44:04", "title": "Pharma Stock Roundup: Q2 Earnings &amp; J&amp;J and PFE&#39;s Coronavirus Updates in Focus", "image": "", "site": "Yahoo", "text": "Pfizer's (PFE) coronavirus vaccine candidate enters phase III. Several drugmakers announce second-quarter results.", "url": "https://finance.yahoo.com/news/pharma-stock-roundup-q2-earnings-164404921.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-31 15:58:07", "title": "AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2020 Results - Earnings Call Transcript", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha.com", "text": "AbbVie Inc. (NYSE:ABBV) Q2 2020 Earnings Conference Call July 31, 2020 9:00 AM ET Company Participants Liz Shea - Vice President, Investor Relations Rick Gonzalez - Chairman of the Board &amp; Chief Executive Officer Michael Severino - Vice Chairman &amp; President Rob Michael - Executive Vice President &amp; Chief Financial Officer Conference Call Participants Randall Stanicky - RBC Capital Markets Navin Jacob - UBS Chris Schott - JPMorgan Steve Scala - Cowen Geoffrey Porges - Leerink Vamil Divan - Mizuho David Risinger - Morgan Stanley Chris Raymond - Piper Sandler Tim Anderson - Wolfe Research Terence Flynn - Goldman Sachs Presentation Operator Good morning.", "url": "https://seekingalpha.com/article/4363134-abbvie-inc-abbv-ceo-rick-gonzalez-on-q2-2020-results-earnings-call-transcript"}, {"symbol": "ABBV", "publishedDate": "2020-07-31 15:54:00", "title": "5 Key Things You&#39;ll Want to Know About AbbVie&#39;s Q2 Update", "image": "", "site": "Yahoo", "text": "AbbVie (NYSE: ABBV) announced its second-quarter results before the market opened on Friday.  How did AbbVie fare in its first quarterly results with Allergan under its wing?  Here are five key things you'll want to know about AbbVie's Q2 update.", "url": "https://finance.yahoo.com/m/79c3c2ad-da0d-3c0a-9fc4-481f41673309/5-key-things-you%26%2339%3Bll-want.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-31 15:28:00", "title": "Coronavirus update: Pandemic will continue for some time, experts tell Congress as U.S. case tally nears 4.5 million", "image": "https://s.marketwatch.com/public/resources/images/MW-IL567_facema_ZG_20200731110836.jpg", "site": "marketwatch", "text": "With close to 4.5 million Americans confirmed to have been infected with the coronavirus illness COVID-19, the pandemic will continue for some time, public...", "url": "https://www.marketwatch.com/story/coronavirus-update-pandemic-will-continue-for-some-time-experts-tell-congress-as-us-case-tally-nears-45-million-2020-07-31"}, {"symbol": "ABBV", "publishedDate": "2020-07-31 15:10:07", "title": "AbbVie Earnings: ABBV Stock Drops 2% Despite Q2 Beats", "image": "https://investorplace.com/wp-content/uploads/2019/08/abbv-stock-1.jpg", "site": "https://investorplace.com", "text": "AbbVie earnings on Friday have ABBV stock slighty lower despite the company beating EPS and revenue estimates from Wall Street.", "url": "https://investorplace.com/2020/07/abbvie-earnings-abbv-stock-drops-2-despite-q2-beats/"}, {"symbol": "ABBV", "publishedDate": "2020-07-31 14:31:00", "title": "Let&#39;s Not Overlook AbbVie&#39;s Q2 Beat", "image": "", "site": "Yahoo", "text": "Apple  and Amazon  have stolen the show.  As a matter of fact, even though this name was one of my picks for the coming year in late 2019, I really have not focused on it as much since the early May closing of the Allergan acquisition.  AbbVie reported on Friday morning.", "url": "https://finance.yahoo.com/m/1db7f2ef-1358-3ed4-b754-cce856ed63f4/let%26%2339%3Bs-not-overlook.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-31 14:26:00", "title": "AbbVie Beats Earnings Expectations but Stock Falls Anyway", "image": "https://images.barrons.com/im-215524/social", "site": "barrons", "text": "The drug company beat Wall Street earnings estimates for the second quarter but issued guidance for the full year that fell below analyst expectations.", "url": "https://www.barrons.com/articles/abbvie-beats-earnings-expectations-but-stock-falls-anyway-51596205604"}, {"symbol": "ABBV", "publishedDate": "2020-07-31 12:45:14", "title": "ABBVIE INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) | MarketScreener", "image": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png", "site": "https://www.marketscreener.com", "text": "", "url": "https://www.marketscreener.com/ABBVIE-INC-12136589/news/ABBVIE-INC-Results-of-Operations-and-Financial-Condition-Financial-Statements-and-Exhibits-form-31030838/"}, {"symbol": "ABBV", "publishedDate": "2020-07-31 00:00:00", "title": "Earnings Scheduled For July 31, 2020", "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/earnings_scheduled_1674.png", "site": "benzinga", "text": "Companies Reporting Before The Bell\n\u2022 Chevron Inc. (NYSE:CVX) is expected to report quarterly loss at $0.92 per share on revenue of $22.10 billion.\n\u2022 Weyerhaeuser Inc. (...", "url": "https://www.benzinga.com/news/earnings/20/07/16868143/earnings-scheduled-for-july-31-2020"}, {"symbol": "ABBV", "publishedDate": "2020-07-30 04:08:44", "title": "3 Low-Beta Blue Chips With High Dividend Yields", "image": "https://static.seekingalpha.com/images/marketing_images/bull_bear/bear_and_bull_12.jpeg", "site": "seekingalpha.com", "text": "During volatile times, low-beta stocks are a welcome sight as they can provide stability to the portfolio.", "url": "https://seekingalpha.com/article/4362149-3-low-beta-blue-chips-high-dividend-yields"}, {"symbol": "ABBV", "publishedDate": "2020-07-27 15:58:10", "title": "The Retiree's Dividend Portfolio - Jane's June Update: Record Dividends During COVID-19", "image": "https://static2.seekingalpha.com/images/marketing_images/electricity/energy_up_money_grow_idea.jpeg", "site": "seekingalpha.com", "text": "Jane's retirement accounts generated a total of $2,047.11 of dividend income for June 2020 vs. $1,561.04 of dividend income for June of 2019.", "url": "https://seekingalpha.com/article/4361121-retirees-dividend-portfolio-janes-june-update-record-dividends-during-covidminus-19"}, {"symbol": "ABBV", "publishedDate": "2020-07-27 15:22:41", "title": "Resource Management LLC Sells 299 Shares of AbbVie Inc (NYSE:ABBV)", "image": "https://www.marketbeat.com/logos/abbvie-inc-logo.jpg", "site": "https://www.thelincolnianonline.com", "text": "Resource Management LLC lowered its position in shares of AbbVie Inc (NYSE:ABBV) by 5.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,634 shares of the company\u2019s stock after selling 299 shares during the quarter. Resource Management LLC\u2019s holdings in AbbVie [\u2026]", "url": "https://www.thelincolnianonline.com/2020/07/27/resource-management-llc-sells-299-shares-of-abbvie-inc-nyseabbv.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-27 15:22:40", "title": "Palisade Asset Management LLC Decreases Stock Holdings in AbbVie Inc (NYSE:ABBV)", "image": "https://www.marketbeat.com/logos/abbvie-inc-logo.jpg", "site": "https://www.thelincolnianonline.com", "text": "Palisade Asset Management LLC decreased its position in shares of AbbVie Inc (NYSE:ABBV) by 19.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,326 shares of the company\u2019s stock after selling 14,530 shares during the quarter. Palisade Asset Management LLC\u2019s holdings in [\u2026]", "url": "https://www.thelincolnianonline.com/2020/07/27/palisade-asset-management-llc-decreases-stock-holdings-in-abbvie-inc-nyseabbv.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-27 14:12:41", "title": "AbbVie Inc (NYSE:ABBV) Shares Acquired by Selway Asset Management", "image": "https://www.marketbeat.com/logos/abbvie-inc-logo.jpg", "site": "https://www.thelincolnianonline.com", "text": "Selway Asset Management increased its holdings in shares of AbbVie Inc (NYSE:ABBV) by 0.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 33,290 shares of the company\u2019s stock after purchasing an additional 175 shares during the period. AbbVie accounts for about [\u2026]", "url": "https://www.thelincolnianonline.com/2020/07/27/abbvie-inc-nyseabbv-shares-acquired-by-selway-asset-management.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-27 13:36:41", "title": "Sumitomo Mitsui Trust Holdings Inc. Has $794.81 Million Holdings in AbbVie Inc (NYSE:ABBV)", "image": "https://www.marketbeat.com/logos/abbvie-inc-logo.jpg", "site": "https://www.thelincolnianonline.com", "text": "Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of AbbVie Inc (NYSE:ABBV) by 24.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,194,271 shares of the company\u2019s stock after purchasing an additional 1,630,022 shares during the period. Sumitomo [\u2026]", "url": "https://www.thelincolnianonline.com/2020/07/27/sumitomo-mitsui-trust-holdings-inc-has-794-81-million-holdings-in-abbvie-inc-nyseabbv.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-27 10:38:41", "title": "Grandfield & Dodd LLC Buys 275 Shares of AbbVie Inc (NYSE:ABBV)", "image": "https://www.marketbeat.com/logos/abbvie-inc-logo.jpg", "site": "https://www.thelincolnianonline.com", "text": "Grandfield & Dodd LLC raised its holdings in AbbVie Inc (NYSE:ABBV) by 5.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,562 shares of the company\u2019s stock after buying an additional 275 shares during the quarter. Grandfield & Dodd LLC\u2019s holdings in AbbVie [\u2026]", "url": "https://www.thelincolnianonline.com/2020/07/27/grandfield-dodd-llc-buys-275-shares-of-abbvie-inc-nyseabbv.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-27 10:02:42", "title": "Rothschild Investment Corp IL Acquires 406 Shares of AbbVie Inc (NYSE:ABBV)", "image": "https://www.marketbeat.com/logos/abbvie-inc-logo.jpg", "site": "https://www.thelincolnianonline.com", "text": "Rothschild Investment Corp IL lifted its stake in AbbVie Inc (NYSE:ABBV) by 0.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 206,349 shares of the company\u2019s stock after buying an additional 406 shares during the quarter. AbbVie makes up 2.4% of Rothschild Investment Corp [\u2026]", "url": "https://www.thelincolnianonline.com/2020/07/27/rothschild-investment-corp-il-acquires-406-shares-of-abbvie-inc-nyseabbv.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-27 07:54:06", "title": "Vanguard Health Care ETF: Outlook Remains Favorable Despite Higher Valuation", "image": "https://static3.seekingalpha.com/uploads/2020/7/25/22895591-159568929035166.png", "site": "seekingalpha.com", "text": "VHT invests in large-cap U.S. healthcare stocks.", "url": "https://seekingalpha.com/article/4360958-vanguard-health-care-etf-outlook-remains-favorable-despite-higher-valuation"}, {"symbol": "ABBV", "publishedDate": "2020-07-27 05:53:23", "title": "The 14 Best High-Yield Dividend Aristocrats Retirees Can Safely Buy Right Now", "image": "https://static.seekingalpha.com/uploads/2020/7/25/47572571-1595667359234323_origin.jpg", "site": "seekingalpha.com", "text": "The broader market is 36% historically overvalued, and short-term correction risk is high. But no matter how irrational a market bubble, quality blue-chips are always on sale.", "url": "https://seekingalpha.com/article/4360931-14-best-high-yield-dividend-aristocrats-retirees-can-safely-buy-right-now"}, {"symbol": "ABBV", "publishedDate": "2020-07-27 00:00:00", "title": "Global Hypertriglyceridemia Therapeutics Market to Generate Revenue of US$ 12,863.1 Million by end of 2027, Says Coherent Market Insights", "image": "https://mms.businesswire.com/media/20200727005428/en/808249/23/logo_400X400.jpg", "site": "businesswire", "text": "The North America hypertriglyceridemia therapeutics market is estimated to be the most lucrative during the period of forecast.", "url": "https://www.businesswire.com/news/home/20200727005428/en/Global-Hypertriglyceridemia-Therapeutics-Market-Generate-Revenue-12863.1"}, {"symbol": "ABBV", "publishedDate": "2020-07-26 00:00:00", "title": "The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings", "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medic-563423_1920_398_23.jpg", "site": "benzinga", "text": "Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.\nAlthough there were promising updates from...", "url": "https://www.benzinga.com/general/biotech/20/07/16778963/the-week-ahead-in-biotech-spotlight-on-gw-pharma-ultragenyx-fda-decisions-pfizer-earnings"}, {"symbol": "ABBV", "publishedDate": "2020-07-24 15:21:33", "title": "Rising Risk? Here's What You Can Buy", "image": "https://static3.seekingalpha.com/uploads/2020/7/24/486106-15955997718157728.png", "site": "seekingalpha.com", "text": "Volatility caused by dismal economic data creates opportunities. Our overbought reading is heating up, suggesting you proactively pick entry points.", "url": "https://seekingalpha.com/article/4360703-rising-risk-what-you-can-buy"}, {"symbol": "ABBV", "publishedDate": "2020-07-22 15:05:51", "title": "3 Reasons You Should Buy AbbVie", "image": "https://static.seekingalpha.com/uploads/2020/7/22/71188-15954289638000658_origin.jpg", "site": "seekingalpha.com", "text": "Selling delayed AbbVie's upward run to hold $100. Atopic dermatitis drug a positive catalyst.", "url": "https://seekingalpha.com/article/4359952-3-reasons-you-should-buy-abbvie"}, {"symbol": "ABBV", "publishedDate": "2020-07-22 10:00:14", "title": "Motorhome Retirement: June Update, Finally Off To The Black Hills", "image": "https://static3.seekingalpha.com/uploads/2020/7/21/36303236-1595383270305747.jpg", "site": "seekingalpha.com", "text": "We finally got to get out and enjoy some the wonders the United States has to offer.\u00a0 We visited the Black Hills National Forest and the Badlands National Park.", "url": "https://seekingalpha.com/article/4359830-motorhome-retirement-june-update-finally-off-to-black-hills"}, {"symbol": "ABBV", "publishedDate": "2020-07-22 01:07:29", "title": "Sand In My Shoes - Carnage And Recovery", "image": "https://static2.seekingalpha.com/uploads/2020/7/21/11339381-15953379004605591.jpg", "site": "seekingalpha.com", "text": "The volatility in the markets seems to have settled down in the past month, and I feel comfortable writing an update article again.", "url": "https://seekingalpha.com/article/4359790-sand-in-shoes-carnage-and-recovery"}, {"symbol": "ABBV", "publishedDate": "2020-07-21 05:27:50", "title": "Dividend Aristocrats Flaunt 7 Surefire August Selections", "image": "https://static.seekingalpha.com/uploads/2020/7/21/748328-15953051416749206_origin.png", "site": "seekingalpha.com", "text": "S&P 500\u00ae Dividend Aristocrats measure performance of S&P 500 companies that have increased dividends every year for 25 consecutive years.---us.spindices.com.", "url": "https://seekingalpha.com/article/4359528-dividend-aristocrats-flaunt-7-surefire-august-selections"}, {"symbol": "ABBV", "publishedDate": "2020-07-19 02:10:41", "title": "AbbVie (NYSE:ABBV) Reaches New 1-Year High at $100.86", "image": "https://www.marketbeat.com/logos/abbvie-inc-logo.jpg", "site": "https://www.thelincolnianonline.com", "text": "AbbVie Inc (NYSE:ABBV)\u2019s stock price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $100.86 and last traded at $100.42, with a volume of 106159 shares changing hands. The stock had previously closed at $99.92. A number of analysts have recently weighed in on ABBV shares. Royal [\u2026]", "url": "https://www.thelincolnianonline.com/2020/07/19/abbvie-nyseabbv-reaches-new-1-year-high-at-100-86.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-18 13:00:00", "title": "How To Fully Benefit From Insider Trading Information: 3 Do's And Don'ts", "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "site": "seekingalpha", "text": "Insider trades are very informative to include in your investment strategy as insiders know their business better than anyone else.", "url": "https://seekingalpha.com/insight/investing-strategy/article/4358859-how-to-fully-benefit-from-insider-information-3-dos-and-donts"}, {"symbol": "ABBV", "publishedDate": "2020-07-18 09:29:00", "title": "The Passive DGI Core Portfolio: Retirement Strategy That Allows You To Sleep Well", "image": "https://static.seekingalpha.com/uploads/2020/7/15/434815-1594825810857963_origin.png", "site": "seekingalpha.com", "text": "We believe a well thought-out DGI strategy provides almost everything that most retirees and conservative investors would need: Decent income, relative safety, and reasonable growth.", "url": "https://seekingalpha.com/article/4358852-passive-dgi-core-portfolio-retirement-strategy-allows-you-to-sleep-well"}, {"symbol": "ABBV", "publishedDate": "2020-07-18 09:00:00", "title": "How To Fully Benefit From Insider Information: 3 Do's And Don'ts", "image": "https://static.seekingalpha.com/uploads/2020/7/15/48562496-15948236906947322_origin.png", "site": "seekingalpha.com", "text": "Insider trades are very informative to include in your investment strategy as insiders know their business better than anyone else.", "url": "https://seekingalpha.com/article/4358859-how-to-fully-benefit-from-insider-information-3-dos-and-donts"}, {"symbol": "ABBV", "publishedDate": "2020-07-18 01:50:41", "title": "$10.06 Billion in Sales Expected for AbbVie Inc (NYSE:ABBV) This Quarter", "image": "https://www.marketbeat.com/logos/abbvie-inc-logo.jpg", "site": "https://www.thelincolnianonline.com", "text": "Equities analysts expect that AbbVie Inc (NYSE:ABBV) will post $10.06 billion in sales for the current quarter, according to Zacks. Two analysts have made estimates for AbbVie\u2019s earnings, with the lowest sales estimate coming in at $9.90 billion and the highest estimate coming in at $10.21 billion. AbbVie posted sales of $8.26 billion during the [\u2026]", "url": "https://www.thelincolnianonline.com/2020/07/18/10-06-billion-in-sales-expected-for-abbvie-inc-nyseabbv-this-quarter.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-17 14:24:02", "title": "J&amp;J Sets in Motion Pharma Q2 Earnings: 3 Stocks to Buy", "image": "", "site": "Yahoo", "text": "Investors typically look at J&J;'s (JNJ) results for signals about how the rest of the big drugmakers will fare.", "url": "https://finance.yahoo.com/news/j-j-sets-motion-pharma-142402649.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-17 14:17:33", "title": "Top Stocks To Buy Now", "image": "", "site": "seekingalpha.com", "text": "", "url": "https://seekingalpha.com/article/4359100-top-stocks-to-buy-now"}, {"symbol": "ABBV", "publishedDate": "2020-07-17 11:45:00", "title": "Distillate Capital Partners Q2 2020 Investment Letter", "image": "https://static2.seekingalpha.com/uploads/sa_presentations/388/57388/slides/1.jpg?1594999318", "site": "seekingalpha.com", "text": "Distillate Capital Partners was formed in 2017 and is based in Chicago, IL. The fund strategies use cash-flow-based measures of value and quality that are designed to avoid accounting distortions that we believe have rendered many traditional metrics less relevant in an increasingly asset-light world.", "url": "https://seekingalpha.com/article/4359054-distillate-capital-partners-q2-2020-investment-letter"}, {"symbol": "ABBV", "publishedDate": "2020-07-17 10:43:00", "title": "These 3 Stocks Are Still Ridiculously Cheap Right Now", "image": "", "site": "Yahoo", "text": "AbbVie (NYSE: ABBV) shares are up more than 20% in the last three months.  There's one obvious reason why AbbVie sports such a cheap valuation.  More importantly, AbbVie has other arrows in its quiver that will help offset future sales declines for Humira, notable among them new immunology drugs Rinvoq and Skyrizi, and cancer drugs Imbruvica and Venclexta.", "url": "https://finance.yahoo.com/m/cc50dc11-63fc-3d1d-a34e-afdd604a9f4f/these-3-stocks-are-still.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-16 22:22:35", "title": "Pharmas Seeking to Overcome Patent Expirations", "image": "", "site": "Yahoo", "text": "Takeda, Amgen among those losing exclusivity on key drugs Continue reading...", "url": "https://finance.yahoo.com/news/pharmas-seeking-overcome-patent-expirations-222235774.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-16 15:50:03", "title": "Should Value Investors Buy AbbVie (ABBV) Stock?", "image": "", "site": "Yahoo", "text": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.", "url": "https://finance.yahoo.com/news/value-investors-buy-abbvie-abbv-155003285.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-15 19:04:02", "title": "CATH: What The 'Catholic S&P 500' ETF Excludes Vs. Overweights", "image": "https://static1.seekingalpha.com/uploads/2020/7/15/27788673-15948193089658825.jpg", "site": "seekingalpha.com", "text": "The Global X S&P 500 Catholic Values Index ETF is the largest US-listed faith-based ETF, applying the ESG process of the United States Conference of Catholic Bishops.", "url": "https://seekingalpha.com/article/4358714-cath-what-catholic-s-and-p-500-etf-excludes-vs-overweights"}, {"symbol": "ABBV", "publishedDate": "2020-07-15 15:47:27", "title": "Eli Lilly: Upside Momentum Fading Fast", "image": "https://static.seekingalpha.com/uploads/2020/7/15/17314402-1594838985162285_origin.jpg", "site": "seekingalpha.com", "text": "Eli Lilly's valuation is stretched and financial leverage is high, both risks if operating results falter.", "url": "https://seekingalpha.com/article/4358678-eli-lilly-upside-momentum-fading-fast"}, {"symbol": "ABBV", "publishedDate": "2020-07-15 12:40:53", "title": "Researchers Say AbbVie&#39;s Tricor Reduced Severity Of COVID-19 Into &#39;Nothing Worse Than A Common Cold&#39;", "image": "", "site": "Yahoo", "text": "AbbVie Inc (NYSE: ABBV) shares popped Tuesday after researchers found that the large-cap pharma's cholesterol-lowering drug Tricor could work against SARS-CoV2, the virus that causes COVID-19.What Happened:  Researchers at Israel's Hebrew University and the Mount Sinai Medical Center in New York said FDA-approved Tricor could potentially downgrade COVID-19's severity into \"nothing worse than a common cold,\" Israeli media reported.Tricor impairs the replicating potential of the new coronavirus or even could eradicate it, the reports said, citing Hebrew University professor Ya'acov Nahmias and Sinai's Dr. Benjamin tenOever.See Also: Moderna's Stock Jumps After Coronavirus Vaccine Shows Positive Results In Phase 1 Clinical TrialHow Tricor Acts:  Following three months of in vitro, or lab, studies and a review of eight already approved drugs, the researchers found that Tricor burns fat, causing the virus to disappear with merely five days of treatment.SARS-Co-V2 was found to impede with the carbohydrate metabolism, leading to the accumulation of fat inside the lung cells, which in turn provides a conducive environment for the thriving of the virus.Tricor's fat-burning mechanism comes in handy to make the environment inclement for the virus, leading to its eventual elimination, studies found.What's Next?  The researchers are advancing the drug into animal studies in the U.S. With the safety of Tricor already proved, they hope to fast track clinical studies both in the U.S. and Israel within the next couple of weeks.After advancing 2.27% to $98.87 in Tuesday's session, AbbVie shares were up 0.95% to $99.81 on Wednesday morning.See more from Benzinga  * The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs  * The Daily Biotech Pulse: Intersect ENT Jumps On M&A; Speculation, VIVUS Files For Bankruptcy  * The Daily Biotech Pulse: Novartis Settles Lawsuit For 8M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.", "url": "https://finance.yahoo.com/news/researchers-abbvies-tricor-reduced-severity-124053251.html"}, {"symbol": "ABBV", "publishedDate": "2020-07-15 07:00:00", "title": "S&P 500: Buybacks - $104 Billion Of Equity Converted To $104 Billion Of Debt - Risky Business", "image": "https://static.seekingalpha.com/uploads/2020/7/13/3764491-15946314278691907_origin.png", "site": "seekingalpha.com", "text": "In the past five years, the number of technically-insolvent companies in the S&P 500 has more than tripled, primarily due to share buybacks funded with debt.", "url": "https://seekingalpha.com/article/4358218-s-and-p-500-buybacks-104-billion-of-equity-converted-to-104-billion-of-debt-risky-business"}, {"symbol": "ABBV", "publishedDate": "2020-07-15 05:28:10", "title": "In Search Of The Best High-Yield Opportunities In The Market Today", "image": "https://static.seekingalpha.com/images/marketing_images/stock_market/yields_up_cc0.jpeg", "site": "seekingalpha.com", "text": "I sold my Dominion Energy stock on Monday morning and now I need to replace that lost income. I discuss now active management can bolster passive income strategies.", "url": "https://seekingalpha.com/article/4358532-in-search-of-best-high-yield-opportunities-in-market-today"}]